WT1

UniProt ID: P19544
Organism: Homo sapiens
Review Status: IN PROGRESS
πŸ“ Provide Detailed Feedback

Gene Description

WT1 (Wilms tumor protein) is a C2H2 zinc-finger transcription factor that plays essential roles in urogenital and cardiac development. The protein contains an N-terminal proline/glutamine-rich regulatory domain (with separate repression and activation domains) and four C-terminal C2H2 zinc fingers (encoded by exons 7-10) that mediate sequence-specific DNA binding to the motif 5'-GCG(T/G)GGGCG-3' with Kd ~1.14 nM. Alternative splicing at intron 9 produces two major isoform classes with distinct functions: the -KTS isoform functions as a classical DNA-binding transcription factor (both activator and repressor depending on cofactors like BASP1/p53 and cellular context), while the +KTS isoform has reduced DNA affinity (due to increased linker flexibility between ZnF3-4) and participates in RNA processing, localizing to nuclear speckles and interacting with splicing factors (U2AF65, RBM4). The normal +KTS/-KTS ratio of ~2:1 is critical; Frasier syndrome results from altered ratio. WT1 functions as a tumor suppressor in kidney (loss causes Wilms tumor) but can act as an oncogene in AML/leukemias. Key transcriptional targets include nephrin/NPHS1 and podocalyxin (activation in podocytes), PAX2 (repression during differentiation), BCL2 and MYC (repression for tumor suppression), DNMT3A (activation), and SF1/SRY (activation in sex determination). WT1 is essential for: (1) mesenchymal-to-epithelial transition during nephrogenesis and podocyte maintenance, (2) gonadal development and sex determination, and (3) epicardial epithelial-to-mesenchymal transition for coronary vasculature formation via Wnt/beta-catenin and retinoic acid signaling.

Functional Isoforms

Curated functional classes representing distinct biological activities. These may be splice variants, cleavage products, or other forms with different functions.

-KTS isoforms SPLICE CLASS
ID: WT1_MINUS_KTS
UNIPROT ISOFORM: P19544-2, P19544-4
DNA-binding transcription factors. The -KTS isoforms lack the KTS tripeptide (Lys-Thr-Ser) between zinc fingers 3 and 4, resulting in a shorter linker that maintains high DNA-binding affinity (Kd ~1 nM) for the consensus motif 5'-GCG(T/G)GGGCG-3'. These isoforms function as classical transcription factors, both activating (SRY, DNMT3A, NPHS1) and repressing (PAX2, BCL2, MYC) target genes depending on cofactors and cellular context. The -KTS isoforms are essential for kidney development (Wilms tumor suppression) and sex determination. PMID:9815658 directly demonstrates SRY promoter activation by -KTS but NOT +KTS.
+KTS isoforms SPLICE CLASS
ID: WT1_PLUS_KTS
UNIPROT ISOFORM: P19544-1, P19544-3
RNA-binding/splicing regulators. The +KTS isoforms have a 3-amino acid insertion (Lys-Thr-Ser) between zinc fingers 3 and 4, increasing linker flexibility and REDUCING DNA-binding affinity by ~10-fold. These isoforms localize to nuclear speckles (not nucleoplasm) and interact with splicing factors (U2AF65, RBM4, WTAP). The +KTS isoforms do NOT function as transcription factors - they participate in mRNA processing. PMID:9815658 shows +KTS does NOT activate the SRY promoter that -KTS strongly activates. Frasier syndrome results from loss of +KTS isoforms specifically, demonstrating their distinct developmental role. The normal +KTS:-KTS ratio of ~2:1 is critical for proper development.
Isoform-specific terms: RNA binding nuclear speck mRNA splicing, via spliceosome

Existing Annotations Review

GO Term Evidence Action Reason
GO:0000978 RNA polymerase II cis-regulatory region sequence-specific DNA binding
IBA
GO_REF:0000033
ACCEPT
Summary: WT1 is well-established as a sequence-specific DNA-binding transcription factor. The -KTS isoform binds with high affinity to the consensus 5'-GCG(T/G)GGGCG-3' motif via its C2H2 zinc fingers [PMID:7862533, PMID:25258363]. Multiple studies demonstrate direct binding to cis-regulatory regions of target genes including PAX2, BCL2, MYC, EGFR, PDGFA, SRY, and DNMT3A promoters.
Reason: Core molecular function well-supported by extensive biochemical and structural evidence. Crystal structures confirm zinc finger-DNA interactions [PMID:25258363]. This is a fundamental function of the -KTS isoform.
GO:0000981 DNA-binding transcription factor activity, RNA polymerase II-specific
IBA
GO_REF:0000033
ACCEPT
Summary: WT1 functions as both a transcriptional activator and repressor depending on target gene and cellular context. The -KTS isoform is the primary transcription factor form. WT1 activates genes like SRY, DNMT3A, and EPO, while repressing PAX2, BCL2, MYC, and EGFR [PMID:9815658, PMID:7720589, PMID:7585606, PMID:23042785].
Reason: Core molecular function. WT1's role as an RNA Pol II transcription factor is foundational to its developmental and tumor suppressor functions. The dual activator/repressor activity is isoform-dependent and context-dependent.
GO:0005634 nucleus
IBA
GO_REF:0000033
ACCEPT
Summary: WT1 is predominantly nuclear, consistent with its role as a transcription factor. Multiple IDA studies confirm nuclear localization [PMID:1662794, PMID:8306891, PMID:7588596]. Both -KTS and +KTS isoforms localize to the nucleus, though with different subnuclear distributions.
Reason: Core cellular component annotation well-supported by immunofluorescence and biochemical fractionation studies. Nuclear localization is essential for WT1's transcriptional regulatory function.
GO:0006357 regulation of transcription by RNA polymerase II
IBA
GO_REF:0000033
ACCEPT
Summary: WT1 regulates transcription of numerous target genes via RNA Pol II machinery. It can both activate and repress transcription depending on target and context. Documented targets include PAX2 (repression), BCL2/MYC (repression), DNMT3A (activation), EPO (activation), SRY (activation), and many others [PMID:23042785, PMID:7720589, PMID:7585606, PMID:9815658].
Reason: Core biological process. Transcriptional regulation is the primary function of WT1, underlying its roles in development and tumor suppression.
GO:0008285 negative regulation of cell population proliferation
IBA
GO_REF:0000033
ACCEPT
Summary: WT1 functions as a tumor suppressor and inhibits cell proliferation. This is mediated through transcriptional repression of growth-promoting genes like BCL2, MYC, and growth factor receptors, as well as through interaction with Hsp70 [PMID:9553041, PMID:7585606].
Reason: Well-supported tumor suppressor function. WT1 loss leads to uncontrolled proliferation in Wilms tumor. The antiproliferative effect is demonstrated through inducible expression studies [PMID:9553041].
GO:0043066 negative regulation of apoptotic process
IBA
GO_REF:0000033
KEEP AS NON CORE
Summary: WT1 has complex effects on apoptosis. While it represses BCL2 which would promote apoptosis [PMID:7585606], developmental studies show that WT1 is required for cell survival during nephrogenesis - Wt1 null embryos show apoptosis in the urogenital ridge [PMID:10101119].
Reason: WT1's role in apoptosis regulation is context-dependent and likely secondary to its primary transcriptional regulatory functions. The anti-apoptotic effect observed in development may reflect regulation of survival factors rather than direct apoptosis pathway involvement.
GO:0000122 negative regulation of transcription by RNA polymerase II
IEA
GO_REF:0000117
ACCEPT
Summary: WT1 functions as a transcriptional repressor for multiple target genes including PAX2, BCL2, MYC, EGFR, and AR [PMID:7720589, PMID:7585606, PMID:7588596, PMID:9815658]. This is a well-documented core function, particularly for the -KTS isoform.
Reason: Although this is an IEA annotation, transcriptional repression is extensively documented by experimental evidence. This represents a core molecular function.
GO:0003677 DNA binding
IEA
GO_REF:0000043
ACCEPT
Summary: WT1 contains four C2H2 zinc fingers that mediate DNA binding. This is a core molecular function, though the more specific term GO:0043565 (sequence-specific DNA binding) is preferable.
Reason: Valid annotation. While more specific terms exist (GO:0043565, GO:0000978), this general DNA binding annotation is correct and supported by extensive evidence.
GO:0003723 RNA binding
IEA
GO_REF:0000043
ACCEPT
Summary: The +KTS isoform of WT1 has documented RNA-binding activity. The zinc finger domain provides overlapping surfaces for DNA and RNA binding [bardeesy1998]. The +KTS isoform associates with splicing factors and participates in RNA processing [PMID:16934801].
Reason: Valid annotation for the +KTS isoform specifically. RNA binding is part of WT1's post-transcriptional regulatory functions. Note this is isoform-specific.
Supporting Evidence:
PMID:16934801
Epub 2006 Jul 25. WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo.
GO:0005634 nucleus
IEA
GO_REF:0000120
ACCEPT
Summary: Nuclear localization is well-established for WT1, consistent with its role as a transcription factor.
Reason: Duplicate of IBA annotation above. Nuclear localization is well-supported.
GO:0005654 nucleoplasm
IEA
GO_REF:0000044
ACCEPT
Summary: WT1 is present in the nucleoplasm. The -KTS isoform has a diffuse nuclear distribution [PMID:15520190], while +KTS localizes more to nuclear speckles.
Reason: Supported by localization studies. The -KTS isoform particularly shows nucleoplasmic distribution.
GO:0005730 nucleolus
IEA
GO_REF:0000044
UNDECIDED
Summary: UniProt indicates nucleolar localization. WT1 has been reported in various nuclear subcompartments.
Reason: Nucleolar localization is not prominently featured in the primary literature. The primary nuclear localizations are nucleoplasm (-KTS) and nuclear speckles (+KTS). This annotation may represent a minor or transient localization.
GO:0005737 cytoplasm
IEA
GO_REF:0000044
KEEP AS NON CORE
Summary: WT1 can shuttle between nucleus and cytoplasm. Cytoplasmic WT1 has been associated with polysome-bound mRNPs, supporting post-transcriptional roles.
Reason: While WT1 can be cytoplasmic, the primary localization and function is nuclear. Cytoplasmic localization may relate to RNA processing or shuttling.
GO:0006355 regulation of DNA-templated transcription
IEA
GO_REF:0000002
ACCEPT
Summary: WT1 is a transcription factor that regulates expression of numerous target genes. This is a core biological process annotation.
Reason: Core function. Equivalent to the more specific GO:0006357 (regulation of transcription by RNA Pol II).
GO:0008270 zinc ion binding
IEA
GO_REF:0000043
ACCEPT
Summary: WT1 contains four C2H2 zinc finger domains that coordinate zinc ions for structural integrity and DNA binding. Zinc binding is experimentally demonstrated [PMID:15518539, PMID:25258363].
Reason: Core molecular function. The zinc fingers are essential for DNA binding activity. Structural studies confirm zinc coordination [PMID:15518539].
GO:0016607 nuclear speck
IEA
GO_REF:0000044
ACCEPT
Summary: The +KTS isoform of WT1 localizes to nuclear speckles, which are sites of pre-mRNA splicing factor storage and modification [PMID:9553041, PMID:15520190, PMID:16934801].
Reason: Well-documented localization for the +KTS isoform, consistent with its role in RNA processing. Colocalization with RBM4 in speckles is demonstrated.
GO:0046872 metal ion binding
IEA
GO_REF:0000043
ACCEPT
Summary: WT1 binds zinc ions via its C2H2 zinc finger domains. This is correct but redundant with the more specific GO:0008270 (zinc ion binding).
Reason: Valid but less informative than GO:0008270. Both terms are appropriate.
GO:0072078 nephron tubule morphogenesis
IEA
GO_REF:0000117
ACCEPT
Summary: WT1 is essential for nephrogenesis. Wt1 knockout mice show complete failure of kidney development [PMID:10101119]. WT1 regulates genes required for nephron formation and glomerular development.
Reason: Well-supported developmental role. WT1 is required throughout nephrogenesis, including tubule formation. This is a core biological process for WT1.
GO:0072359 circulatory system development
IEA
GO_REF:0000117
KEEP AS NON CORE
Summary: WT1 is expressed in the epicardium and is required for heart development. Wt1 null mice die at E13.5 due to heart failure with pericardial bleeding [PMID:10101119].
Reason: Valid annotation but represents a secondary developmental role. The primary functions of WT1 are in kidney and gonad development. Heart involvement is through epicardial/mesothelial functions.
GO:1990837 sequence-specific double-stranded DNA binding
IEA
GO_REF:0000117
ACCEPT
Summary: WT1 binds sequence-specifically to double-stranded DNA containing the motif 5'-GCG(T/G)GGGCG-3'. Crystal structures confirm this binding mode [PMID:25258363].
Reason: Core molecular function. Equivalent to GO:0043565 which has experimental support.
GO:0005515 protein binding
IPI
PMID:19447967
Shifted Transversal Design smart-pooling for high coverage i...
KEEP AS NON CORE
Summary: High-throughput interaction study (Shifted Transversal Design smart-pooling). Interaction with DVL3 (Dishevelled 3) reported.
Reason: "Protein binding" is an uninformative term. The specific interaction partner (DVL3) is identified but functional significance for WT1 is unclear. Retain as evidence of protein interaction capacity but not informative about core function.
Supporting Evidence:
PMID:19447967
Shifted Transversal Design smart-pooling for high coverage interactome mapping.
GO:0005515 protein binding
IPI
PMID:21900206
A directed protein interaction network for investigating int...
KEEP AS NON CORE
Summary: High-throughput directed protein interaction network study. Interaction with DVL3.
Reason: Uninformative term from high-throughput study. The specific interaction (DVL3) lacks clear functional context for WT1 biology.
Supporting Evidence:
PMID:21900206
A directed protein interaction network for investigating intracellular signal transduction.
GO:0005515 protein binding
IPI
PMID:25416956
A proteome-scale map of the human interactome network.
KEEP AS NON CORE
Summary: Large-scale human interactome mapping study. Interactions with KRTAP10-8 and KRT40.
Reason: High-throughput study. Keratin-associated proteins are not obviously relevant to known WT1 biology. May represent non-specific interactions.
Supporting Evidence:
PMID:25416956
A proteome-scale map of the human interactome network.
GO:0005515 protein binding
IPI
PMID:25601757
WT1 recruits TET2 to regulate its target gene expression and...
MODIFY
Summary: WT1 recruits TET2 to regulate target gene expression and suppress leukemia cell proliferation. This represents a functionally important interaction.
Reason: This is a functionally significant interaction with TET2 (methylcytosine dioxygenase) involved in epigenetic regulation. The generic "protein binding" term does not capture the functional significance.
Supporting Evidence:
PMID:25601757
2015 Jan 15. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
GO:0005515 protein binding
IPI
PMID:27229929
Systematic interactome mapping of acute lymphoblastic leukem...
KEEP AS NON CORE
Summary: Interactome mapping of ALL cancer gene products. WT1-DVL3 interaction.
Reason: Uninformative term. Part of cancer gene product interactome study. DVL3 interaction functional significance unclear.
Supporting Evidence:
PMID:27229929
Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.
GO:0005515 protein binding
IPI
PMID:31515488
Extensive disruption of protein interactions by genetic vari...
KEEP AS NON CORE
Summary: Study of genetic variants disrupting protein interactions. Interaction with KRT40.
Reason: Uninformative term. Keratin interaction not obviously relevant to WT1 function.
Supporting Evidence:
PMID:31515488
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
GO:0005515 protein binding
IPI
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor supp...
MODIFY
Summary: WT1 interacts with Hsp70 (HSPA1A/HSPA1B). This is a functionally important interaction required for WT1's growth suppression activity [PMID:9553041].
Reason: Functionally significant interaction. Hsp70 binding is required for WT1 antiproliferative function. Should be annotated with a more specific term.
Proposed replacements: chaperone binding
Supporting Evidence:
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.
GO:0005515 protein binding
IPI
PMID:7720589
Repression of Pax-2 by WT1 during normal kidney development.
MODIFY
Summary: WT1 interacts with PAX2, its transcriptional target. The study demonstrates WT1 binding to PAX2 regulatory sequences and repression of PAX2 expression.
Reason: This represents DNA binding to PAX2 promoter rather than protein-protein interaction. The IPI annotation may be misattributed.
Supporting Evidence:
PMID:7720589
Repression of Pax-2 by WT1 during normal kidney development.
GO:0005515 protein binding
IPI
PMID:16934801
WT1 interacts with the splicing protein RBM4
MODIFY
Summary: WT1 interacts with RBM4, a splicing regulator. The +KTS isoform specifically modulates RBM4's effect on alternative splicing [PMID:16934801].
Reason: Functionally significant interaction related to WT1's RNA processing function. Should use a more specific MF term.
Supporting Evidence:
PMID:16934801
Epub 2006 Jul 25. WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo.
GO:0005515 protein binding
IPI
PMID:21390327
PINCH1 is transcriptional regulator in podocytes that intera...
KEEP AS NON CORE
Summary: WT1 interacts with PINCH1 (LIMS1). PINCH1 represses podocalyxin expression and interacts with WT1 in podocytes.
Reason: PINCH1 interaction is documented but the term "protein binding" is uninformative. The functional significance relates to podocyte gene regulation.
Supporting Evidence:
PMID:21390327
PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression.
GO:0005515 protein binding
IPI
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor...
MODIFY
Summary: WT1 interacts with BASP1, a transcriptional cosuppressor. BASP1 binding converts WT1 from an activator to a repressor at specific promoters.
Reason: Functionally important interaction that modulates WT1's transcriptional activity. BASP1 is a documented WT1 cofactor.
Supporting Evidence:
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1.
GO:0005515 protein binding
IPI
PMID:9178767
Differential regulation of the human Wilms tumour suppressor...
KEEP AS NON CORE
Summary: WT1 interacts with PAX2. PAX2 regulates WT1 promoter activity in a reciprocal regulatory relationship.
Reason: Documents interaction between two kidney development transcription factors. Generic term is uninformative.
Supporting Evidence:
PMID:9178767
Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2.
GO:0005515 protein binding
IPI
PMID:8119964
WT1 is negatively autoregulated
ACCEPT
Summary: WT1 can form homodimers and binds to its own promoter for autoregulation. The interaction is via the zinc finger domain (C2H2 zinc finger domain binding).
Reason: Documents WT1 homodimerization. Also annotated with GO:0070742 (C2H2 zinc finger domain binding) which is more specific.
Supporting Evidence:
PMID:8119964
The Wilms' tumor suppressor gene WT1 is negatively autoregulated.
GO:0005654 nucleoplasm
IDA
GO_REF:0000052
ACCEPT
Summary: HPA immunofluorescence data showing nucleoplasmic localization.
Reason: Supported by imaging data. Consistent with WT1's nuclear transcription factor function.
GO:0005829 cytosol
IDA
GO_REF:0000052
KEEP AS NON CORE
Summary: HPA immunofluorescence data indicating cytosolic presence.
Reason: WT1 can shuttle to cytoplasm but primary function is nuclear. Cytosolic localization may relate to shuttling or RNA processing functions.
GO:0008270 zinc ion binding
IDA
PMID:25258363
Wilms tumor protein recognizes 5-carboxylcytosine within a s...
ACCEPT
Summary: Crystal structure of WT1 zinc finger domain bound to DNA confirms zinc coordination in C2H2 zinc fingers [PMID:25258363].
Reason: Core molecular function confirmed by structural biology.
Supporting Evidence:
PMID:25258363
Sep 25. Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence.
GO:0010385 double-stranded methylated DNA binding
IDA
PMID:25258363
Wilms tumor protein recognizes 5-carboxylcytosine within a s...
ACCEPT
Summary: WT1 can bind to methylated DNA. The study shows WT1 has slightly higher affinity for 5mC-containing sequences compared to unmethylated, but much lower affinity for oxidized forms (5hmC, 5fC, 5caC) [PMID:25258363].
Reason: Directly demonstrated by biochemical and structural studies. This is a specialized aspect of WT1's DNA binding activity.
Supporting Evidence:
PMID:25258363
Sep 25. Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence.
GO:0043565 sequence-specific DNA binding
IDA
PMID:25258363
Wilms tumor protein recognizes 5-carboxylcytosine within a s...
ACCEPT
Summary: WT1 binds to the consensus sequence 5'-GCG(T/G)GGGCG-3' with high affinity and specificity [PMID:25258363, PMID:7862533].
Reason: Core molecular function demonstrated by multiple methods including gel shift, footprinting, and X-ray crystallography.
Supporting Evidence:
PMID:25258363
Sep 25. Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence.
GO:0044729 hemi-methylated DNA-binding
IDA
PMID:25258363
Wilms tumor protein recognizes 5-carboxylcytosine within a s...
ACCEPT
Summary: Study demonstrates WT1 can bind hemi-methylated DNA substrates [PMID:25258363].
Reason: Directly demonstrated in the structural/biochemical study.
Supporting Evidence:
PMID:25258363
Sep 25. Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence.
GO:0016607 nuclear speck
IDA
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor supp...
ACCEPT
Summary: WT1 localizes to nuclear speckles, particularly the +KTS isoform which colocalizes with splicing factors [PMID:9553041, PMID:16934801].
Reason: Isoform-specific localization related to RNA processing function.
Supporting Evidence:
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.
GO:0000978 RNA polymerase II cis-regulatory region sequence-specific DNA binding
IDA
PMID:23042785
Control of epigenetic states by WT1 via regulation of de nov...
ACCEPT
Summary: ChIP assays demonstrate WT1 recruitment to the DNMT3A promoter region [PMID:23042785].
Reason: Core molecular function demonstrated by chromatin immunoprecipitation.
Supporting Evidence:
PMID:23042785
Chromatin immunoprecipitation assays demonstrate WT1 recruitment to the DNMT3A promoter region
GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific
IDA
PMID:23042785
Control of epigenetic states by WT1 via regulation of de nov...
ACCEPT
Summary: WT1 directly transactivates DNMT3A expression. Reporter assays confirm transcriptional activation [PMID:23042785].
Reason: Core molecular function. WT1 activates transcription of multiple target genes including DNMT3A, EPO, and SRY.
Supporting Evidence:
PMID:23042785
reporter assays confirm that WT1 directly transactivates DNMT3A expression
GO:0005634 nucleus
IDA
PMID:16934801
WT1 interacts with the splicing protein RBM4
ACCEPT
Summary: Immunofluorescence shows nuclear localization of WT1 [PMID:16934801].
Reason: Duplicate of multiple other annotations. Nuclear localization is core.
Supporting Evidence:
PMID:16934801
Epub 2006 Jul 25. WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo.
GO:0016607 nuclear speck
IDA
PMID:16934801
WT1 interacts with the splicing protein RBM4
ACCEPT
Summary: WT1 colocalizes with RBM4 in nuclear speckles [PMID:16934801].
Reason: Consistent with +KTS isoform's role in RNA processing.
Supporting Evidence:
PMID:16934801
Epub 2006 Jul 25. WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo.
GO:0043565 sequence-specific DNA binding
IDA
PMID:7720589
Repression of Pax-2 by WT1 during normal kidney development.
ACCEPT
Summary: DNase I footprinting demonstrates WT1 binding to specific sites in the PAX2 promoter [PMID:7720589].
Reason: Core molecular function demonstrated by direct biochemical assay.
Supporting Evidence:
PMID:7720589
Repression of Pax-2 by WT1 during normal kidney development.
GO:0045892 negative regulation of DNA-templated transcription
IDA
PMID:7720589
Repression of Pax-2 by WT1 during normal kidney development.
ACCEPT
Summary: WT1 represses PAX2 transcription. Co-transfection assays demonstrate WT1-dependent transcriptional repression [PMID:7720589].
Reason: Core function. WT1 represses multiple target genes. PAX2 repression is important for kidney development.
Supporting Evidence:
PMID:7720589
Repression of Pax-2 by WT1 during normal kidney development.
GO:0000976 transcription cis-regulatory region binding
IDA
PMID:9815658
The Wilms' tumor gene WT1 can regulate genes involved in sex...
ACCEPT
Summary: EMSA shows WT1 binding to promoter elements of SRY, MIS, and androgen receptor genes [PMID:9815658].
Reason: Core molecular function demonstrated for multiple target gene promoters.
Supporting Evidence:
PMID:9815658
The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, MΓΌllerian-inhibiting substance, and the androgen receptor.
GO:0007530 sex determination
IDA
PMID:9815658
The Wilms' tumor gene WT1 can regulate genes involved in sex...
ACCEPT
Summary: WT1 regulates transcription of sex determination genes SRY, MIS, and androgen receptor [PMID:9815658]. Genital abnormalities in DDS patients and Wt1 knockout mice support this role.
Reason: Core biological process. WT1 is essential for gonadal development and sex determination, regulating key genes in the pathway.
Supporting Evidence:
PMID:9815658
The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, MΓΌllerian-inhibiting substance, and the androgen receptor.
GO:0043565 sequence-specific DNA binding
IDA
PMID:1662794
Characterization of the zinc finger protein encoded by the W...
ACCEPT
Summary: WT1 binds to the EGR consensus sequence in gel-retardation assays [PMID:1662794].
Reason: One of the earliest demonstrations of WT1's sequence-specific DNA binding.
Supporting Evidence:
PMID:1662794
Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:8132626
Transcriptional regulation of the human Wilms' tumor gene (W...
ACCEPT
Summary: WT1 activates transcription in certain contexts.
Reason: Core function. WT1 can act as both activator and repressor.
Supporting Evidence:
PMID:8132626
Transcriptional regulation of the human Wilms' tumor gene (WT1).
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:21390327
PINCH1 is transcriptional regulator in podocytes that intera...
ACCEPT
Summary: WT1 regulates podocalyxin expression in podocytes.
Reason: Supports WT1's role in podocyte gene regulation.
Supporting Evidence:
PMID:21390327
PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression.
GO:0008285 negative regulation of cell population proliferation
IDA
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor supp...
ACCEPT
Summary: Inducible WT1 expression inhibits cellular proliferation. This requires association with Hsp70 [PMID:9553041].
Reason: Core tumor suppressor function demonstrated by inducible expression studies.
Supporting Evidence:
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.
GO:0030308 negative regulation of cell growth
IDA
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor supp...
ACCEPT
Summary: WT1 inhibits cell growth [PMID:9553041].
Reason: Related to tumor suppressor function. Equivalent to GO:0008285.
Supporting Evidence:
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:9178767
Differential regulation of the human Wilms tumour suppressor...
REMOVE
Summary: PMID:9178767 investigates PAX2 regulation of the WT1 promoter, not WT1's transcriptional activity. The study shows "PAX2 transactivated the WT1 promoter up to 35-fold" - this is PAX2's function, not WT1's.
Reason: This annotation is incorrectly attributed. The referenced paper demonstrates that PAX2 activates WT1 transcription (PAX2 -> WT1), not that WT1 positively regulates other genes. This should be an annotation on PAX2, not WT1.
Supporting Evidence:
PMID:9178767
Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2.
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor supp...
ACCEPT
Summary: WT1 can activate transcription of certain target genes.
Reason: WT1 has dual activator/repressor function.
Supporting Evidence:
PMID:9553041
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.
GO:0000976 transcription cis-regulatory region binding
IDA
PMID:7588596
WT1 suppresses synthesis of the epidermal growth factor rece...
ACCEPT
Summary: WT1 binds to EGFR promoter elements [PMID:7588596].
Reason: Core molecular function for regulation of EGFR.
Supporting Evidence:
PMID:7588596
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
GO:0045892 negative regulation of DNA-templated transcription
IDA
P19544-1
PMID:9815658
The Wilms' tumor gene WT1 can regulate genes involved in sex...
ACCEPT
Summary: WT1 represses transcription of MIS and androgen receptor genes [PMID:9815658].
Reason: Core repressor function on sex determination genes.
Supporting Evidence:
PMID:9815658
The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, MΓΌllerian-inhibiting substance, and the androgen receptor.
GO:0008270 zinc ion binding
IDA
PMID:15518539
Why zinc fingers prefer zinc
ACCEPT
Summary: NMR structure of WT1 zinc fingers in complex with zinc [PMID:15518539].
Reason: Structural confirmation of zinc binding.
Supporting Evidence:
PMID:15518539
Why zinc fingers prefer zinc: ligand-field symmetry and the hidden thermodynamics of metal ion selectivity.
GO:0000976 transcription cis-regulatory region binding
IDA
PMID:1332065
Human platelet-derived growth factor A chain is transcriptio...
ACCEPT
Summary: WT1 binds to PDGFA promoter [PMID:1332065].
Reason: Core molecular function.
Supporting Evidence:
PMID:1332065
Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.
GO:0000976 transcription cis-regulatory region binding
IDA
PMID:7585606
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wil...
ACCEPT
Summary: WT1 binds to BCL2 and MYC promoter elements [PMID:7585606].
Reason: Core molecular function for tumor suppressor activity.
Supporting Evidence:
PMID:7585606
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
GO:0045892 negative regulation of DNA-templated transcription
IDA
PMID:1332065
Human platelet-derived growth factor A chain is transcriptio...
ACCEPT
Summary: WT1 represses PDGFA transcription.
Reason: Core repressor function.
Supporting Evidence:
PMID:1332065
Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.
GO:0045892 negative regulation of DNA-templated transcription
IDA
PMID:7585606
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wil...
ACCEPT
Summary: WT1 represses BCL2 and MYC transcription [PMID:7585606].
Reason: Core tumor suppressor function.
Supporting Evidence:
PMID:7585606
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
GO:0005634 nucleus
IDA
PMID:7588596
WT1 suppresses synthesis of the epidermal growth factor rece...
ACCEPT
Summary: Nuclear localization confirmed.
Reason: Duplicate annotation. Nuclear localization is core.
Supporting Evidence:
PMID:7588596
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
GO:0005634 nucleus
IDA
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor...
ACCEPT
Summary: Nuclear localization confirmed.
Reason: Duplicate annotation.
Supporting Evidence:
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1.
GO:0045892 negative regulation of DNA-templated transcription
IDA
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor...
ACCEPT
Summary: WT1 with BASP1 represses transcription [PMID:14701728].
Reason: Core function. BASP1 modulates WT1's repressor activity.
Supporting Evidence:
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1.
GO:0045892 negative regulation of DNA-templated transcription
IDA
PMID:19050011
Dynamic interaction between WT1 and BASP1 in transcriptional...
ACCEPT
Summary: Dynamic WT1-BASP1 interaction regulates transcription during differentiation.
Reason: Supports repressor function.
Supporting Evidence:
PMID:19050011
Dec 2. Dynamic interaction between WT1 and BASP1 in transcriptional regulation during differentiation.
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor...
ACCEPT
Summary: WT1 without BASP1 can activate transcription.
Reason: Dual activator/repressor function depends on cofactor context.
Supporting Evidence:
PMID:14701728
BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1.
GO:0008285 negative regulation of cell population proliferation
IDA
PMID:9765217
Induction of Rb-associated protein (RbAp46) by Wilms' tumor ...
ACCEPT
Summary: WT1 induces RbAp46 which mediates growth inhibition [PMID:9765217].
Reason: Tumor suppressor mechanism.
Supporting Evidence:
PMID:9765217
Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition.
GO:0030308 negative regulation of cell growth
IDA
PMID:9765217
Induction of Rb-associated protein (RbAp46) by Wilms' tumor ...
ACCEPT
Summary: WT1-induced growth inhibition via RbAp46.
Reason: Related to tumor suppressor function.
Supporting Evidence:
PMID:9765217
Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition.
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:9765217
Induction of Rb-associated protein (RbAp46) by Wilms' tumor ...
ACCEPT
Summary: WT1 activates RbAp46 transcription.
Reason: WT1 can activate transcription of certain targets.
Supporting Evidence:
PMID:9765217
Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition.
GO:0005634 nucleus
IDA
PMID:1662794
Characterization of the zinc finger protein encoded by the W...
ACCEPT
Summary: Immunofluorescence shows nuclear localization [PMID:1662794].
Reason: Core localization.
Supporting Evidence:
PMID:1662794
Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
GO:0005634 nucleus
IDA
PMID:8306891
Nuclear localization of the protein encoded by the Wilms' tu...
ACCEPT
Summary: Nuclear localization in embryonic and adult tissues.
Reason: Core localization.
Supporting Evidence:
PMID:8306891
Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues.
GO:0043565 sequence-specific DNA binding
IDA
PMID:8119964
WT1 is negatively autoregulated
ACCEPT
Summary: WT1 binds specifically to its own promoter for autoregulation.
Reason: Core molecular function.
Supporting Evidence:
PMID:8119964
The Wilms' tumor suppressor gene WT1 is negatively autoregulated.
GO:0045892 negative regulation of DNA-templated transcription
IDA
PMID:12802290
Upregulation of c-MYC in WT1-mutant tumors: assessment of WT...
ACCEPT
Summary: WT1 regulates c-MYC expression. c-MYC is upregulated in WT1-mutant tumors.
Reason: Core tumor suppressor mechanism.
Supporting Evidence:
PMID:12802290
Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
GO:0045892 negative regulation of DNA-templated transcription
IDA
PMID:8119964
WT1 is negatively autoregulated
ACCEPT
Summary: WT1 negatively autoregulates its own expression.
Reason: Autoregulatory repression.
Supporting Evidence:
PMID:8119964
The Wilms' tumor suppressor gene WT1 is negatively autoregulated.
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:12802290
Upregulation of c-MYC in WT1-mutant tumors: assessment of WT...
REMOVE
Summary: PMID:12802290 shows "c-MYC...was upregulated in WT1-mutant tumors", meaning WT1 normally represses c-MYC. The paper states WT1 "represses or activates the expression of a variety of putative target genes" but the specific finding for c-MYC supports repression.
Reason: This annotation contradicts the evidence in the referenced paper. PMID:12802290 demonstrates that c-MYC is upregulated when WT1 is mutated, indicating WT1 normally represses (not activates) c-MYC transcription. The negative regulation annotation from this paper is correct; this positive regulation annotation is erroneous.
Supporting Evidence:
PMID:12802290
Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
GO:0070742 C2H2 zinc finger domain binding
IPI
PMID:8119964
WT1 is negatively autoregulated
ACCEPT
Summary: WT1 homodimerizes via zinc finger domains.
Reason: Specific molecular function for homodimerization.
Supporting Evidence:
PMID:8119964
The Wilms' tumor suppressor gene WT1 is negatively autoregulated.
GO:0016607 nuclear speck
IDA
P19544-1
PMID:15520190
SUMO-1 modification of the Wilms' tumor suppressor WT1.
ACCEPT
Summary: +KTS isoform (isoform 1) localizes to nuclear speckles [PMID:15520190].
Reason: Isoform-specific localization related to RNA processing.
Supporting Evidence:
PMID:15520190
SUMO-1 modification of the Wilms' tumor suppressor WT1.
GO:0000976 transcription cis-regulatory region binding
IDA
PMID:16467207
Wilms tumor suppressor, Wt1, is a transcriptional activator ...
ACCEPT
Summary: WT1 binds to erythropoietin (EPO) gene promoter [PMID:16467207].
Reason: Core molecular function for EPO regulation.
Supporting Evidence:
PMID:16467207
Feb 7. Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene.
GO:0045893 positive regulation of DNA-templated transcription
IDA
PMID:16467207
Wilms tumor suppressor, Wt1, is a transcriptional activator ...
ACCEPT
Summary: WT1 activates EPO gene transcription [PMID:16467207].
Reason: Core activator function.
Supporting Evidence:
PMID:16467207
Feb 7. Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene.
GO:0000122 negative regulation of transcription by RNA polymerase II
IDA
PMID:7585606
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wil...
ACCEPT
Summary: WT1 represses BCL2 and MYC via RNA Pol II [PMID:7585606].
Reason: Core repressor function.
Supporting Evidence:
PMID:7585606
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
GO:0044027 negative regulation of gene expression via chromosomal CpG island methylation
IMP
PMID:23042785
Control of epigenetic states by WT1 via regulation of de nov...
ACCEPT
Summary: WT1 regulates DNMT3A, leading to DNA methylation changes at specific promoters. WT1 overexpression causes hypermethylation and silencing [PMID:23042785].
Reason: Novel regulatory function linking WT1 to epigenetic regulation via DNMT3A. Well-supported by the study.
Supporting Evidence:
PMID:23042785
human embryonal kidney cells over-expressing WT1 acquire DNA methylation changes at specific gene promoters where DNMT3A recruitment is increased, with hypermethylation being associated with silencing of gene expression
GO:0000122 negative regulation of transcription by RNA polymerase II
IMP
PMID:23042785
Control of epigenetic states by WT1 via regulation of de nov...
ACCEPT
Summary: WT1 depletion affects transcription of methylated genes.
Reason: Supported by knockdown studies in the paper.
Supporting Evidence:
PMID:23042785
depletion of WT1 in Wilms' tumour cells can lead to reactivation of gene expression from methylated promoters
GO:0010628 positive regulation of gene expression
IMP
PMID:23042785
Control of epigenetic states by WT1 via regulation of de nov...
ACCEPT
Summary: WT1 positively regulates DNMT3A expression.
Reason: Direct evidence from the study.
Supporting Evidence:
PMID:23042785
depletion of WT1 by short-interfering RNAs leads to reduced DNMT3A in Wilms' tumour cells
GO:0045944 positive regulation of transcription by RNA polymerase II
IDA
PMID:23042785
Control of epigenetic states by WT1 via regulation of de nov...
ACCEPT
Summary: WT1 activates DNMT3A transcription.
Reason: Core activator function demonstrated by reporter assays.
Supporting Evidence:
PMID:23042785
Wilms' tumour 1 (WT1), a developmental master regulator that can also act as a tumour suppressor or oncoprotein, transcriptionally regulates the de novo DNA methyltransferase 3A (DNMT3A)
GO:1902895 positive regulation of miRNA transcription
IMP
PMID:23042785
Control of epigenetic states by WT1 via regulation of de nov...
UNDECIDED
Summary: WT1 may regulate miRNA transcription through DNMT3A-mediated epigenetic effects.
Reason: The PMID:23042785 paper focuses on DNMT3A regulation. The connection to miRNA transcription is not directly documented in the abstract. Need to verify this specific claim.
Supporting Evidence:
PMID:23042785
Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A.
GO:0032836 glomerular basement membrane development
IMP
PMID:19205749
Membranoproliferative glomerulonephritis associated with a m...
ACCEPT
Summary: WT1 mutation associated with glomerular defects.
Reason: WT1 is essential for podocyte function and glomerular development. Mutations cause glomerular disease.
Supporting Evidence:
PMID:19205749
2009 Feb 11. Membranoproliferative glomerulonephritis associated with a mutation in Wilms' tumour suppressor gene 1.
GO:0007507 heart development
IGI
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
KEEP AS NON CORE
Summary: Wt1 knockout mice show heart defects with pericardial bleeding. YAC rescue experiments demonstrate WT1 requirement for heart development [PMID:10101119].
Reason: Valid developmental role but secondary to kidney/gonad functions. Heart involvement is through epicardial development.
Supporting Evidence:
PMID:10101119
Lack of WT1 leads to severe defects in the epicardial layer and a concomitant absence of SEMCs, which explains the pericardial bleeding and subsequent embryonic death observed in Wt1 null embryos
GO:0030325 adrenal gland development
IGI
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
KEEP AS NON CORE
Summary: Partially rescued Wt1 mutant embryos show severely affected adrenal gland development [PMID:10101119].
Reason: Valid developmental role but less prominent than kidney/gonad. Related to WT1's role in intermediate mesoderm-derived organs.
Supporting Evidence:
PMID:10101119
the development of adrenal glands is also severely affected in partially rescued embryos
GO:0072284 metanephric S-shaped body morphogenesis
IGI
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
ACCEPT
Summary: WT1 required for nephron morphogenesis including S-shaped body stage.
Reason: Core kidney development function.
Supporting Evidence:
PMID:10101119
Analysis of the observed hypoplastic kidneys demonstrate a continuous requirement for WT1 during nephrogenesis, in particular, in the formation of mature glomeruli
GO:0061032 visceral serous pericardium development
IGI
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
KEEP AS NON CORE
Summary: WT1 is expressed in epicardium and required for its development.
Reason: Valid but secondary to kidney/gonad roles.
Supporting Evidence:
PMID:10101119
WT1 is expressed in the early proepicardium, the epicardium and the subepicardial mesenchymal cells (SEMC)
GO:0001658 branching involved in ureteric bud morphogenesis
IGI
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
ACCEPT
Summary: WT1 regulates ureteric bud development.
Reason: Core kidney development function.
Supporting Evidence:
PMID:10101119
a general requirement for this protein in the formation of organs derived from the intermediate mesoderm
GO:0001822 kidney development
IGI
PMID:11912180
WT1 is a key regulator of podocyte function
ACCEPT
Summary: Reduced WT1 levels cause crescentic glomerulonephritis or mesangial sclerosis depending on dosage. WT1 regulates podocyte genes nphs1 and podocalyxin [PMID:11912180].
Reason: Core biological process. WT1 is essential for all stages of kidney development and podocyte maintenance.
Supporting Evidence:
PMID:11912180
WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.
GO:0032835 glomerulus development
IGI
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
ACCEPT
Summary: WT1 required for mature glomeruli formation.
Reason: Core kidney development function.
Supporting Evidence:
PMID:10101119
a continuous requirement for WT1 during nephrogenesis, in particular, in the formation of mature glomeruli
GO:0043066 negative regulation of apoptotic process
IGI
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
KEEP AS NON CORE
Summary: WT1 prevents apoptosis in developing kidney/epicardium.
Reason: Likely secondary to WT1's role in regulating survival genes.
Supporting Evidence:
PMID:10101119
YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.
GO:0045893 positive regulation of DNA-templated transcription
IGI
PMID:11912180
WT1 is a key regulator of podocyte function
ACCEPT
Summary: WT1 activates podocyte-specific genes like nphs1 and podocalyxin.
Reason: Core function in podocyte gene regulation.
Supporting Evidence:
PMID:11912180
WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.
GO:0072207 metanephric epithelium development
IEP
PMID:7856737
Comparative in situ hybridization analysis of PAX2, PAX8, an...
ACCEPT
Summary: WT1 expressed in developing metanephric epithelium, consistent with role.
Reason: Expression pattern supports functional role in kidney development.
Supporting Evidence:
PMID:7856737
Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors.
GO:0071320 cellular response to cAMP
IEP
PMID:15961562
Expression, regulation, and function of paired-box gene 8 in...
KEEP AS NON CORE
Summary: WT1 expression regulated by cAMP signaling in placenta.
Reason: IEP evidence only. Expression response to cAMP does not indicate direct function in cAMP signaling pathway.
Supporting Evidence:
PMID:15961562
Jun 16. Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines.
GO:0071371 cellular response to gonadotropin stimulus
IDA
PMID:15961562
Expression, regulation, and function of paired-box gene 8 in...
KEEP AS NON CORE
Summary: WT1 expression responsive to gonadotropin in placenta.
Reason: Placental expression context. Not a core function but reflects tissue-specific regulation.
Supporting Evidence:
PMID:15961562
Jun 16. Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines.
GO:0008584 male gonad development
IEP
PMID:17848411
Developmental changes in human fetal testicular cell numbers...
ACCEPT
Summary: WT1 expressed during fetal testis development.
Reason: Supports core role in gonad development. Expression pattern is consistent with functional requirement.
Supporting Evidence:
PMID:17848411
Epub 2007 Sep 11. Developmental changes in human fetal testicular cell numbers and messenger ribonucleic acid levels during the second trimester.
GO:0005634 nucleus
IDA
PMID:15961562
Expression, regulation, and function of paired-box gene 8 in...
ACCEPT
Summary: Nuclear localization in placental cells.
Reason: Consistent with nuclear localization in all tissues.
Supporting Evidence:
PMID:15961562
Jun 16. Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines.
GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific
ISS
GO_REF:0000024
ACCEPT
Summary: Transfer from mouse WT1. Well-supported by direct human evidence.
Reason: Human WT1 has documented transcription activator activity (IDA evidence exists).
GO:0003700 DNA-binding transcription factor activity
ISS
GO_REF:0000024
ACCEPT
Summary: Transfer from mouse WT1. Core function.
Reason: Well-supported by human experimental evidence.
GO:2001076 positive regulation of metanephric ureteric bud development
ISS
GO_REF:0000024
ACCEPT
Summary: Transfer from mouse knockout studies.
Reason: Consistent with human WT1's role in kidney development.
GO:0007356 thorax and anterior abdomen determination
ISS
GO_REF:0000024
REMOVE
Summary: Transfer from mouse. This is a Drosophila-centric term.
Reason: This GO term is specific to Drosophila body segmentation. Not applicable to mammalian WT1 biology. Likely annotation error.
GO:0008406 gonad development
ISS
GO_REF:0000024
ACCEPT
Summary: Transfer from mouse knockout studies. Core function.
Reason: Well-supported by human genetics (DDS, Frasier syndrome).
GO:0060421 positive regulation of heart growth
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: Transfer from mouse. Heart involvement via epicardium.
Reason: Valid but secondary to kidney/gonad roles.
GO:0060539 diaphragm development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: Transfer from mouse. WT1 mutations cause Meacham syndrome with diaphragm defects.
Reason: Documented in Meacham syndrome but not core function.
GO:0072075 metanephric mesenchyme development
ISS
GO_REF:0000024
ACCEPT
Summary: Transfer from mouse. Core kidney development function.
Reason: WT1 essential for metanephric mesenchyme development and MET.
GO:0035802 adrenal cortex formation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: Transfer from mouse. Adrenal development affected in Wt1 mutants.
Reason: Valid but secondary developmental role.
GO:0060923 cardiac muscle cell fate commitment
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: Transfer from mouse. Epicardial progenitor role.
Reason: Secondary to kidney/gonad functions.
GO:0001570 vasculogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: Transfer from mouse. Related to epicardial/heart development.
Reason: Secondary developmental role.
GO:0001657 ureteric bud development
ISS
GO_REF:0000024
ACCEPT
Summary: Core kidney development function.
Reason: Essential for nephrogenesis.
GO:0003156 regulation of animal organ formation
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: Generic term for developmental regulation.
Reason: Overly broad term. More specific terms for kidney, gonad, heart development are more appropriate.
GO:0005737 cytoplasm
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: WT1 can be cytoplasmic but primarily nuclear.
Reason: Minor localization compared to nucleus.
GO:0006355 regulation of DNA-templated transcription
ISS
GO_REF:0000024
ACCEPT
Summary: Core function.
Reason: Well-supported by human evidence.
GO:0006357 regulation of transcription by RNA polymerase II
ISS
GO_REF:0000024
ACCEPT
Summary: Core function.
Reason: Well-supported by human evidence.
GO:0007281 germ cell development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: WT1 role in germ cell development via gonad function.
Reason: Related to gonad development but indirect.
GO:0008380 RNA splicing
ISS
GO_REF:0000024
ACCEPT
Summary: +KTS isoform participates in RNA processing/splicing, interacting with RBM4 and other splicing factors [PMID:16934801].
Reason: Isoform-specific function of +KTS variant.
GO:0009888 tissue development
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: Generic developmental term.
Reason: Too broad. More specific terms exist.
GO:0030539 male genitalia development
ISS
GO_REF:0000024
ACCEPT
Summary: WT1 required for male genital development. DDS patients have genital abnormalities.
Reason: Core function in sex development.
GO:0030855 epithelial cell differentiation
ISS
GO_REF:0000024
ACCEPT
Summary: WT1 drives mesenchymal-to-epithelial transition in nephrogenesis.
Reason: Core function in kidney development.
GO:0043010 camera-type eye development
ISS
GO_REF:0000024
REMOVE
Summary: Eye involvement in WAGR syndrome includes aniridia, but that is due to PAX6.
Reason: WT1 is not the cause of eye defects in WAGR syndrome - that is due to contiguous deletion including PAX6. This appears to be an annotation error.
GO:0060231 mesenchymal to epithelial transition
ISS
GO_REF:0000024
ACCEPT
Summary: Core function in nephrogenesis. WT1 required for MET during kidney development.
Reason: Well-documented developmental function.
GO:0072166 posterior mesonephric tubule development
ISS
GO_REF:0000024
ACCEPT
Summary: WT1 required for mesonephric development.
Reason: Part of urogenital development.
GO:0072302 negative regulation of metanephric glomerular mesangial cell proliferation
ISS
GO_REF:0000024
ACCEPT
Summary: WT1 regulates mesangial cell proliferation. Reduced WT1 causes mesangial sclerosis.
Reason: Consistent with podocyte/glomerular function.
GO:2000020 positive regulation of male gonad development
ISS
GO_REF:0000024
ACCEPT
Summary: WT1 activates SRY and promotes male gonad development.
Reason: Core function in sex determination.
GO:2000195 negative regulation of female gonad development
ISS
GO_REF:0000024
UNDECIDED
Summary: WT1 promotes male development, which indirectly suppresses female pathway.
Reason: The relationship is complex. WT1 is required for gonad development of both sexes. The negative regulation of female gonad development may be overstated.
GO:0072112 podocyte differentiation
ISS
GO_REF:0000024
ACCEPT
Summary: WT1 essential for podocyte differentiation and maintenance.
Reason: Core function. WT1 regulates podocyte-specific genes (nphs1, podocalyxin) [PMID:11912180].
GO:0005654 nucleoplasm
TAS
Reactome:R-HSA-9767700
ACCEPT
Summary: Reactome pathway annotation. WT1 binds CDH1 gene promoter.
Reason: Consistent with nuclear localization.
GO:0003700 DNA-binding transcription factor activity
NAS
PMID:7862533
High affinity binding sites for the Wilms' tumour suppressor...
ACCEPT
Summary: Review article documenting WT1 as transcription factor.
Reason: Core function with extensive experimental support.
Supporting Evidence:
PMID:7862533
High affinity binding sites for the Wilms' tumour suppressor protein WT1.
GO:0006355 regulation of DNA-templated transcription
NAS
PMID:7862533
High affinity binding sites for the Wilms' tumour suppressor...
ACCEPT
Summary: Core function from review.
Reason: Well-supported.
Supporting Evidence:
PMID:7862533
High affinity binding sites for the Wilms' tumour suppressor protein WT1.
GO:0003700 DNA-binding transcription factor activity
NAS
PMID:8393820
The WT1 Wilms tumor gene product: a developmentally regulate...
ACCEPT
Summary: Review characterizing WT1 as transcription factor.
Reason: Core function.
Supporting Evidence:
PMID:8393820
The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
GO:0006355 regulation of DNA-templated transcription
NAS
PMID:8393820
The WT1 Wilms tumor gene product: a developmentally regulate...
ACCEPT
Summary: Core function from review.
Reason: Well-supported.
Supporting Evidence:
PMID:8393820
The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
GO:0003344 pericardium morphogenesis
TAS
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
NEW
Summary: WT1 is expressed in proepicardium and epicardium. Wt1 null mice die at E13.5 due to heart failure from defective epicardial development. YAC complementation studies demonstrate continuous requirement for WT1 in epicardial/pericardial development.
Reason: Well-supported by knockout studies showing WT1 is essential for epicardial development. The epicardium is the visceral layer of the pericardium.
Supporting Evidence:
PMID:10101119
YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.
file:human/WT1/WT1-deep-research-cyberian.md
GO:0060317 cardiac epithelial to mesenchymal transition
TAS
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
NEW
Summary: WT1 is required for epicardial epithelial-to-mesenchymal transition (EMT) that generates cardiovascular progenitor cells. WT1 regulates epicardial EMT through Wnt/beta-catenin signaling and retinoic acid signaling via direct Raldh2 regulation.
Reason: WT1 drives EMT in epicardium (opposite to MET in kidney), generating cardiac fibroblasts, vascular smooth muscle cells, and coronary endothelial cells.
Supporting Evidence:
PMID:10101119
YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.
file:human/WT1/WT1-deep-research-cyberian.md
GO:0060947 cardiac vascular smooth muscle cell differentiation
TAS
PMID:10101119
YAC complementation shows a requirement for Wt1 in the devel...
NEW
Summary: Epicardial EMT driven by WT1 generates cardiac vascular smooth muscle cells that contribute to coronary vasculature formation. Wt1 null mice show impaired coronary plexus formation.
Reason: WT1-dependent epicardial EMT produces vascular smooth muscle cells for coronary vessels.
Supporting Evidence:
PMID:10101119
YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.
file:human/WT1/WT1-deep-research-cyberian.md
GO:0045893 positive regulation of DNA-templated transcription
IDA NOT
P19544-1
PMID:9815658
The Wilms' tumor gene WT1 can regulate genes involved in sex...
ACCEPT
Summary: The +KTS isoform (P19544-1) does NOT activate transcription. PMID:9815658 shows the SRY promoter was strongly activated by WT1(-KTS) isoforms but was NOT activated by WT1(+KTS) isoforms. The +KTS tripeptide insertion alters DNA binding capability. This is a classic example of isoform-specific function where the two splice variants have opposite activities.
Reason: Well-documented isoform-specific NOT annotation. The +KTS isoform lacks transcriptional activation ability that the -KTS isoform possesses, due to altered DNA binding from the KTS insertion. This is a paradigm case of functional divergence between splice isoforms.
Supporting Evidence:
PMID:9815658
by the WT1 isoforms without the KTS tripeptide, WT1(-)KTS, but was not activated by the WT1 isoforms with the KTS tripeptide, WT1(+)KTS, in all cells tested

Core Functions

Sequence-specific DNA-binding transcription factor (-KTS isoform) that regulates kidney development by activating podocyte-specific genes (nphs1, podocalyxin) and repressing PAX2 during mesenchymal-to-epithelial transition. Binds the 5'-GCG(T/G)GGGCG-3' consensus motif via C2H2 zinc fingers.

Transcription factor (-KTS isoform) that regulates gonad development and sex determination by activating SRY and regulating MIS/AMH and androgen receptor expression. Isoform-specific activity is critical as Frasier syndrome results from splice site mutations altering +KTS/-KTS ratio.

Transcriptional repressor (-KTS isoform) that suppresses cell proliferation by repressing growth-promoting genes including BCL2, MYC, PDGFA, and EGFR. Growth suppression requires Hsp70 association. Loss-of-function mutations cause Wilms tumor.

RNA-binding protein (+KTS isoform) that participates in post-transcriptional regulation. Localizes to nuclear speckles where it interacts with splicing factors (U2AF65, RBM4) and modulates alternative splicing. ZnF1 is more important for RNA binding than DNA binding. The +KTS isoform has reduced DNA-binding affinity due to the three amino acid insertion between zinc fingers 3 and 4 which increases linker flexibility and abolishes ZnF4 DNA contact.

Molecular Function:
RNA binding
Directly Involved In:
Cellular Locations:

Transcription factor required for epicardial epithelial-to-mesenchymal transition (EMT) during heart development. Expressed in proepicardium and epicardium, WT1 regulates EMT through Wnt/beta-catenin signaling (via Lef1, Ctnnb1), non-canonical Wnt5a signaling, and retinoic acid signaling (via direct Raldh2 regulation). Epicardial EMT generates cardiac fibroblasts, vascular smooth muscle cells, and coronary endothelial cells. WT1 null embryos die at E13.5 due to heart failure from defective epicardium.

Supporting Evidence:

References

Gene Ontology annotation through association of InterPro records with GO terms
Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity
Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping
Gene Ontology annotation based on curation of immunofluorescence data
Electronic Gene Ontology annotations created by ARBA machine learning models
Combined Automated Annotation using Multiple IEA Methods
YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.
  • WT1 expressed in proepicardium, epicardium, and subepicardial mesenchymal cells
    "Using a lacZ reporter gene inserted into a YAC construct, we demonstrate that WT1 is expressed in the early proepicardium, the epicardium and the subepicardial mesenchymal cells (SEMC)."
  • Wt1 null mice die at E13.5 due to heart failure
    "Knock-out mice were shown to have defects in the urogenital system and to die at embryonic day E13.5, probably due to heart failure."
  • Continuous requirement for WT1 during nephrogenesis
    "Analysis of the observed hypoplastic kidneys demonstrate a continuous requirement for WT1 during nephrogenesis, in particular, in the formation of mature glomeruli."
  • Adrenal gland development severely affected
    "Finally, we show that the development of adrenal glands is also severely affected in partially rescued embryos."
WT1 is a key regulator of podocyte function
  • Reduced WT1 causes crescentic glomerulonephritis or mesangial sclerosis
    "we demonstrate that reduced expression levels of WT1 result in either crescentic glomerulonephritis or mesangial sclerosis depending on the gene dosage."
  • WT1 regulates nphs1 and podocalyxin expression
    "Strikingly, the two podocyte-specific genes nphs1 and podocalyxin are dramatically downregulated in mice with decreased levels of Wt1, suggesting that these two genes act downstream of Wt1."
Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.
  • WT1 represses PDGFA transcription
    "WT1 bound to several sites in this region of the promoter, as demonstrated by gel-shift analysis and DNase I footprinting, and functioned as a powerful repressor of PDGF-A transcription in vivo."
BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1.
  • BASP1 interacts with WT1
    "WT1 and BASP1 associate within the nuclei of cells that naturally express both proteins."
  • BASP1 converts WT1 from activator to repressor
    "BASP1 can confer WT1 cosuppressor activity in transfection assays, and elimination of endogenous BASP1 expression augments transcriptional activation by WT1."
Why zinc fingers prefer zinc
  • NMR structure of WT1 zinc fingers with zinc
SUMO-1 modification of the Wilms' tumor suppressor WT1.
  • +KTS isoform localizes to nuclear speckles
  • -KTS isoform has diffuse nuclear distribution
Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
  • WT1 binds EGR consensus sequence
  • Nuclear localization demonstrated
Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene.
  • WT1 activates EPO gene transcription
WT1 interacts with the splicing protein RBM4
  • WT1 interacts with RBM4
    "Here we show that WT1 interacts with the novel splicing regulator RBM4."
  • +KTS isoform modulates RBM4 splicing activity
    "We found that overexpressed WT1(+KTS) abrogated this effect of RBM4 on splice-site selection, whereas WT1(-KTS) did not. We conclude that the (+KTS) form of WT1 is able to inhibit the effect of RBM4 on alternative splicing."
  • Colocalization in nuclear speckles
    "Each protein was found to colocalize in nuclear speckles and to cosediment with supraspliceosomes in glycerol gradients."
Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A.
  • WT1 transactivates DNMT3A expression
    "We demonstrate that depletion of WT1 by short-interfering RNAs leads to reduced DNMT3A in Wilms' tumour cells and human embryonal kidney-derived cell lines."
  • WT1 recruited to DNMT3A promoter by ChIP
    "Chromatin immunoprecipitation assays demonstrate WT1 recruitment to the DNMT3A promoter region and reporter assays confirm that WT1 directly transactivates DNMT3A expression."
  • WT1 overexpression causes promoter methylation changes
    "Using genome-wide promoter methylation arrays, we show that human embryonal kidney cells over-expressing WT1 acquire DNA methylation changes at specific gene promoters where DNMT3A recruitment is increased, with hypermethylation being associated with silencing of gene expression."
Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence
  • WT1 binds 5'-GCG(T/G)GGGCG-3' motif
    "Consequently, WT1 binds the same consensus sequence as Egr1/Zif268 (Stoll et al. 2007)"
  • High affinity for unmethylated and 5mC-containing DNA
    "Egr1/Zif268 and WT1 showed slightly higher affinity for the fully methylated sequence by factors of ∼2.8 (Egr1) and ∼1.8 (WT1)"
  • Lower affinity for oxidized forms (5hmC, 5fC, 5caC)
    "Both displayed high affinity for the sequence when C or 5 mC was present and much reduced affinity when 5 hmC or 5 fC was present"
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
  • WT1 represses BCL2 and MYC transcription
    "We found that WT1 can repress transcription of both the bcl-2 and c-myc promoters. This suggests that WT1 regulates bcl-2 and c-myc during renal development, and the loss of functional WT1 results in deregulation of bcl-2 and c-myc, contributing to tumor formation."
Repression of Pax-2 by WT1 during normal kidney development.
  • WT1 binds PAX2 promoter elements
    "Binding of WT1 to three high affinity sites in the 5' untranslated Pax-2 leader sequence was demonstrated by DNAseI footprinting analysis."
  • WT1-dependent transcriptional repression of PAX2
    "Furthermore, co-transfection assays using CAT reporter constructs under the control of Pax-2 regulatory sequences demonstrated WT1-dependent transcriptional repression."
High affinity binding sites for the Wilms' tumour suppressor protein WT1.
  • Characterized WT1 DNA-binding consensus
WT1 is negatively autoregulated
  • WT1 represses its own transcription
  • WT1 homodimerization via zinc fingers
The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
  • Review of WT1 function in development and cancer
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.
  • WT1 interacts with Hsp70
    "By immunoprecipitation and protein microsequencing analysis, we have identified a major cellular protein associated with endogenous WT1 to be the inducible chaperone Hsp70."
  • Hsp70 required for WT1 antiproliferative function
    "These observations indicate that Hsp70 is an important cofactor for the function of WT1, and suggest a potential role for this chaperone during kidney differentiation."
  • WT1 localizes to nuclear speckles
    "Hsp70 is recruited to the characteristic subnuclear clusters that contain WT1."
The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, MΓΌllerian-inhibiting substance, and the androgen receptor.
  • WT1 activates SRY promoter
    "SRY (the sex-determining region of the Y chromosome) promoter was strongly activated by the WT1 isoforms without the KTS tripeptide, WT1(-)KTS, but was not activated by the WT1 isoforms with the KTS tripeptide, WT1(+)KTS, in all cells tested."
  • WT1 represses MIS and androgen receptor
    "The MΓΌAdullerian-inhibiting substance (MIS) promoter was strongly repressed by WT1(-)KTS isoforms and more weakly repressed by the WT1(+)KTS isoforms in Sertoli cells but not in HeLa cells."
  • Isoform-specific effects (-KTS vs +KTS)
    "The second alternative splicing site, which inserts the tripeptide KTS, alters the DNA binding capability."
Shifted Transversal Design smart-pooling for high coverage interactome mapping.
A directed protein interaction network for investigating intracellular signal transduction.
A proteome-scale map of the human interactome network.
WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression.
  • PINCH1 interacts with WT1 via LIM1 domain and zinc-finger domain
Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2.
Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter.
WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
  • WT1 represses PDGF-A transcription
Dynamic interaction between WT1 and BASP1 in transcriptional regulation during differentiation.
Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition.
  • WT1 inhibits cell proliferation
Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues.
  • WT1 localizes to nucleus
Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Membranoproliferative glomerulonephritis associated with a mutation in Wilms' tumour suppressor gene 1.
  • WT1 role in glomerular basement membrane development
Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors.
  • WT1 expression during kidney development
Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines.
  • WT1 response to gonadotropin stimulus
  • WT1 response to cAMP
Developmental changes in human fetal testicular cell numbers and messenger ribonucleic acid levels during the second trimester.
  • WT1 expression in male gonad development
Reactome:R-HSA-9767700
Reactome pathway annotation
file:human/WT1/WT1-deep-research-falcon.md
Deep research report (falcon provider) - WT1 functional annotation
  • WT1 contains four C2H2 zinc fingers mediating high-affinity binding to GC-rich motifs such as 5'-GCG(T/G)GGGCG-3' in target promoters/enhancers
    "Domain architecture and nucleic-acid interactions: WT1 contains four C2H2 zinc fingers (exons 7-10) mediating high-affinity binding to GC-rich motifs such as 5'-GCG(T/G)GGGCG-3' in target promoters/enhancers"
  • The -KTS isoform binds DNA sequence-specifically and drives transcriptional programs, while +KTS shows low DNA affinity and has RNA-binding/processing roles
    "The -KTS isoform binds DNA sequence-specifically and drives transcriptional programs, whereas the +KTS isoform shows low DNA affinity, associates with spliceosomal components, and has RNA-binding/processing roles"
  • WT1(+KTS) co-localizes with splicing speckles and interacts with splicing factors U2AF65 and WTAP
    "WT1(+KTS) co-localizes with splicing speckles, interacts with splicing factors (U2AF65, WTAP), forms complexes with ZNF255 and BASP1 that participate in RNA maturation"
  • WT1 is essential for nephron development and adult podocyte integrity
    "Nephrogenesis and podocyte maintenance: WT1 binds and regulates kidney lineage and podocyte genes and is essential for nephron development and adult podocyte integrity"
  • WT1 mRNA is overexpressed in >80% of AML and used for MRD monitoring
    "WT1 mRNA is overexpressed in >80% of AML; standardized ELN qRT-PCR thresholds are widely used for MRD risk stratification and post-transplant surveillance"
file:human/WT1/WT1-deep-research-cyberian.md
Deep research report (cyberian provider) - WT1 comprehensive functional analysis
  • WT1 zinc fingers 2-4 insert into major groove for base-specific DNA contacts; ZnF1 amplifies affinity without contributing to sequence specificity
    "The second, third, and fourth zinc finger domains insert deep into the major groove of DNA where they make base-specific contacts. Zinc fingers 2 and 3 are primarily responsible for most of the binding affinity and can function as a minimal DNA binding domain, while zinc finger 4 is indispensable for target specificity"
  • WT1-DNA binding has Kd of 1.14 x 10^-9 M and is entropy-driven, unlike EGR1
    "Quantitative binding studies have demonstrated that recombinant WT1 zinc fingers bind to the dodecamer DNA sequence GCG-TGG-GCG-TGT with high affinity, exhibiting a dissociation constant (Kd) of 1.14 x 10^-9 M under physiological conditions. Thermodynamic analysis revealed that WT1-DNA interaction is an entropy-driven process"
  • KTS insertion increases linker flexibility between ZnF3-4, abolishing ZnF4 DNA contact
    "The molecular basis for the functional differences between +KTS and -KTS isoforms was elucidated by NMR structural studies demonstrating that the KTS insertion increases the flexibility of the linker between fingers 3 and 4, abrogating the binding of the fourth zinc finger to its cognate site in the DNA major groove"
  • Normal +KTS/-KTS ratio is 2:1; Frasier syndrome results from altered ratio to 1:2
    "The physiological importance of maintaining the correct ratio of +KTS to -KTS isoforms (normally approximately 2:1) is dramatically illustrated by Frasier syndrome, in which mutations disrupting the +KTS splice site alter this ratio to 1:2"
  • p53 interaction converts WT1 from repressor to activator; WT1 stabilizes p53 protein
    "In the absence of p53, WT1 functions as a potent transcriptional activator of EGR1-like promoter sequences rather than as a repressor. WT1 expression can stabilize p53 protein, enhance its DNA binding to target sequences"
  • BASP1 myristoylation recruits PIP2 to promoters, enabling HDAC1-mediated repression
    "Mechanistically, myristoylated BASP1 binds to nuclear phosphatidylinositol 4,5-bisphosphate (PIP2), which leads to the recruitment of PIP2 to the promoter regions of WT1-dependent target genes. This association with PIP2 is required for the interaction of BASP1 with histone deacetylase 1 (HDAC1), enabling chromatin deacetylation and gene silencing"
  • WT1 directly activates nephrin (NPHS1) transcription >10-fold via specific promoter element
    "WT1 binds to a specific responsive element in the nephrin promoter and activates transcription more than 10-fold. Transgenic mouse analysis confirmed that this WT1 binding site is required for podocyte-specific nephrin expression in vivo"
  • WT1 directly activates SF1 and SRY in gonad development; DDS mutations fail to activate SRY
    "The -KTS isoform of WT1, but not the +KTS form, directly binds to and transactivates the Sf1 promoter through four identified binding sites. WT1 also directly regulates the sex-determining gene SRY by activating its expression. Mutant WT1 proteins found in Denys-Drash syndrome patients fail to activate the SRY promoter"
  • WT1 required for epicardial EMT in heart development via Wnt/beta-catenin and retinoic acid pathways
    "WT1 is expressed in the proepicardium and developing epicardium, where it is required for epithelial-to-mesenchymal transition (EMT) that generates cardiovascular progenitor cells. WT1 regulates epicardial EMT through multiple signaling pathways including canonical Wnt/beta-catenin signaling and retinoic acid signaling through direct regulation of Raldh2 expression"
  • WT1 ZnF1 is more important for RNA binding than DNA binding; +KTS and -KTS bind RNA similarly
    "While zinc fingers 2, 3, and 4 are required for high-affinity DNA binding, zinc finger 1β€”which is dispensable for DNA bindingβ€”is more important for RNA binding. Consequently, the KTS insertion has minimal effect on RNA affinity"

Suggested Questions for Experts

Q: What is the precise mechanism by which WT1 switches between activator and repressor function?

Q: What are the distinct RNA targets of the +KTS isoform?

Suggested Experiments

Experiment: ChIP-seq for WT1 isoforms to systematically identify genome-wide binding sites for -KTS vs +KTS isoforms, which would clarify their distinct transcriptional targets.

Experiment: CLIP-seq for +KTS isoform to identify RNA binding targets, which would elucidate its post-transcriptional regulatory functions.

πŸ“š Additional Documentation

Deep Research Cyberian

(WT1-deep-research-cyberian.md)

provider: cyberian
model: deep-research
cached: false
start_time: '2026-01-11T22:29:24.984547'
end_time: '2026-01-11T22:43:43.879283'
duration_seconds: 858.89
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: WT1
gene_symbol: WT1
uniprot_accession: P19544
protein_description: 'RecName: Full=Wilms tumor protein; AltName: Full=WT33;'
gene_info: Name=WT1;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the EGR C2H2-type zinc-finger protein family.
protein_domains: Wilms_tumour_N. (IPR000976); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type.
(IPR013087); WT1 (PF02165); zf-C2H2 (PF00096)
provider_config:
timeout: 1800
max_retries: 3
parameters:
allowed_domains: []
agent_type: claude
port: 3284
skip_permissions: true
citation_count: 15


Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: P19544
  • Protein Description: RecName: Full=Wilms tumor protein; AltName: Full=WT33;
  • Gene Information: Name=WT1;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Belongs to the EGR C2H2-type zinc-finger protein family.
  • Key Domains: Wilms_tumour_N. (IPR000976); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087); WT1 (PF02165); zf-C2H2 (PF00096)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "WT1" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'WT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene WT1 (gene ID: WT1, UniProt: P19544) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

WT1 (Wilms Tumor Protein): A Comprehensive Functional Annotation Report

1. Introduction and Overview

The Wilms tumor 1 gene (WT1) encodes a zinc finger transcription factor that plays essential roles in the development of the urogenital system and functions as both a tumor suppressor and oncogene depending on cellular context [toska-2014-wt1-review-abstract]. First identified in 1990 as a tumor suppressor gene associated with Wilms tumor (nephroblastoma), WT1 has since emerged as a remarkably complex master regulator of organogenesis, differentiation, and cellular homeostasis [rauscher-1993-wt1-tumor-suppressor-abstract]. The protein contains a proline- and glutamine-rich N-terminal domain and four C-terminal C2H2-type zinc fingers of the KrΓΌppel class, which mediate both DNA and RNA binding [toska-2014-wt1-review-abstract]. WT1 is characterized by its capacity to function as either a transcriptional activator or repressor depending on the presence of specific cofactors, cellular context, and post-translational modifications.

WT1 belongs to the EGR (Early Growth Response) C2H2-type zinc-finger protein family and demonstrates high-affinity DNA binding to GC-rich sequences closely related to the EGR-1 consensus site [hamilton-1998-dna-binding-abstract]. The remarkable complexity of WT1 biology stems from the existence of at least 24 distinct protein isoforms generated through alternative splicing and alternate translation initiation sites, with the two most functionally significant splice variants differing by the presence or absence of three amino acids (lysine-threonine-serine, KTS) between zinc fingers 3 and 4 [laity-2000-kts-splicing-abstract]. This single modification dramatically alters the protein's DNA binding capacity and subcellular localization, enabling a single gene to serve multiple distinct cellular functions [larsson-1995-localization-abstract].

2. Protein Structure and DNA Binding Properties

The WT1 protein architecture comprises several functionally distinct domains. The N-terminus contains a proline- and glutamine-rich region capable of transcriptional regulation, with a defined repression domain (residues 71-180) and a separate activation domain (residues 180-250) [toska-2014-wt1-review-abstract]. The C-terminal region houses four canonical Cys2-His2 zinc fingers that constitute the nucleic acid binding domain.

Structural studies using X-ray crystallography and NMR spectroscopy have elucidated the molecular basis of WT1-DNA interaction [stoll-2007-wt1-structure-abstract]. The second, third, and fourth zinc finger domains insert deep into the major groove of DNA where they make base-specific contacts. Zinc fingers 2 and 3 are primarily responsible for most of the binding affinity and can function as a minimal DNA binding domain, while zinc finger 4 is indispensable for target specificity, pinpointing a particular position on the target sequence and preventing register promiscuity [stoll-2007-wt1-structure-abstract]. In contrast, zinc finger 1 functions primarily to anchor WT1 to the DNA by amplifying binding affinity, although it does not contribute significantly to sequence specificity.

Quantitative binding studies have demonstrated that recombinant WT1 zinc fingers bind to the dodecamer DNA sequence GCG-TGG-GCG-TGT with high affinity, exhibiting a dissociation constant (Kd) of 1.14 Γ— 10⁻⁹ M under physiological conditions [hamilton-1998-dna-binding-abstract]. The consensus DNA binding sequence for WT1 has been characterized as 5'-GCG(T/G)GGGCG-3', which is closely related to but distinct from the EGR-1 binding site [hamilton-1998-dna-binding-abstract]. Thermodynamic analysis revealed that WT1-DNA interaction is an entropy-driven process, distinguishing it from the related EGR1 protein whose DNA binding is favored by both enthalpy and entropy [hamilton-1998-dna-binding-abstract].

3. Alternative Splicing and Isoform-Specific Functions

Alternative splicing generates functionally distinct WT1 isoforms that perform remarkably different cellular roles. The two most critical splice variants involve exon 5 (which adds 17 amino acids in the central region) and an alternative splice donor site at exon 9 that inserts the three amino acids KTS (lysine-threonine-serine) between zinc fingers 3 and 4 [toska-2014-wt1-review-abstract]. The +KTS/-KTS splicing event has profound functional consequences.

The molecular basis for the functional differences between +KTS and -KTS isoforms was elucidated by NMR structural studies demonstrating that the KTS insertion increases the flexibility of the linker between fingers 3 and 4, abrogating the binding of the fourth zinc finger to its cognate site in the DNA major groove [laity-2000-kts-splicing-abstract]. Consequently, the -KTS isoform binds EGR-like recognition elements with high affinity and functions primarily as a transcription factor, while the +KTS isoform binds DNA weakly and is preferentially associated with the splicing machinery [laity-2000-kts-splicing-abstract].

The physiological importance of maintaining the correct ratio of +KTS to -KTS isoforms (normally approximately 2:1) is dramatically illustrated by Frasier syndrome, in which mutations disrupting the +KTS splice site alter this ratio to 1:2, resulting in severe abnormalities in kidney and gonad development despite the production of structurally normal WT1 protein [laity-2000-kts-splicing-abstract]. Mouse knockout studies ablating either the +KTS or -KTS isoform specifically have provided direct evidence that these splice variants perform distinct essential functions in embryonic development. Recent studies have demonstrated that the -KTS splice variant is essential for ovarian determination in mice, highlighting the isoform-specific roles in sex determination pathways.

4. Subcellular Localization and Nuclear Functions

The subnuclear localization of WT1 is splice form-dependent, providing additional insight into the distinct functions of the isoforms [larsson-1995-localization-abstract]. The +KTS isoforms preferentially colocalize with molecules implicated in mRNA splicing in characteristic nuclear speckles, while -KTS proteins colocalize predominantly with transcription factors [larsson-1995-localization-abstract]. Nuclear speckles are now recognized as storage sites from which splicing factors are recruited to new sites of transcription, where pre-mRNA splicing occurs cotranscriptionally.

The association of WT1 with the splicing machinery has been demonstrated through its interaction with U2AF65, an essential splice factor that binds to the polypyrimidine tract upstream of the 3' splice site and promotes U2 snRNA annealing to the branch point [davies-1998-u2af65-abstract]. WT1 associates specifically with U2AF65 in a manner enhanced by the KTS insertion, and WT1 can be incorporated directly into spliceosomes [davies-1998-u2af65-abstract]. Both the amino-terminal RS domain and linker region of U2AF65 are required for WT1 binding. Additionally, WT1 interacts with the splicing regulator RBM4, and overexpressed WT1(+KTS) can abrogate the effects of RBM4 on splice-site selection, providing evidence for a post-transcriptional regulatory role [davies-1998-u2af65-abstract].

Post-translational modifications also regulate WT1 subcellular distribution. Phosphorylation by PKA or PKC at serines 365 and 393 within the zinc finger domain inhibits DNA binding and results in cytoplasmic retention of WT1, effectively suppressing its transcriptional functions while leaving RNA-binding activity intact [toska-2014-wt1-review-abstract]. WT1 is also SUMOylated at lysine residues 73 and 177 within the repression domain, though the functional consequences of this modification remain unclear. The WT1-binding partner BASP1 is SUMOylated by SUMO-3, raising the potential for differential regulation of WT1 and its cofactors.

5. Transcriptional Activation and Repression Mechanisms

WT1 exhibits remarkable functional duality, acting as either a transcriptional activator or repressor depending on cellular context and cofactor availability [toska-2014-wt1-review-abstract]. This dichotomous behavior enables WT1 to orchestrate complex developmental programs and respond appropriately to different physiological signals.

A key determinant of WT1's activator versus repressor function is its physical and functional interaction with the tumor suppressor p53. Coimmunoprecipitation experiments demonstrated that p53 and WT1 physically associate in cells, and this interaction profoundly modulates transcriptional output [maheswaran-1993-p53-interaction-abstract]. In the absence of p53, WT1 functions as a potent transcriptional activator of EGR1-like promoter sequences rather than as a repressor. Conversely, WT1 enhances p53's ability to transactivate target promoters such as the muscle creatine kinase promoter, indicating a cooperative relationship between these tumor suppressors [maheswaran-1993-p53-interaction-abstract]. Subsequent studies showed that WT1 expression can stabilize p53 protein, enhance its DNA binding to target sequences, and inhibit p53-mediated apoptosis while not affecting p53-mediated cell cycle arrest. This functional interaction may explain the elevated levels of wild-type p53 protein observed in Wilms' tumors.

The conversion of WT1 from a transcriptional activator to a repressor is also mediated through its interaction with the corepressor BASP1 (brain acid soluble protein 1) [toska-2012-basp1-hdac-abstract]. The N-terminal myristoylation of BASP1 is essential for eliciting transcriptional repression at WT1 target genes. Mechanistically, myristoylated BASP1 binds to nuclear phosphatidylinositol 4,5-bisphosphate (PIP2), which leads to the recruitment of PIP2 to the promoter regions of WT1-dependent target genes. This association with PIP2 is required for the interaction of BASP1 with histone deacetylase 1 (HDAC1), enabling chromatin deacetylation and gene silencing [toska-2012-basp1-hdac-abstract].

The transcriptional repression complex also includes prohibitin as an essential component [toska-2014-prohibitin-abstract]. Prohibitin interacts with BASP1, colocalizes with BASP1 in the nucleus, and is recruited to the promoter regions of WT1 target genes. Prohibitin and BASP1 cooperate to recruit the chromatin remodeling factor BRG1 (brahma-related gene 1) to WT1-responsive promoters, resulting in the dissociation of the histone acetyltransferase CBP from the promoter region and subsequent gene silencing [toska-2014-prohibitin-abstract].

The interplay between WT1 and BASP1 is dynamically regulated during cellular differentiation. In podocyte precursor cells, both WT1 and BASP1 occupy the promoters of genes including Bak, c-myc, and podocalyxin. During differentiation-dependent upregulation of podocalyxin expression, BASP1 occupancy of the podocalyxin promoter decreases while WT1 remains bound, allowing transcriptional activation. The regulation of BASP1 promoter occupancy involves sumoylation of BASP1, which can result in its redistribution within the nucleus from chromatin to the nuclear matrix [toska-2012-basp1-hdac-abstract].

6. Target Genes and Developmental Pathways

WT1 regulates a diverse array of target genes involved in development, differentiation, cell growth, and apoptosis. ChIP-chip analysis coupled with morpholino knockdown experiments in embryonic kidney explants has identified many WT1 targets in the context of kidney development [toska-2014-wt1-review-abstract].

In kidney development and podocyte function, WT1 is essential for the mesenchymal-to-epithelial transition (MET) of metanephric mesenchyme and subsequent nephron formation. WT1 controls metanephric mesenchyme self-renewal and proliferation by regulating FGF and BMP-pSMAD signaling pathways as well as Sall1 and Pax2. WT1 drives mesenchyme differentiation and MET by targeting Fgf8 and Wnt4, and defines podocyte identity by activation of podocyte-specific transcription factors including Mafb, Lmx1b, FoxC2, and Tcf21.

A critical direct target of WT1 in podocytes is nephrin (encoded by NPHS1), a transmembrane protein that is a constituent of the podocyte slit diaphragm and essential for the glomerular filtration barrier [wagner-2004-nephrin-abstract]. WT1 binds to a specific responsive element in the nephrin promoter and activates transcription more than 10-fold. Transgenic mouse analysis confirmed that this WT1 binding site is required for podocyte-specific nephrin expression in vivo [wagner-2004-nephrin-abstract]. Deletion of WT1 from adult kidneys results in severe podocyte injury, failure of the glomerular filtration barrier, and loss of expression of key podocyte genes.

In gonad development, WT1 functions upstream of SF1 (steroidogenic factor 1) and is essential for early gonadogenesis. The -KTS isoform of WT1, but not the +KTS form, directly binds to and transactivates the Sf1 promoter through four identified binding sites [wilhelm-2002-gonad-sf1-abstract]. WT1 also directly regulates the sex-determining gene SRY by activating its expression via proximal EGR-1-like DNA-binding sequences in the core promoter [hossain-2001-sry-abstract]. Mutant WT1 proteins found in Denys-Drash syndrome patients fail to activate the SRY promoter, providing a molecular explanation for the gonadal abnormalities in these patients [hossain-2001-sry-abstract]. The transcriptional co-factor CITED2 acts with WT1 and SF1 to increase SRY expression to levels sufficient for efficient testis development initiation.

Additional categories of WT1 target genes include growth factor receptors (IGF1R, EGFR, PDGF-A), signaling molecules (amphiregulin, sprouty, Wnt4, CSF-1), cell cycle regulators (p21, c-Myc, cyclin D2), apoptosis regulators (BCL2, A1/BFL1, BAK), and epigenetic factors (DNMT3A, histone modifiers Jmjd1a, Myst2, Rest) [toska-2014-wt1-review-abstract].

Beyond the urogenital system, WT1 plays an essential role in cardiac development, specifically in the epicardium, the epithelial tissue lining the heart surface. WT1 is expressed in the proepicardium and developing epicardium, where it is required for epithelial-to-mesenchymal transition (EMT) that generates cardiovascular progenitor cells [vongise-2011-epicardial-emt-abstract]. Genetic knockout studies demonstrated that Wt1-null epicardium fails to undergo EMT, resulting in diminished myocardial proliferation and impaired coronary plexus formation. WT1 regulates epicardial EMT through multiple signaling pathways including canonical Wnt/Ξ²-catenin signaling (via reduced Lef1 and Ctnnb1 expression in knockouts), non-canonical Wnt5a signaling, and retinoic acid signaling through direct regulation of Raldh2 expression [vongise-2011-epicardial-emt-abstract]. Notably, while WT1 drives mesenchymal-to-epithelial transition (MET) in the developing kidney, it promotes the reverse process (EMT) in the epicardium, demonstrating that WT1's effects on epithelial-mesenchymal transitions are highly context-dependent. The epicardial EMT generates cardiac fibroblasts, vascular smooth muscle cells, and a subset of coronary endothelial cells. Intriguingly, WT1 is reactivated in adult epicardium following myocardial infarction, suggesting a role in cardiac repair responses.

7. Role in Disease: Wilms Tumor and Associated Syndromes

WT1 was originally identified as a tumor suppressor gene mutated in Wilms tumor, a pediatric kidney cancer. However, the relationship between WT1 and cancer is complex, as WT1 can function as either a tumor suppressor or oncogene depending on cellular context [toska-2014-wt1-review-abstract].

Denys-Drash syndrome (DDS) is caused by dominant-negative mutations in WT1 and is characterized by the triad of congenital nephropathy (diffuse mesangial sclerosis), Wilms tumor susceptibility, and disorders of sexual development [rauscher-1993-wt1-tumor-suppressor-abstract]. The majority of DDS patients harbor point mutations in one WT1 allele, frequently missense mutations affecting the zinc finger DNA-binding domains. Structural studies have categorized these mutations as either destabilizing zinc finger structures or replacing critical base-contact residues [stoll-2007-wt1-structure-abstract]. Interestingly, some DDS mutations enhance WT1 binding to U2AF65, suggesting a potential gain-of-function mechanism contributing to disease pathogenesis [davies-1998-u2af65-abstract].

Frasier syndrome is caused by mutations in intron 9 of the WT1 gene that prevent production of the +KTS isoform, thereby altering the normal +KTS/-KTS ratio from 2:1 to 1:2. Unlike DDS, Frasier syndrome patients produce structurally normal WT1 proteins but with an imbalanced isoform ratio [laity-2000-kts-splicing-abstract]. Frasier syndrome is characterized by focal segmental glomerulosclerosis (rather than the diffuse mesangial sclerosis of DDS), male pseudohermaphroditism, and gonadoblastoma susceptibility, but no increased risk of Wilms tumor because the -KTS isoform retains tumor suppressor function.

Beyond Wilms tumor, WT1 is overexpressed in various adult malignancies including acute myeloid leukemia (AML), where it serves as a prognostic marker and therapeutic target. In AML, WT1 is mutated in a mutually exclusive manner with TET2, IDH1, and IDH2. WT1 is also aberrantly expressed in solid tumors derived from tissues that normally lack WT1 expression, including colon, breast, desmoid tumors, and brain tumors [toska-2014-wt1-review-abstract]. In these contexts, WT1 appears to function as an oncogene rather than a tumor suppressor.

8. RNA Binding and Post-Transcriptional Functions

In addition to its well-characterized role as a transcription factor, WT1 binds RNA and participates in post-transcriptional gene regulation. The zinc finger domain of WT1 can bind both DNA and RNA, with different subsets of zinc fingers contributing to each interaction [caricasole-1996-rna-binding-abstract]. While zinc fingers 2, 3, and 4 are required for high-affinity DNA binding, zinc finger 1β€”which is dispensable for DNA bindingβ€”is more important for RNA binding. Consequently, the KTS insertion, which disrupts zinc finger 4 function, has minimal effect on RNA affinity, explaining why both +KTS and -KTS isoforms bind RNA with similar affinity despite their dramatically different DNA binding properties.

Structural studies have revealed that WT1 zinc fingers 1-3 bind in a widened major groove of RNA stem-loop structures, with a bulge nucleotide facilitating groove widening [caricasole-1996-rna-binding-abstract]. Zinc fingers 2 and 3 make specific contacts with nucleobases in a conserved AUGG sequence within the RNA helical stem. The +KTS isoform has been shown to associate with actively translating polysomes in the cytoplasm and can shuttle between nucleus and cytoplasm, suggesting roles in mRNA transport and translation regulation.

The WT1(+KTS) isoform functions with a constitutive transport element (CTE) to enhance translation from unspliced RNA with a retained intron, demonstrating a specific post-transcriptional regulatory function distinct from the transcriptional roles of the -KTS isoform. The identification of specific mRNA targets including IGF2 mRNA suggests that WT1 may coordinate transcriptional and post-transcriptional regulation of key developmental genes.

9. Open Questions

Despite decades of research, several fundamental questions about WT1 biology remain unresolved:

  1. Isoform-specific target genes: While it is clear that +KTS and -KTS isoforms have distinct functions, a comprehensive genome-wide identification of isoform-specific target genes and RNAs is lacking. What is the full repertoire of genes regulated transcriptionally by -KTS versus post-transcriptionally by +KTS?

  2. Context-dependent activation vs. repression: What determines whether WT1 activates or represses a given target gene in a specific cellular context? The role of BASP1 is established, but other factors likely contribute to this decision.

  3. SUMOylation function: The functional consequences of WT1 SUMOylation remain unclear. Does this modification affect DNA binding, protein interactions, or subcellular localization?

  4. RNA targets and mechanisms: While WT1 RNA binding has been demonstrated, the identity and functional consequences of most RNA targets remain unknown. How does WT1 coordinate transcriptional and post-transcriptional regulation?

  5. Adult tissue functions: WT1 expression persists in adult podocytes, Sertoli cells, and granulosa cells. What are its functions in tissue homeostasis beyond development, and how does its dysregulation contribute to adult-onset diseases?

  6. Oncogenic mechanisms: How does WT1 switch from tumor suppressor to oncogene in different cancers? What target genes mediate its oncogenic effects?

  7. Therapeutic targeting: Can WT1 be effectively targeted for cancer therapy? WT1 peptide vaccines and T cell therapies are in clinical trials, but optimal approaches remain to be defined.

References

  • [caricasole-1996-rna-binding-abstract]: Caricasole A, et al. RNA binding by the Wilms tumor suppressor zinc finger proteins. PNAS. 1996;93(15):7562-6. PMID: 8755511

  • [maheswaran-1993-p53-interaction-abstract]: Maheswaran S, et al. Physical and functional interaction between WT1 and p53 proteins. PNAS. 1993;90(11):5100-4. PMID: 8389468. DOI: 10.1073/pnas.90.11.5100

  • [davies-1998-u2af65-abstract]: Davies RC, et al. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes & Development. 1998;12(20):3217-25. PMID: 9784496. DOI: 10.1101/gad.12.20.3217

  • [hamilton-1998-dna-binding-abstract]: Hamilton TB, et al. Comparison of the DNA binding characteristics of the related zinc finger proteins WT1 and EGR1. Biochemistry. 1998;37(7):2051-8. PMID: 9485332. DOI: 10.1021/bi9717993

  • [hossain-2001-sry-abstract]: Hossain A, Saunders GF. The human sex-determining gene SRY is a direct target of WT1. J Biol Chem. 2001;276(20):16817-23. PMID: 11278460. DOI: 10.1074/jbc.M009056200

  • [laity-2000-kts-splicing-abstract]: Laity JH, et al. Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein. PNAS. 2000;97(22):11932-5. PMID: 11050227. DOI: 10.1073/pnas.97.22.11932

  • [larsson-1995-localization-abstract]: Larsson SH, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell. 1995;81(3):391-401. PMID: 7736591. DOI: 10.1016/0092-8674(95)90392-5

  • [rauscher-1993-wt1-tumor-suppressor-abstract]: Rauscher FJ 3rd. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J. 1993;7(10):896-903. PMID: 8393820

  • [stoll-2007-wt1-structure-abstract]: Stoll R, et al. Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. J Mol Biol. 2007;372(5):1227-45. PMID: 17716689. DOI: 10.1016/j.jmb.2007.07.017

  • [toska-2012-basp1-hdac-abstract]: Toska E, et al. Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase. Cell Reports. 2012;2(3):462-9. PMID: 22939983. DOI: 10.1016/j.celrep.2012.08.005

  • [toska-2014-prohibitin-abstract]: Toska E, et al. Prohibitin is required for transcriptional repression by the WT1-BASP1 complex. Oncogene. 2014;33(43):5100-8. PMID: 24166496. DOI: 10.1038/onc.2013.447

  • [toska-2014-wt1-review-abstract]: Toska E, Roberts SGE. Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). Biochem J. 2014;461(1):15-32. PMID: 24927120. DOI: 10.1042/BJ20131587

  • [vongise-2011-epicardial-emt-abstract]: von Gise A, et al. WT1 regulates epicardial epithelial to mesenchymal transition through Ξ²-catenin and retinoic acid signaling pathways. Dev Biol. 2011;356(2):421-31. PMID: 21663736. DOI: 10.1016/j.ydbio.2011.05.668

  • [wagner-2004-nephrin-abstract]: Wagner N, et al. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. J Am Soc Nephrol. 2004;15(12):3044-51. PMID: 15579507. DOI: 10.1097/01.ASN.0000146687.99058.25

  • [wilhelm-2002-gonad-sf1-abstract]: Wilhelm D, Englert C. The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1. Genes & Development. 2002;16(14):1839-51. DOI: 10.1101/gad.220102

Citations

  1. caricasole-1996-rna-binding-abstract.md
  2. davies-1998-u2af65-abstract.md
  3. hamilton-1998-dna-binding-abstract.md
  4. hossain-2001-sry-abstract.md
  5. laity-2000-kts-splicing-abstract.md
  6. larsson-1995-localization-abstract.md
  7. maheswaran-1993-p53-interaction-abstract.md
  8. rauscher-1993-wt1-tumor-suppressor-abstract.md
  9. stoll-2007-wt1-structure-abstract.md
  10. toska-2012-basp1-hdac-abstract.md
  11. toska-2014-prohibitin-abstract.md
  12. toska-2014-wt1-review-abstract.md
  13. vongise-2011-epicardial-emt-abstract.md
  14. wagner-2004-nephrin-abstract.md
  15. wilhelm-2002-gonad-sf1-abstract.md

Deep Research Falcon

(WT1-deep-research-falcon.md)

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-11T21:55:03.186349'
end_time: '2026-01-11T22:00:33.693030'
duration_seconds: 330.51
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: WT1
gene_symbol: WT1
uniprot_accession: P19544
protein_description: 'RecName: Full=Wilms tumor protein; AltName: Full=WT33;'
gene_info: Name=WT1;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the EGR C2H2-type zinc-finger protein family.
protein_domains: Wilms_tumour_N. (IPR000976); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type.
(IPR013087); WT1 (PF02165); zf-C2H2 (PF00096)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 22


Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: P19544
  • Protein Description: RecName: Full=Wilms tumor protein; AltName: Full=WT33;
  • Gene Information: Name=WT1;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Belongs to the EGR C2H2-type zinc-finger protein family.
  • Key Domains: Wilms_tumour_N. (IPR000976); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087); WT1 (PF02165); zf-C2H2 (PF00096)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "WT1" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'WT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene WT1 (gene ID: WT1, UniProt: P19544) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: P19544
  • Protein Description: RecName: Full=Wilms tumor protein; AltName: Full=WT33;
  • Gene Information: Name=WT1;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Belongs to the EGR C2H2-type zinc-finger protein family.
  • Key Domains: Wilms_tumour_N. (IPR000976); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087); WT1 (PF02165); zf-C2H2 (PF00096)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "WT1" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'WT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene WT1 (gene ID: WT1, UniProt: P19544) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Gene/protein verification and identity
- Target verified: Human WT1 (UniProt P19544) encodes Wilms tumor protein, a transcriptional regulator with an N‑terminal regulatory region (Wilms_tumour_N) and four C2H2 zinc fingers at the C‑terminus; it belongs to the EGR C2H2-type zinc-finger family and functions primarily as a sequence-specific DNA-binding factor with additional RNA-related roles (review, accepted July 2024) (nagano2025areviewof pages 1-3). Alternative splicing at intron 9 inserts a three–amino‑acid KTS motif between zinc fingers 3 and 4 to produce +KTS and βˆ’KTS isoforms; βˆ’KTS acts mainly as a classical transcription factor, while +KTS participates in post‑transcriptional/RNA processes (nagano2025areviewof pages 1-3, cassiday2002havingitboth pages 3-4).

Key concepts and definitions (current understanding)
- Domain architecture and nucleic-acid interactions: WT1 contains four C2H2 zinc fingers (exons 7–10) mediating high‑affinity binding to GC‑rich motifs such as 5′‑GCG(T/G)GGGCG‑3β€² in target promoters/enhancers; the zinc‑finger region also provides overlapping surfaces for DNA and RNA binding (EGR-like zinc fingers) (nagano2025areviewof pages 1-3, bardeesy1998overlappingrnaand pages 7-8). Early biochemical work demonstrated that zinc fingers II–IV are indispensable for RNA and DNA recognition and that RNA can compete with DNA for binding to the same interface (bardeesy1998overlappingrnaand pages 7-8, bardeesy1998overlappingrnaand pages 8-8).
- Isoforms and functional partitioning: The βˆ’KTS isoform binds DNA sequence‑specifically and drives transcriptional programs, whereas the +KTS isoform shows low DNA affinity, associates with spliceosomal components, and has RNA-binding/processing roles; both isoforms can localize to the nucleus, with +KTS enriched in nuclear speckles/splicing domains (cassiday2002havingitboth pages 3-4, florio2010biochemicalandfunctional pages 2-3, florio2010biochemicalandfunctional pages 1-1). Reviews consolidating structural and genomic data reiterate these isoform‑specific roles and the context‑dependent activator/repressor functions of WT1’s N‑terminus (hirahata2025wt1genea pages 23-24, hirahata2025wt1genea pages 3-4).
- Cellular localization and modality: WT1 is predominantly nuclear for transcriptional regulation, but shuttling to the cytoplasm has been observed, including association with translating polysomes and mRNPs, supporting additional post‑transcriptional/translation‑related roles; nuclear WT1 frequently colocalizes with splicing factors (U2AF65, WTAP) and BASP1/ZNF224 partners that tune its transcriptional output (florio2010biochemicalandfunctional pages 2-3, bardeesy1998overlappingrnaand pages 8-8, florio2010biochemicalandfunctional pages 1-1).

Biological processes and pathways (concise)
- Nephrogenesis and podocyte maintenance: WT1 binds and regulates kidney lineage and podocyte genes and is essential for nephron development and adult podocyte integrity (nagano2025areviewof pages 1-3). The WT1–BASP1 complex dynamically modulates podocyte precursor gene expression during differentiation (florio2010biochemicalandfunctional pages 2-3).
- Gonadal development and sex determination: Alternative splicing (+/βˆ’KTS) contributes to distinct roles in supporting cell lineages during gonadal differentiation (cassiday2002havingitboth pages 3-4, nagano2025areviewof pages 1-3).
- Hematopoiesis and leukemogenesis: WT1 expression is high in most AML and is leveraged diagnostically (see Applications) (hirahata2025wt1genea pages 12-14).

Recent developments and latest research (priority to 2023–2024)
- Consolidated 2024 mechanistic review: A 2024 review emphasizes WT1’s dual DNA/RNA modalities, KTS-dependent isoform functions, canonical DNA-recognition motif, and roles in kidney/podocyte biology (Clinical and Experimental Nephrology; published July 2024; URL: https://doi.org/10.1007/s10157-024-02539-x) (nagano2025areviewof pages 1-3).
- WT1-targeted immunotherapy advances (2024 synthesis): A 2024 mini‑review summarizes Phase I/II WT1 peptide and DC/mRNA-DC vaccine results, noting enhanced immunogenicity when combining HLA class I and II peptides, emerging combinations with checkpoint blockade, and the need for Phase III confirmation (Human Vaccines & Immunotherapeutics; Dec 2024; URL: https://doi.org/10.1080/21645515.2023.2296735) (ogasawara2024wilms’tumor1 pages 1-2, ogasawara2024wilms’tumor1 pages 2-3, ogasawara2024wilms’tumor1 pages 3-4).
- MRD standardization and thresholds: Updated summaries of ELN‑standardized WT1 qRT‑PCR provide actionable thresholds (bone marrow β‰₯250 copies/10^4 ABL; peripheral blood β‰₯50/10^4 ABL) and emphasize integration with flow cytometry/genomics (Clinical and Experimental Medicine; Oct 2025; includes 2013 ELN standardization and subsequent practice; URL: https://doi.org/10.1007/s10238-025-01769-x) (hirahata2025wt1genea pages 12-14).

Subcellular localization and RNA-processing evidence
- Nuclear transcriptional roles: WT1(βˆ’KTS) engages promoters/enhancers of podocyte and lineage genes; ChIP-based analyses and motif studies corroborate direct DNA binding in the nucleus (nagano2025areviewof pages 1-3).
- RNA processing roles: WT1(+KTS) co-localizes with splicing speckles, interacts with splicing factors (U2AF65, WTAP), forms complexes with ZNF255 and BASP1 that participate in RNA maturation, and associates with translating polysomes, indicating roles spanning splicing to translation (Human Mol Genet 2010; Nucleic Acids Res 2004, 1998; URLs: https://doi.org/10.1093/hmg/ddq270; https://doi.org/10.1093/nar/gkn955; https://doi.org/10.1093/nar/26.7.1784) (florio2010biochemicalandfunctional pages 2-3, florio2010biochemicalandfunctional pages 1-1, bardeesy1998overlappingrnaand pages 8-8, bardeesy1998overlappingrnaand pages 7-8).

Current applications and real‑world implementations
- Diagnostic pathology (mesothelium and other lineages): WT1 protein is expressed in mesothelium and select normal tissues; this restricted pattern underlies its frequent use in diagnostic immunohistochemistry panels, especially for mesothelioma and ovarian serous tumors; WT1’s tumor-associated expression across many cancers underpins its targeting in immunotherapy (2024 review) (ogasawara2024wilms’tumor1 pages 1-2).
- Hematologic MRD monitoring: WT1 mRNA is overexpressed in >80% of AML; standardized ELN qRT‑PCR thresholds are widely used for MRD risk stratification and post‑transplant surveillance, with elevated WT1 early after allo‑HSCT predicting relapse and guiding pre‑emptive therapy decisions (e.g., DLI, hypomethylating agents) (Clinical and Experimental Medicine 2025; URL: https://doi.org/10.1007/s10238-025-01769-x) (hirahata2025wt1genea pages 12-14). Clinical series summarized in 2024/2025 sources indicate WT1 monitoring complements flow cytometry and can detect residual disease when mutation-based markers are absent (hirahata2025wt1genea pages 14-15, hirahata2025wt1genea pages 12-14).
- Immunotherapy:
- Peptide vaccines: Across multiple Phase I/II trials, WT1 class I CTL peptide vaccines, often augmented with class II helper peptides, show safety, strong WT1-specific T‑cell and IgG responses, and disease-control signals in glioma, mesothelioma, ovarian, and pancreatic cancers (Human Vaccines & Immunotherapeutics 2024) (ogasawara2024wilms’tumor1 pages 1-2, ogasawara2024wilms’tumor1 pages 2-3). For example, in temozolomide‑resistant brain tumors, WT1 CTL+helper vaccination yielded stable disease in 43%, 1‑year OS 36%, and median OS 24.7 weeks (ogasawara2024wilms’tumor1 pages 2-3). In a randomized pancreatic study, adding WT1 CTL peptide to gemcitabine improved 1‑year OS to 35.7% vs 20.9% and reduced hazard for progression (HR 0.66) (ogasawara2024wilms’tumor1 pages 1-2).
- Dendritic cell (DC) vaccines: WT1 peptide‑pulsed or WT1 mRNA‑loaded DCs demonstrated disease control, median PFS 6.4–8.1 months, and median OS 12.1–15.1 months in Phase 1/2 studies; an adjuvant trial reported 3‑year OS 77.8% with RFS 35% (ogasawara2024wilms’tumor1 pages 2-3). A 2024 systematic review in pancreatic cancer found feasibility and safety with skin‑site reactions as common AEs, and reported pooled signals including 20% objective responses in one series and 1‑year survival ~29% in another; all studies were Phase I/II and mostly HLA‑A*24:02–selected populations (Cureus 2024; URL: https://doi.org/10.7759/cureus.56934) (gugulothu2024wt1cancervaccine pages 4-4, gugulothu2024wt1cancervaccine pages 5-6).
- Combination with ICIs: Combining multipeptide WT1 vaccine (e.g., galinpepimut‑S) with nivolumab showed high T‑cell (91%) and WT1‑IgG (88%) response rates and promising 1‑year PFS in early-phase evaluation (ogasawara2024wilms’tumor1 pages 2-3).
- Hematologic settings: In AML complete remission, WT1 peptide vaccination yielded 2‑year RFS 25% and 2‑year OS 40% in one Phase II; a multivalent WT1 vaccine reported median DFS from CR 16.9 months and estimated OS >67.6 months (ogasawara2024wilms’tumor1 pages 3-4).

Expert opinions and analysis (authoritative sources)
- 2024 immunotherapy review (Human Vaccines & Immunotherapeutics) concludes WT1 is a compelling tumor‑associated antigen with acceptable safety across Phase I/II studies; combining class I/II peptides improves immunogenicity and combinations with checkpoint inhibitors are rational next steps, but large Phase III trials are needed to validate efficacy (ogasawara2024wilms’tumor1 pages 1-2, ogasawara2024wilms’tumor1 pages 2-3, ogasawara2024wilms’tumor1 pages 3-4).
- 2024 nephrology review underscores the mechanistic foundationβ€”WT1’s domain structure, KTS isoforms, and target DNA motifβ€”connecting developmental roles in kidney/podocyte biology to genotype‑phenotype in disease, reinforcing that βˆ’KTS is primarily transcriptional and +KTS is post‑transcriptional (nagano2025areviewof pages 1-3).
- Clinical MRD perspective (summary including ELN practice) emphasizes standardized WT1 thresholds and integration with other MRD modalities due to low‑level expression in some healthy tissues, guiding nuanced interpretation (hirahata2025wt1genea pages 12-14).

Relevant statistics and recent data points (with sources)
- DNA/RNA binding and isoforms: Distinct +KTS/βˆ’KTS functional partitioning and overlapping RNA/DNA binding via zinc fingers II–IV (Nucleic Acids Res 1998; URL: https://doi.org/10.1093/nar/26.7.1784) (bardeesy1998overlappingrnaand pages 7-8, bardeesy1998overlappingrnaand pages 8-8); +KTS enriched in nuclear splicing domains and associates with splicing factors (Nucleic Acids Res 2002; URL: https://doi.org/10.1093/nar/gkf512) (cassiday2002havingitboth pages 3-4); WT1 partners BASP1/ZNF224/ZNF255 modulate transcription vs RNA maturation (HMG 2010; URL: https://doi.org/10.1093/hmg/ddq270) (florio2010biochemicalandfunctional pages 2-3, florio2010biochemicalandfunctional pages 1-1).
- MRD thresholds: ELN‑standardized cutoffsβ€”bone marrow 250 copies WT1/10^4 ABL, peripheral blood 50/10^4 ABLβ€”used for AML/MDS MRD risk and relapse prediction after HSCT (Clinical and Experimental Medicine 2025; URL: https://doi.org/10.1007/s10238-025-01769-x) (hirahata2025wt1genea pages 12-14).
- Vaccine outcomes (examples, 2023–2024 emphasis):
- Glioma (Phase I CTL+helper): SD 43%, 1‑year OS 36%, mOS 24.7 weeks (ogasawara2024wilms’tumor1 pages 2-3).
- Pancreatic (randomized): 1‑year OS 35.7% vs 20.9% and HR 0.66 for PFS with WT1 peptide + gemcitabine vs gemcitabine alone (ogasawara2024wilms’tumor1 pages 1-2).
- DC vaccines across mixed tumors: DCR 45%, mPFS 6.4 months, mOS 12.1 months (one series); mPFS 8.1 months, mOS 15.1 months (another); adjuvant 3‑year OS 77.8% (ogasawara2024wilms’tumor1 pages 2-3).
- Pancreatic (systematic review): Objective response 20% in one cohort; 1‑year survival ~29% in another; safety dominated by grade 1 skin reactions (gugulothu2024wt1cancervaccine pages 4-4, gugulothu2024wt1cancervaccine pages 5-6).
- AML CR vaccination: 2‑year RFS 25%, 2‑year OS 40%; multivalent WT1 vaccine mDFS 16.9 months, estimated OS >67.6 months (ogasawara2024wilms’tumor1 pages 3-4).

Conclusions
Human WT1 (P19544) is a C2H2 zinc‑finger transcription factor with a Wilms_tumour_N regulatory N‑terminus and alternative +/βˆ’KTS isoforms that partition nuclear DNA‑dependent transcription from RNA processing functions. Its essential roles in kidney development/podocyte maintenance and gonadal support lineages are underpinned by direct DNA binding and nuclear complexes that also engage RNA metabolism. Clinically, WT1 is entrenched in hematology as a standardized MRD biomarker and is an active oncology target for peptide and DC/mRNA vaccines, with 2023–2024 studies showing consistent safety, robust immunogenicity, and signals of clinical benefit, particularly when helper peptides or checkpoint inhibitors are added. Larger randomized trials remain necessary to establish definitive efficacy endpoints across tumor types (nagano2025areviewof pages 1-3, bardeesy1998overlappingrnaand pages 7-8, cassiday2002havingitboth pages 3-4, florio2010biochemicalandfunctional pages 2-3, bardeesy1998overlappingrnaand pages 8-8, florio2010biochemicalandfunctional pages 1-1, ogasawara2024wilms’tumor1 pages 1-2, ogasawara2024wilms’tumor1 pages 2-3, ogasawara2024wilms’tumor1 pages 3-4, hirahata2025wt1genea pages 12-14).

References

  1. (nagano2025areviewof pages 1-3): China Nagano and Kandai Nozu. A review of the genetic background in complicated wt1-related disorders. Clinical and Experimental Nephrology, 29:1-9, Jul 2025. URL: https://doi.org/10.1007/s10157-024-02539-x, doi:10.1007/s10157-024-02539-x. This article has 10 citations and is from a peer-reviewed journal.

  2. (cassiday2002havingitboth pages 3-4): Laura A. Cassiday, L. James, and Maher Iii. Having it both ways: transcription factors that bind dna and rna. Nucleic acids research, 30 19:4118-26, Oct 2002. URL: https://doi.org/10.1093/nar/gkf512, doi:10.1093/nar/gkf512. This article has 219 citations and is from a highest quality peer-reviewed journal.

  3. (bardeesy1998overlappingrnaand pages 7-8): Nabeel Bardeesy and Jerry Pelletier. Overlapping rna and dna binding domains of the wt1 tumor suppressor gene product. Nucleic acids research, 26 7:1784-92, Apr 1998. URL: https://doi.org/10.1093/nar/26.7.1784, doi:10.1093/nar/26.7.1784. This article has 103 citations and is from a highest quality peer-reviewed journal.

  4. (bardeesy1998overlappingrnaand pages 8-8): Nabeel Bardeesy and Jerry Pelletier. Overlapping rna and dna binding domains of the wt1 tumor suppressor gene product. Nucleic acids research, 26 7:1784-92, Apr 1998. URL: https://doi.org/10.1093/nar/26.7.1784, doi:10.1093/nar/26.7.1784. This article has 103 citations and is from a highest quality peer-reviewed journal.

  5. (florio2010biochemicalandfunctional pages 2-3): F. Florio, Elena Cesaro, Giorgia Montano, P. Izzo, C. Miles, and P. Costanzo. Biochemical and functional interaction between znf224 and znf255, two members of the kruppel-like zinc-finger protein family and wt1 protein isoforms. Human molecular genetics, 19 18:3544-56, Sep 2010. URL: https://doi.org/10.1093/hmg/ddq270, doi:10.1093/hmg/ddq270. This article has 38 citations and is from a domain leading peer-reviewed journal.

  6. (florio2010biochemicalandfunctional pages 1-1): F. Florio, Elena Cesaro, Giorgia Montano, P. Izzo, C. Miles, and P. Costanzo. Biochemical and functional interaction between znf224 and znf255, two members of the kruppel-like zinc-finger protein family and wt1 protein isoforms. Human molecular genetics, 19 18:3544-56, Sep 2010. URL: https://doi.org/10.1093/hmg/ddq270, doi:10.1093/hmg/ddq270. This article has 38 citations and is from a domain leading peer-reviewed journal.

  7. (hirahata2025wt1genea pages 23-24): Tetsuyuki Hirahata, Reeshan ul Quraish, Afraz ul Quraish, Shahan ul Quraish, and Reezan Ul Quraish. Wt1 gene: a potential therapeutic target for multiple cancer treatment strategies. Clinical and Experimental Medicine, Oct 2025. URL: https://doi.org/10.1007/s10238-025-01769-x, doi:10.1007/s10238-025-01769-x. This article has 0 citations and is from a peer-reviewed journal.

  8. (hirahata2025wt1genea pages 3-4): Tetsuyuki Hirahata, Reeshan ul Quraish, Afraz ul Quraish, Shahan ul Quraish, and Reezan Ul Quraish. Wt1 gene: a potential therapeutic target for multiple cancer treatment strategies. Clinical and Experimental Medicine, Oct 2025. URL: https://doi.org/10.1007/s10238-025-01769-x, doi:10.1007/s10238-025-01769-x. This article has 0 citations and is from a peer-reviewed journal.

  9. (hirahata2025wt1genea pages 12-14): Tetsuyuki Hirahata, Reeshan ul Quraish, Afraz ul Quraish, Shahan ul Quraish, and Reezan Ul Quraish. Wt1 gene: a potential therapeutic target for multiple cancer treatment strategies. Clinical and Experimental Medicine, Oct 2025. URL: https://doi.org/10.1007/s10238-025-01769-x, doi:10.1007/s10238-025-01769-x. This article has 0 citations and is from a peer-reviewed journal.

  10. (ogasawara2024wilms’tumor1 pages 1-2): Masahiro Ogasawara. Wilms’ tumor 1 -targeting cancer vaccine: recent advancements and future perspectives. Human Vaccines & Immunotherapeutics, Dec 2024. URL: https://doi.org/10.1080/21645515.2023.2296735, doi:10.1080/21645515.2023.2296735. This article has 22 citations and is from a peer-reviewed journal.

  11. (ogasawara2024wilms’tumor1 pages 2-3): Masahiro Ogasawara. Wilms’ tumor 1 -targeting cancer vaccine: recent advancements and future perspectives. Human Vaccines & Immunotherapeutics, Dec 2024. URL: https://doi.org/10.1080/21645515.2023.2296735, doi:10.1080/21645515.2023.2296735. This article has 22 citations and is from a peer-reviewed journal.

  12. (ogasawara2024wilms’tumor1 pages 3-4): Masahiro Ogasawara. Wilms’ tumor 1 -targeting cancer vaccine: recent advancements and future perspectives. Human Vaccines & Immunotherapeutics, Dec 2024. URL: https://doi.org/10.1080/21645515.2023.2296735, doi:10.1080/21645515.2023.2296735. This article has 22 citations and is from a peer-reviewed journal.

  13. (hirahata2025wt1genea pages 14-15): Tetsuyuki Hirahata, Reeshan ul Quraish, Afraz ul Quraish, Shahan ul Quraish, and Reezan Ul Quraish. Wt1 gene: a potential therapeutic target for multiple cancer treatment strategies. Clinical and Experimental Medicine, Oct 2025. URL: https://doi.org/10.1007/s10238-025-01769-x, doi:10.1007/s10238-025-01769-x. This article has 0 citations and is from a peer-reviewed journal.

  14. (gugulothu2024wt1cancervaccine pages 4-4): Kalyan Naik Gugulothu, Pampatti Anvesh Sai, Sonika Suraparaju, Sai Prasad Karuturi, Ganesh Pendli, Ravi babu Kamma, Kethana Nimmagadda, Alekhya Modepalli, Mahesh Mamilla, and Shambhavi Vashist. Wt1 cancer vaccine in advanced pancreatic cancer: a systematic review. Cureus, Mar 2024. URL: https://doi.org/10.7759/cureus.56934, doi:10.7759/cureus.56934. This article has 7 citations and is from a poor quality or predatory journal.

  15. (gugulothu2024wt1cancervaccine pages 5-6): Kalyan Naik Gugulothu, Pampatti Anvesh Sai, Sonika Suraparaju, Sai Prasad Karuturi, Ganesh Pendli, Ravi babu Kamma, Kethana Nimmagadda, Alekhya Modepalli, Mahesh Mamilla, and Shambhavi Vashist. Wt1 cancer vaccine in advanced pancreatic cancer: a systematic review. Cureus, Mar 2024. URL: https://doi.org/10.7759/cureus.56934, doi:10.7759/cureus.56934. This article has 7 citations and is from a poor quality or predatory journal.

Citations

  1. nagano2025areviewof pages 1-3
  2. florio2010biochemicalandfunctional pages 2-3
  3. cassiday2002havingitboth pages 3-4
  4. bardeesy1998overlappingrnaand pages 7-8
  5. bardeesy1998overlappingrnaand pages 8-8
  6. florio2010biochemicalandfunctional pages 1-1
  7. https://doi.org/10.1007/s10157-024-02539-x
  8. https://doi.org/10.1080/21645515.2023.2296735
  9. https://doi.org/10.1007/s10238-025-01769-x
  10. https://doi.org/10.1093/hmg/ddq270;
  11. https://doi.org/10.1093/nar/gkn955;
  12. https://doi.org/10.1093/nar/26.7.1784
  13. https://doi.org/10.7759/cureus.56934
  14. https://doi.org/10.1093/nar/gkf512
  15. https://doi.org/10.1093/hmg/ddq270
  16. https://doi.org/10.1007/s10157-024-02539-x,
  17. https://doi.org/10.1093/nar/gkf512,
  18. https://doi.org/10.1093/nar/26.7.1784,
  19. https://doi.org/10.1093/hmg/ddq270,
  20. https://doi.org/10.1007/s10238-025-01769-x,
  21. https://doi.org/10.1080/21645515.2023.2296735,
  22. https://doi.org/10.7759/cureus.56934,

πŸ“„ View Raw YAML

id: P19544
gene_symbol: WT1
product_type: PROTEIN
status: IN_PROGRESS
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: 'WT1 (Wilms tumor protein) is a C2H2 zinc-finger transcription factor
  that plays essential roles in urogenital and cardiac development. The protein contains
  an N-terminal proline/glutamine-rich regulatory domain (with separate repression
  and activation domains) and four C-terminal C2H2 zinc fingers (encoded by exons
  7-10) that mediate sequence-specific DNA binding to the motif 5''-GCG(T/G)GGGCG-3''
  with Kd ~1.14 nM. Alternative splicing at intron 9 produces two major isoform classes
  with distinct functions: the -KTS isoform functions as a classical DNA-binding transcription
  factor (both activator and repressor depending on cofactors like BASP1/p53 and cellular
  context), while the +KTS isoform has reduced DNA affinity (due to increased linker
  flexibility between ZnF3-4) and participates in RNA processing, localizing to nuclear
  speckles and interacting with splicing factors (U2AF65, RBM4). The normal +KTS/-KTS
  ratio of ~2:1 is critical; Frasier syndrome results from altered ratio. WT1 functions
  as a tumor suppressor in kidney (loss causes Wilms tumor) but can act as an oncogene
  in AML/leukemias. Key transcriptional targets include nephrin/NPHS1 and podocalyxin
  (activation in podocytes), PAX2 (repression during differentiation), BCL2 and MYC
  (repression for tumor suppression), DNMT3A (activation), and SF1/SRY (activation
  in sex determination). WT1 is essential for: (1) mesenchymal-to-epithelial transition
  during nephrogenesis and podocyte maintenance, (2) gonadal development and sex determination,
  and (3) epicardial epithelial-to-mesenchymal transition for coronary vasculature
  formation via Wnt/beta-catenin and retinoic acid signaling.'
functional_isoforms:
  - id: WT1_MINUS_KTS
    name: "-KTS isoforms"
    type: SPLICE_CLASS
    maps_to:
      - type: UNIPROT_ISOFORM
        ids: [P19544-2, P19544-4]
    description: >
      DNA-binding transcription factors. The -KTS isoforms lack the KTS tripeptide
      (Lys-Thr-Ser) between zinc fingers 3 and 4, resulting in a shorter linker
      that maintains high DNA-binding affinity (Kd ~1 nM) for the consensus motif
      5'-GCG(T/G)GGGCG-3'. These isoforms function as classical transcription factors,
      both activating (SRY, DNMT3A, NPHS1) and repressing (PAX2, BCL2, MYC) target
      genes depending on cofactors and cellular context. The -KTS isoforms are
      essential for kidney development (Wilms tumor suppression) and sex determination.
      PMID:9815658 directly demonstrates SRY promoter activation by -KTS but NOT +KTS.
    isoform_specific_terms:
      - id: GO:0000981
        label: DNA-binding transcription factor activity, RNA polymerase 
          II-specific
      - id: GO:0045944
        label: positive regulation of transcription by RNA polymerase II
      - id: GO:0045892
        label: negative regulation of DNA-templated transcription

  - id: WT1_PLUS_KTS
    name: "+KTS isoforms"
    type: SPLICE_CLASS
    maps_to:
      - type: UNIPROT_ISOFORM
        ids: [P19544-1, P19544-3]
    description: >
      RNA-binding/splicing regulators. The +KTS isoforms have a 3-amino acid insertion
      (Lys-Thr-Ser) between zinc fingers 3 and 4, increasing linker flexibility and
      REDUCING DNA-binding affinity by ~10-fold. These isoforms localize to nuclear
      speckles (not nucleoplasm) and interact with splicing factors (U2AF65, RBM4,
      WTAP). The +KTS isoforms do NOT function as transcription factors - they
      participate in mRNA processing. PMID:9815658 shows +KTS does NOT activate the
      SRY promoter that -KTS strongly activates. Frasier syndrome results from loss
      of +KTS isoforms specifically, demonstrating their distinct developmental role.
      The normal +KTS:-KTS ratio of ~2:1 is critical for proper development.
    isoform_specific_terms:
      - id: GO:0003723
        label: RNA binding
      - id: GO:0016607
        label: nuclear speck
      - id: GO:0000398
        label: mRNA splicing, via spliceosome
existing_annotations:
  - term:
      id: GO:0000978
      label: RNA polymerase II cis-regulatory region sequence-specific DNA 
        binding
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: WT1 is well-established as a sequence-specific DNA-binding 
        transcription factor. The -KTS isoform binds with high affinity to the 
        consensus 5'-GCG(T/G)GGGCG-3' motif via its C2H2 zinc fingers 
        [PMID:7862533, PMID:25258363]. Multiple studies demonstrate direct 
        binding to cis-regulatory regions of target genes including PAX2, BCL2, 
        MYC, EGFR, PDGFA, SRY, and DNMT3A promoters.
      action: ACCEPT
      reason: Core molecular function well-supported by extensive biochemical 
        and structural evidence. Crystal structures confirm zinc finger-DNA 
        interactions [PMID:25258363]. This is a fundamental function of the -KTS
        isoform.
  - term:
      id: GO:0000981
      label: DNA-binding transcription factor activity, RNA polymerase 
        II-specific
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: WT1 functions as both a transcriptional activator and repressor 
        depending on target gene and cellular context. The -KTS isoform is the 
        primary transcription factor form. WT1 activates genes like SRY, DNMT3A,
        and EPO, while repressing PAX2, BCL2, MYC, and EGFR [PMID:9815658, 
        PMID:7720589, PMID:7585606, PMID:23042785].
      action: ACCEPT
      reason: Core molecular function. WT1's role as an RNA Pol II transcription
        factor is foundational to its developmental and tumor suppressor 
        functions. The dual activator/repressor activity is isoform-dependent 
        and context-dependent.
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: WT1 is predominantly nuclear, consistent with its role as a 
        transcription factor. Multiple IDA studies confirm nuclear localization 
        [PMID:1662794, PMID:8306891, PMID:7588596]. Both -KTS and +KTS isoforms 
        localize to the nucleus, though with different subnuclear distributions.
      action: ACCEPT
      reason: Core cellular component annotation well-supported by 
        immunofluorescence and biochemical fractionation studies. Nuclear 
        localization is essential for WT1's transcriptional regulatory function.
  - term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: WT1 regulates transcription of numerous target genes via RNA Pol 
        II machinery. It can both activate and repress transcription depending 
        on target and context. Documented targets include PAX2 (repression), 
        BCL2/MYC (repression), DNMT3A (activation), EPO (activation), SRY 
        (activation), and many others [PMID:23042785, PMID:7720589, 
        PMID:7585606, PMID:9815658].
      action: ACCEPT
      reason: Core biological process. Transcriptional regulation is the primary
        function of WT1, underlying its roles in development and tumor 
        suppression.
  - term:
      id: GO:0008285
      label: negative regulation of cell population proliferation
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: WT1 functions as a tumor suppressor and inhibits cell 
        proliferation. This is mediated through transcriptional repression of 
        growth-promoting genes like BCL2, MYC, and growth factor receptors, as 
        well as through interaction with Hsp70 [PMID:9553041, PMID:7585606].
      action: ACCEPT
      reason: Well-supported tumor suppressor function. WT1 loss leads to 
        uncontrolled proliferation in Wilms tumor. The antiproliferative effect 
        is demonstrated through inducible expression studies [PMID:9553041].
  - term:
      id: GO:0043066
      label: negative regulation of apoptotic process
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: WT1 has complex effects on apoptosis. While it represses BCL2 
        which would promote apoptosis [PMID:7585606], developmental studies show
        that WT1 is required for cell survival during nephrogenesis - Wt1 null 
        embryos show apoptosis in the urogenital ridge [PMID:10101119].
      action: KEEP_AS_NON_CORE
      reason: WT1's role in apoptosis regulation is context-dependent and likely
        secondary to its primary transcriptional regulatory functions. The 
        anti-apoptotic effect observed in development may reflect regulation of 
        survival factors rather than direct apoptosis pathway involvement.
  - term:
      id: GO:0000122
      label: negative regulation of transcription by RNA polymerase II
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: WT1 functions as a transcriptional repressor for multiple target 
        genes including PAX2, BCL2, MYC, EGFR, and AR [PMID:7720589, 
        PMID:7585606, PMID:7588596, PMID:9815658]. This is a well-documented 
        core function, particularly for the -KTS isoform.
      action: ACCEPT
      reason: Although this is an IEA annotation, transcriptional repression is 
        extensively documented by experimental evidence. This represents a core 
        molecular function.
  - term:
      id: GO:0003677
      label: DNA binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: WT1 contains four C2H2 zinc fingers that mediate DNA binding. 
        This is a core molecular function, though the more specific term 
        GO:0043565 (sequence-specific DNA binding) is preferable.
      action: ACCEPT
      reason: Valid annotation. While more specific terms exist (GO:0043565, 
        GO:0000978), this general DNA binding annotation is correct and 
        supported by extensive evidence.
  - term:
      id: GO:0003723
      label: RNA binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: The +KTS isoform of WT1 has documented RNA-binding activity. The 
        zinc finger domain provides overlapping surfaces for DNA and RNA binding
        [bardeesy1998]. The +KTS isoform associates with splicing factors and 
        participates in RNA processing [PMID:16934801].
      action: ACCEPT
      reason: Valid annotation for the +KTS isoform specifically. RNA binding is
        part of WT1's post-transcriptional regulatory functions. Note this is 
        isoform-specific.
      additional_reference_ids:
        - PMID:16934801
      supported_by:
        - reference_id: PMID:16934801
          supporting_text: Epub 2006 Jul 25. WT1 interacts with the splicing 
            protein RBM4 and regulates its ability to modulate alternative 
            splicing in vivo.
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: Nuclear localization is well-established for WT1, consistent with
        its role as a transcription factor.
      action: ACCEPT
      reason: Duplicate of IBA annotation above. Nuclear localization is 
        well-supported.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: WT1 is present in the nucleoplasm. The -KTS isoform has a diffuse
        nuclear distribution [PMID:15520190], while +KTS localizes more to 
        nuclear speckles.
      action: ACCEPT
      reason: Supported by localization studies. The -KTS isoform particularly 
        shows nucleoplasmic distribution.
  - term:
      id: GO:0005730
      label: nucleolus
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: UniProt indicates nucleolar localization. WT1 has been reported 
        in various nuclear subcompartments.
      action: UNDECIDED
      reason: Nucleolar localization is not prominently featured in the primary 
        literature. The primary nuclear localizations are nucleoplasm (-KTS) and
        nuclear speckles (+KTS). This annotation may represent a minor or 
        transient localization.
  - term:
      id: GO:0005737
      label: cytoplasm
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: WT1 can shuttle between nucleus and cytoplasm. Cytoplasmic WT1 
        has been associated with polysome-bound mRNPs, supporting 
        post-transcriptional roles.
      action: KEEP_AS_NON_CORE
      reason: While WT1 can be cytoplasmic, the primary localization and 
        function is nuclear. Cytoplasmic localization may relate to RNA 
        processing or shuttling.
  - term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    evidence_type: IEA
    original_reference_id: GO_REF:0000002
    review:
      summary: WT1 is a transcription factor that regulates expression of 
        numerous target genes. This is a core biological process annotation.
      action: ACCEPT
      reason: Core function. Equivalent to the more specific GO:0006357 
        (regulation of transcription by RNA Pol II).
  - term:
      id: GO:0008270
      label: zinc ion binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: WT1 contains four C2H2 zinc finger domains that coordinate zinc 
        ions for structural integrity and DNA binding. Zinc binding is 
        experimentally demonstrated [PMID:15518539, PMID:25258363].
      action: ACCEPT
      reason: Core molecular function. The zinc fingers are essential for DNA 
        binding activity. Structural studies confirm zinc coordination 
        [PMID:15518539].
  - term:
      id: GO:0016607
      label: nuclear speck
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: The +KTS isoform of WT1 localizes to nuclear speckles, which are 
        sites of pre-mRNA splicing factor storage and modification 
        [PMID:9553041, PMID:15520190, PMID:16934801].
      action: ACCEPT
      reason: Well-documented localization for the +KTS isoform, consistent with
        its role in RNA processing. Colocalization with RBM4 in speckles is 
        demonstrated.
  - term:
      id: GO:0046872
      label: metal ion binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: WT1 binds zinc ions via its C2H2 zinc finger domains. This is 
        correct but redundant with the more specific GO:0008270 (zinc ion 
        binding).
      action: ACCEPT
      reason: Valid but less informative than GO:0008270. Both terms are 
        appropriate.
  - term:
      id: GO:0072078
      label: nephron tubule morphogenesis
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: WT1 is essential for nephrogenesis. Wt1 knockout mice show 
        complete failure of kidney development [PMID:10101119]. WT1 regulates 
        genes required for nephron formation and glomerular development.
      action: ACCEPT
      reason: Well-supported developmental role. WT1 is required throughout 
        nephrogenesis, including tubule formation. This is a core biological 
        process for WT1.
  - term:
      id: GO:0072359
      label: circulatory system development
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: WT1 is expressed in the epicardium and is required for heart 
        development. Wt1 null mice die at E13.5 due to heart failure with 
        pericardial bleeding [PMID:10101119].
      action: KEEP_AS_NON_CORE
      reason: Valid annotation but represents a secondary developmental role. 
        The primary functions of WT1 are in kidney and gonad development. Heart 
        involvement is through epicardial/mesothelial functions.
  - term:
      id: GO:1990837
      label: sequence-specific double-stranded DNA binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: WT1 binds sequence-specifically to double-stranded DNA containing
        the motif 5'-GCG(T/G)GGGCG-3'. Crystal structures confirm this binding 
        mode [PMID:25258363].
      action: ACCEPT
      reason: Core molecular function. Equivalent to GO:0043565 which has 
        experimental support.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:19447967
    review:
      summary: High-throughput interaction study (Shifted Transversal Design 
        smart-pooling). Interaction with DVL3 (Dishevelled 3) reported.
      action: KEEP_AS_NON_CORE
      reason: '"Protein binding" is an uninformative term. The specific interaction
        partner (DVL3) is identified but functional significance for WT1 is unclear.
        Retain as evidence of protein interaction capacity but not informative about
        core function.'
      supported_by:
        - reference_id: PMID:19447967
          supporting_text: Shifted Transversal Design smart-pooling for high 
            coverage interactome mapping.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:21900206
    review:
      summary: High-throughput directed protein interaction network study. 
        Interaction with DVL3.
      action: KEEP_AS_NON_CORE
      reason: Uninformative term from high-throughput study. The specific 
        interaction (DVL3) lacks clear functional context for WT1 biology.
      supported_by:
        - reference_id: PMID:21900206
          supporting_text: A directed protein interaction network for 
            investigating intracellular signal transduction.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:25416956
    review:
      summary: Large-scale human interactome mapping study. Interactions with 
        KRTAP10-8 and KRT40.
      action: KEEP_AS_NON_CORE
      reason: High-throughput study. Keratin-associated proteins are not 
        obviously relevant to known WT1 biology. May represent non-specific 
        interactions.
      supported_by:
        - reference_id: PMID:25416956
          supporting_text: A proteome-scale map of the human interactome 
            network.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:25601757
    review:
      summary: WT1 recruits TET2 to regulate target gene expression and suppress
        leukemia cell proliferation. This represents a functionally important 
        interaction.
      action: MODIFY
      reason: This is a functionally significant interaction with TET2 
        (methylcytosine dioxygenase) involved in epigenetic regulation. The 
        generic "protein binding" term does not capture the functional 
        significance.
      proposed_replacement_terms:
        - id: GO:0140678
          label: molecular function activator activity
      supported_by:
        - reference_id: PMID:25601757
          supporting_text: 2015 Jan 15. WT1 recruits TET2 to regulate its target
            gene expression and suppress leukemia cell proliferation.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:27229929
    review:
      summary: Interactome mapping of ALL cancer gene products. WT1-DVL3 
        interaction.
      action: KEEP_AS_NON_CORE
      reason: Uninformative term. Part of cancer gene product interactome study.
        DVL3 interaction functional significance unclear.
      supported_by:
        - reference_id: PMID:27229929
          supporting_text: Systematic interactome mapping of acute lymphoblastic
            leukemia cancer gene products reveals EXT-1 tumor suppressor as a 
            Notch1 and FBWX7 common interactor.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:31515488
    review:
      summary: Study of genetic variants disrupting protein interactions. 
        Interaction with KRT40.
      action: KEEP_AS_NON_CORE
      reason: Uninformative term. Keratin interaction not obviously relevant to 
        WT1 function.
      supported_by:
        - reference_id: PMID:31515488
          supporting_text: Extensive disruption of protein interactions by 
            genetic variants across the allele frequency spectrum in human 
            populations.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:9553041
    review:
      summary: WT1 interacts with Hsp70 (HSPA1A/HSPA1B). This is a functionally 
        important interaction required for WT1's growth suppression activity 
        [PMID:9553041].
      action: MODIFY
      reason: Functionally significant interaction. Hsp70 binding is required 
        for WT1 antiproliferative function. Should be annotated with a more 
        specific term.
      proposed_replacement_terms:
        - id: GO:0051087
          label: chaperone binding
      supported_by:
        - reference_id: PMID:9553041
          supporting_text: Inhibition of cellular proliferation by the Wilms 
            tumor suppressor WT1 requires association with the inducible 
            chaperone Hsp70.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:7720589
    review:
      summary: WT1 interacts with PAX2, its transcriptional target. The study 
        demonstrates WT1 binding to PAX2 regulatory sequences and repression of 
        PAX2 expression.
      action: MODIFY
      reason: This represents DNA binding to PAX2 promoter rather than 
        protein-protein interaction. The IPI annotation may be misattributed.
      proposed_replacement_terms:
        - id: GO:0000976
          label: transcription cis-regulatory region binding
      supported_by:
        - reference_id: PMID:7720589
          supporting_text: Repression of Pax-2 by WT1 during normal kidney 
            development.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:16934801
    review:
      summary: WT1 interacts with RBM4, a splicing regulator. The +KTS isoform 
        specifically modulates RBM4's effect on alternative splicing 
        [PMID:16934801].
      action: MODIFY
      reason: Functionally significant interaction related to WT1's RNA 
        processing function. Should use a more specific MF term.
      proposed_replacement_terms:
        - id: GO:0140678
          label: molecular function activator activity
      supported_by:
        - reference_id: PMID:16934801
          supporting_text: Epub 2006 Jul 25. WT1 interacts with the splicing 
            protein RBM4 and regulates its ability to modulate alternative 
            splicing in vivo.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:21390327
    review:
      summary: WT1 interacts with PINCH1 (LIMS1). PINCH1 represses podocalyxin 
        expression and interacts with WT1 in podocytes.
      action: KEEP_AS_NON_CORE
      reason: PINCH1 interaction is documented but the term "protein binding" is
        uninformative. The functional significance relates to podocyte gene 
        regulation.
      supported_by:
        - reference_id: PMID:21390327
          supporting_text: PINCH1 is transcriptional regulator in podocytes that
            interacts with WT1 and represses podocalyxin expression.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:14701728
    review:
      summary: WT1 interacts with BASP1, a transcriptional cosuppressor. BASP1 
        binding converts WT1 from an activator to a repressor at specific 
        promoters.
      action: MODIFY
      reason: Functionally important interaction that modulates WT1's 
        transcriptional activity. BASP1 is a documented WT1 cofactor.
      proposed_replacement_terms:
        - id: GO:0003714
          label: transcription corepressor activity
      supported_by:
        - reference_id: PMID:14701728
          supporting_text: BASP1 is a transcriptional cosuppressor for the 
            Wilms' tumor suppressor protein WT1.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:9178767
    review:
      summary: WT1 interacts with PAX2. PAX2 regulates WT1 promoter activity in 
        a reciprocal regulatory relationship.
      action: KEEP_AS_NON_CORE
      reason: Documents interaction between two kidney development transcription
        factors. Generic term is uninformative.
      supported_by:
        - reference_id: PMID:9178767
          supporting_text: Differential regulation of the human Wilms tumour 
            suppressor gene (WT1) promoter by two isoforms of PAX2.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:8119964
    review:
      summary: WT1 can form homodimers and binds to its own promoter for 
        autoregulation. The interaction is via the zinc finger domain (C2H2 zinc
        finger domain binding).
      action: ACCEPT
      reason: Documents WT1 homodimerization. Also annotated with GO:0070742 
        (C2H2 zinc finger domain binding) which is more specific.
      supported_by:
        - reference_id: PMID:8119964
          supporting_text: The Wilms' tumor suppressor gene WT1 is negatively 
            autoregulated.
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: IDA
    original_reference_id: GO_REF:0000052
    review:
      summary: HPA immunofluorescence data showing nucleoplasmic localization.
      action: ACCEPT
      reason: Supported by imaging data. Consistent with WT1's nuclear 
        transcription factor function.
  - term:
      id: GO:0005829
      label: cytosol
    evidence_type: IDA
    original_reference_id: GO_REF:0000052
    review:
      summary: HPA immunofluorescence data indicating cytosolic presence.
      action: KEEP_AS_NON_CORE
      reason: WT1 can shuttle to cytoplasm but primary function is nuclear. 
        Cytosolic localization may relate to shuttling or RNA processing 
        functions.
  - term:
      id: GO:0008270
      label: zinc ion binding
    evidence_type: IDA
    original_reference_id: PMID:25258363
    review:
      summary: Crystal structure of WT1 zinc finger domain bound to DNA confirms
        zinc coordination in C2H2 zinc fingers [PMID:25258363].
      action: ACCEPT
      reason: Core molecular function confirmed by structural biology.
      supported_by:
        - reference_id: PMID:25258363
          supporting_text: Sep 25. Wilms tumor protein recognizes 
            5-carboxylcytosine within a specific DNA sequence.
  - term:
      id: GO:0010385
      label: double-stranded methylated DNA binding
    evidence_type: IDA
    original_reference_id: PMID:25258363
    review:
      summary: WT1 can bind to methylated DNA. The study shows WT1 has slightly 
        higher affinity for 5mC-containing sequences compared to unmethylated, 
        but much lower affinity for oxidized forms (5hmC, 5fC, 5caC) 
        [PMID:25258363].
      action: ACCEPT
      reason: Directly demonstrated by biochemical and structural studies. This 
        is a specialized aspect of WT1's DNA binding activity.
      supported_by:
        - reference_id: PMID:25258363
          supporting_text: Sep 25. Wilms tumor protein recognizes 
            5-carboxylcytosine within a specific DNA sequence.
  - term:
      id: GO:0043565
      label: sequence-specific DNA binding
    evidence_type: IDA
    original_reference_id: PMID:25258363
    review:
      summary: WT1 binds to the consensus sequence 5'-GCG(T/G)GGGCG-3' with high
        affinity and specificity [PMID:25258363, PMID:7862533].
      action: ACCEPT
      reason: Core molecular function demonstrated by multiple methods including
        gel shift, footprinting, and X-ray crystallography.
      supported_by:
        - reference_id: PMID:25258363
          supporting_text: Sep 25. Wilms tumor protein recognizes 
            5-carboxylcytosine within a specific DNA sequence.
  - term:
      id: GO:0044729
      label: hemi-methylated DNA-binding
    evidence_type: IDA
    original_reference_id: PMID:25258363
    review:
      summary: Study demonstrates WT1 can bind hemi-methylated DNA substrates 
        [PMID:25258363].
      action: ACCEPT
      reason: Directly demonstrated in the structural/biochemical study.
      supported_by:
        - reference_id: PMID:25258363
          supporting_text: Sep 25. Wilms tumor protein recognizes 
            5-carboxylcytosine within a specific DNA sequence.
  - term:
      id: GO:0016607
      label: nuclear speck
    evidence_type: IDA
    original_reference_id: PMID:9553041
    review:
      summary: WT1 localizes to nuclear speckles, particularly the +KTS isoform 
        which colocalizes with splicing factors [PMID:9553041, PMID:16934801].
      action: ACCEPT
      reason: Isoform-specific localization related to RNA processing function.
      supported_by:
        - reference_id: PMID:9553041
          supporting_text: Inhibition of cellular proliferation by the Wilms 
            tumor suppressor WT1 requires association with the inducible 
            chaperone Hsp70.
  - term:
      id: GO:0000978
      label: RNA polymerase II cis-regulatory region sequence-specific DNA 
        binding
    evidence_type: IDA
    original_reference_id: PMID:23042785
    review:
      summary: ChIP assays demonstrate WT1 recruitment to the DNMT3A promoter 
        region [PMID:23042785].
      action: ACCEPT
      reason: Core molecular function demonstrated by chromatin 
        immunoprecipitation.
      supported_by:
        - reference_id: PMID:23042785
          supporting_text: 'Chromatin immunoprecipitation assays demonstrate WT1 recruitment
            to the DNMT3A promoter region'
  - term:
      id: GO:0001228
      label: DNA-binding transcription activator activity, RNA polymerase 
        II-specific
    evidence_type: IDA
    original_reference_id: PMID:23042785
    review:
      summary: WT1 directly transactivates DNMT3A expression. Reporter assays 
        confirm transcriptional activation [PMID:23042785].
      action: ACCEPT
      reason: Core molecular function. WT1 activates transcription of multiple 
        target genes including DNMT3A, EPO, and SRY.
      supported_by:
        - reference_id: PMID:23042785
          supporting_text: 'reporter assays confirm that WT1 directly transactivates
            DNMT3A expression'
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:16934801
    review:
      summary: Immunofluorescence shows nuclear localization of WT1 
        [PMID:16934801].
      action: ACCEPT
      reason: Duplicate of multiple other annotations. Nuclear localization is 
        core.
      supported_by:
        - reference_id: PMID:16934801
          supporting_text: Epub 2006 Jul 25. WT1 interacts with the splicing 
            protein RBM4 and regulates its ability to modulate alternative 
            splicing in vivo.
  - term:
      id: GO:0016607
      label: nuclear speck
    evidence_type: IDA
    original_reference_id: PMID:16934801
    review:
      summary: WT1 colocalizes with RBM4 in nuclear speckles [PMID:16934801].
      action: ACCEPT
      reason: Consistent with +KTS isoform's role in RNA processing.
      supported_by:
        - reference_id: PMID:16934801
          supporting_text: Epub 2006 Jul 25. WT1 interacts with the splicing 
            protein RBM4 and regulates its ability to modulate alternative 
            splicing in vivo.
  - term:
      id: GO:0043565
      label: sequence-specific DNA binding
    evidence_type: IDA
    original_reference_id: PMID:7720589
    review:
      summary: DNase I footprinting demonstrates WT1 binding to specific sites 
        in the PAX2 promoter [PMID:7720589].
      action: ACCEPT
      reason: Core molecular function demonstrated by direct biochemical assay.
      supported_by:
        - reference_id: PMID:7720589
          supporting_text: Repression of Pax-2 by WT1 during normal kidney 
            development.
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:7720589
    review:
      summary: WT1 represses PAX2 transcription. Co-transfection assays 
        demonstrate WT1-dependent transcriptional repression [PMID:7720589].
      action: ACCEPT
      reason: Core function. WT1 represses multiple target genes. PAX2 
        repression is important for kidney development.
      supported_by:
        - reference_id: PMID:7720589
          supporting_text: Repression of Pax-2 by WT1 during normal kidney 
            development.
  - term:
      id: GO:0000976
      label: transcription cis-regulatory region binding
    evidence_type: IDA
    original_reference_id: PMID:9815658
    review:
      summary: EMSA shows WT1 binding to promoter elements of SRY, MIS, and 
        androgen receptor genes [PMID:9815658].
      action: ACCEPT
      reason: Core molecular function demonstrated for multiple target gene 
        promoters.
      supported_by:
        - reference_id: PMID:9815658
          supporting_text: "The Wilms' tumor gene WT1 can regulate genes involved
            in sex determination and differentiation: SRY, MΓΌllerian-inhibiting substance,
            and the androgen receptor."
  - term:
      id: GO:0007530
      label: sex determination
    evidence_type: IDA
    original_reference_id: PMID:9815658
    review:
      summary: WT1 regulates transcription of sex determination genes SRY, MIS, 
        and androgen receptor [PMID:9815658]. Genital abnormalities in DDS 
        patients and Wt1 knockout mice support this role.
      action: ACCEPT
      reason: Core biological process. WT1 is essential for gonadal development 
        and sex determination, regulating key genes in the pathway.
      supported_by:
        - reference_id: PMID:9815658
          supporting_text: "The Wilms' tumor gene WT1 can regulate genes involved
            in sex determination and differentiation: SRY, MΓΌllerian-inhibiting substance,
            and the androgen receptor."
  - term:
      id: GO:0043565
      label: sequence-specific DNA binding
    evidence_type: IDA
    original_reference_id: PMID:1662794
    review:
      summary: WT1 binds to the EGR consensus sequence in gel-retardation assays
        [PMID:1662794].
      action: ACCEPT
      reason: One of the earliest demonstrations of WT1's sequence-specific DNA 
        binding.
      supported_by:
        - reference_id: PMID:1662794
          supporting_text: Characterization of the zinc finger protein encoded 
            by the WT1 Wilms' tumor locus.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:8132626
    review:
      summary: WT1 activates transcription in certain contexts.
      action: ACCEPT
      reason: Core function. WT1 can act as both activator and repressor.
      supported_by:
        - reference_id: PMID:8132626
          supporting_text: Transcriptional regulation of the human Wilms' tumor 
            gene (WT1).
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:21390327
    review:
      summary: WT1 regulates podocalyxin expression in podocytes.
      action: ACCEPT
      reason: Supports WT1's role in podocyte gene regulation.
      supported_by:
        - reference_id: PMID:21390327
          supporting_text: PINCH1 is transcriptional regulator in podocytes that
            interacts with WT1 and represses podocalyxin expression.
  - term:
      id: GO:0008285
      label: negative regulation of cell population proliferation
    evidence_type: IDA
    original_reference_id: PMID:9553041
    review:
      summary: Inducible WT1 expression inhibits cellular proliferation. This 
        requires association with Hsp70 [PMID:9553041].
      action: ACCEPT
      reason: Core tumor suppressor function demonstrated by inducible 
        expression studies.
      supported_by:
        - reference_id: PMID:9553041
          supporting_text: Inhibition of cellular proliferation by the Wilms 
            tumor suppressor WT1 requires association with the inducible 
            chaperone Hsp70.
  - term:
      id: GO:0030308
      label: negative regulation of cell growth
    evidence_type: IDA
    original_reference_id: PMID:9553041
    review:
      summary: WT1 inhibits cell growth [PMID:9553041].
      action: ACCEPT
      reason: Related to tumor suppressor function. Equivalent to GO:0008285.
      supported_by:
        - reference_id: PMID:9553041
          supporting_text: Inhibition of cellular proliferation by the Wilms 
            tumor suppressor WT1 requires association with the inducible 
            chaperone Hsp70.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:9178767
    review:
      summary: PMID:9178767 investigates PAX2 regulation of the WT1 promoter, 
        not WT1's transcriptional activity. The study shows "PAX2 transactivated
        the WT1 promoter up to 35-fold" - this is PAX2's function, not WT1's.
      action: REMOVE
      reason: This annotation is incorrectly attributed. The referenced paper 
        demonstrates that PAX2 activates WT1 transcription (PAX2 -> WT1), not 
        that WT1 positively regulates other genes. This should be an annotation 
        on PAX2, not WT1.
      supported_by:
        - reference_id: PMID:9178767
          supporting_text: Differential regulation of the human Wilms tumour 
            suppressor gene (WT1) promoter by two isoforms of PAX2.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:9553041
    review:
      summary: WT1 can activate transcription of certain target genes.
      action: ACCEPT
      reason: WT1 has dual activator/repressor function.
      supported_by:
        - reference_id: PMID:9553041
          supporting_text: Inhibition of cellular proliferation by the Wilms 
            tumor suppressor WT1 requires association with the inducible 
            chaperone Hsp70.
  - term:
      id: GO:0000976
      label: transcription cis-regulatory region binding
    evidence_type: IDA
    original_reference_id: PMID:7588596
    review:
      summary: WT1 binds to EGFR promoter elements [PMID:7588596].
      action: ACCEPT
      reason: Core molecular function for regulation of EGFR.
      supported_by:
        - reference_id: PMID:7588596
          supporting_text: WT1 suppresses synthesis of the epidermal growth 
            factor receptor and induces apoptosis.
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:9815658
    review:
      summary: WT1 represses transcription of MIS and androgen receptor genes 
        [PMID:9815658].
      action: ACCEPT
      reason: Core repressor function on sex determination genes.
      supported_by:
        - reference_id: PMID:9815658
          supporting_text: "The Wilms' tumor gene WT1 can regulate genes involved
            in sex determination and differentiation: SRY, MΓΌllerian-inhibiting substance,
            and the androgen receptor."
    isoform: P19544-1
  - term:
      id: GO:0008270
      label: zinc ion binding
    evidence_type: IDA
    original_reference_id: PMID:15518539
    review:
      summary: NMR structure of WT1 zinc fingers in complex with zinc 
        [PMID:15518539].
      action: ACCEPT
      reason: Structural confirmation of zinc binding.
      supported_by:
        - reference_id: PMID:15518539
          supporting_text: 'Why zinc fingers prefer zinc: ligand-field symmetry and
            the hidden thermodynamics of metal ion selectivity.'
  - term:
      id: GO:0000976
      label: transcription cis-regulatory region binding
    evidence_type: IDA
    original_reference_id: PMID:1332065
    review:
      summary: WT1 binds to PDGFA promoter [PMID:1332065].
      action: ACCEPT
      reason: Core molecular function.
      supported_by:
        - reference_id: PMID:1332065
          supporting_text: Human platelet-derived growth factor A chain is 
            transcriptionally repressed by the Wilms tumor suppressor WT1.
  - term:
      id: GO:0000976
      label: transcription cis-regulatory region binding
    evidence_type: IDA
    original_reference_id: PMID:7585606
    review:
      summary: WT1 binds to BCL2 and MYC promoter elements [PMID:7585606].
      action: ACCEPT
      reason: Core molecular function for tumor suppressor activity.
      supported_by:
        - reference_id: PMID:7585606
          supporting_text: Regulation of the proto-oncogenes bcl-2 and c-myc by 
            the Wilms' tumor suppressor gene WT1.
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:1332065
    review:
      summary: WT1 represses PDGFA transcription.
      action: ACCEPT
      reason: Core repressor function.
      supported_by:
        - reference_id: PMID:1332065
          supporting_text: Human platelet-derived growth factor A chain is 
            transcriptionally repressed by the Wilms tumor suppressor WT1.
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:7585606
    review:
      summary: WT1 represses BCL2 and MYC transcription [PMID:7585606].
      action: ACCEPT
      reason: Core tumor suppressor function.
      supported_by:
        - reference_id: PMID:7585606
          supporting_text: Regulation of the proto-oncogenes bcl-2 and c-myc by 
            the Wilms' tumor suppressor gene WT1.
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:7588596
    review:
      summary: Nuclear localization confirmed.
      action: ACCEPT
      reason: Duplicate annotation. Nuclear localization is core.
      supported_by:
        - reference_id: PMID:7588596
          supporting_text: WT1 suppresses synthesis of the epidermal growth 
            factor receptor and induces apoptosis.
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:14701728
    review:
      summary: Nuclear localization confirmed.
      action: ACCEPT
      reason: Duplicate annotation.
      supported_by:
        - reference_id: PMID:14701728
          supporting_text: BASP1 is a transcriptional cosuppressor for the 
            Wilms' tumor suppressor protein WT1.
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:14701728
    review:
      summary: WT1 with BASP1 represses transcription [PMID:14701728].
      action: ACCEPT
      reason: Core function. BASP1 modulates WT1's repressor activity.
      supported_by:
        - reference_id: PMID:14701728
          supporting_text: BASP1 is a transcriptional cosuppressor for the 
            Wilms' tumor suppressor protein WT1.
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:19050011
    review:
      summary: Dynamic WT1-BASP1 interaction regulates transcription during 
        differentiation.
      action: ACCEPT
      reason: Supports repressor function.
      supported_by:
        - reference_id: PMID:19050011
          supporting_text: Dec 2. Dynamic interaction between WT1 and BASP1 in 
            transcriptional regulation during differentiation.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:14701728
    review:
      summary: WT1 without BASP1 can activate transcription.
      action: ACCEPT
      reason: Dual activator/repressor function depends on cofactor context.
      supported_by:
        - reference_id: PMID:14701728
          supporting_text: BASP1 is a transcriptional cosuppressor for the 
            Wilms' tumor suppressor protein WT1.
  - term:
      id: GO:0008285
      label: negative regulation of cell population proliferation
    evidence_type: IDA
    original_reference_id: PMID:9765217
    review:
      summary: WT1 induces RbAp46 which mediates growth inhibition 
        [PMID:9765217].
      action: ACCEPT
      reason: Tumor suppressor mechanism.
      supported_by:
        - reference_id: PMID:9765217
          supporting_text: Induction of Rb-associated protein (RbAp46) by Wilms'
            tumor suppressor WT1 mediates growth inhibition.
  - term:
      id: GO:0030308
      label: negative regulation of cell growth
    evidence_type: IDA
    original_reference_id: PMID:9765217
    review:
      summary: WT1-induced growth inhibition via RbAp46.
      action: ACCEPT
      reason: Related to tumor suppressor function.
      supported_by:
        - reference_id: PMID:9765217
          supporting_text: Induction of Rb-associated protein (RbAp46) by Wilms'
            tumor suppressor WT1 mediates growth inhibition.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:9765217
    review:
      summary: WT1 activates RbAp46 transcription.
      action: ACCEPT
      reason: WT1 can activate transcription of certain targets.
      supported_by:
        - reference_id: PMID:9765217
          supporting_text: Induction of Rb-associated protein (RbAp46) by Wilms'
            tumor suppressor WT1 mediates growth inhibition.
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:1662794
    review:
      summary: Immunofluorescence shows nuclear localization [PMID:1662794].
      action: ACCEPT
      reason: Core localization.
      supported_by:
        - reference_id: PMID:1662794
          supporting_text: Characterization of the zinc finger protein encoded 
            by the WT1 Wilms' tumor locus.
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:8306891
    review:
      summary: Nuclear localization in embryonic and adult tissues.
      action: ACCEPT
      reason: Core localization.
      supported_by:
        - reference_id: PMID:8306891
          supporting_text: Nuclear localization of the protein encoded by the 
            Wilms' tumor gene WT1 in embryonic and adult tissues.
  - term:
      id: GO:0043565
      label: sequence-specific DNA binding
    evidence_type: IDA
    original_reference_id: PMID:8119964
    review:
      summary: WT1 binds specifically to its own promoter for autoregulation.
      action: ACCEPT
      reason: Core molecular function.
      supported_by:
        - reference_id: PMID:8119964
          supporting_text: The Wilms' tumor suppressor gene WT1 is negatively 
            autoregulated.
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:12802290
    review:
      summary: WT1 regulates c-MYC expression. c-MYC is upregulated in 
        WT1-mutant tumors.
      action: ACCEPT
      reason: Core tumor suppressor mechanism.
      supported_by:
        - reference_id: PMID:12802290
          supporting_text: "Upregulation of c-MYC in WT1-mutant tumors: assessment
            of WT1 putative transcriptional targets using cDNA microarray expression
            profiling of genetically defined Wilms' tumors."
  - term:
      id: GO:0045892
      label: negative regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:8119964
    review:
      summary: WT1 negatively autoregulates its own expression.
      action: ACCEPT
      reason: Autoregulatory repression.
      supported_by:
        - reference_id: PMID:8119964
          supporting_text: The Wilms' tumor suppressor gene WT1 is negatively 
            autoregulated.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:12802290
    review:
      summary: PMID:12802290 shows "c-MYC...was upregulated in WT1-mutant 
        tumors", meaning WT1 normally represses c-MYC. The paper states WT1 
        "represses or activates the expression of a variety of putative target 
        genes" but the specific finding for c-MYC supports repression.
      action: REMOVE
      reason: This annotation contradicts the evidence in the referenced paper. 
        PMID:12802290 demonstrates that c-MYC is upregulated when WT1 is 
        mutated, indicating WT1 normally represses (not activates) c-MYC 
        transcription. The negative regulation annotation from this paper is 
        correct; this positive regulation annotation is erroneous.
      supported_by:
        - reference_id: PMID:12802290
          supporting_text: "Upregulation of c-MYC in WT1-mutant tumors: assessment
            of WT1 putative transcriptional targets using cDNA microarray expression
            profiling of genetically defined Wilms' tumors."
  - term:
      id: GO:0070742
      label: C2H2 zinc finger domain binding
    evidence_type: IPI
    original_reference_id: PMID:8119964
    review:
      summary: WT1 homodimerizes via zinc finger domains.
      action: ACCEPT
      reason: Specific molecular function for homodimerization.
      supported_by:
        - reference_id: PMID:8119964
          supporting_text: The Wilms' tumor suppressor gene WT1 is negatively 
            autoregulated.
  - term:
      id: GO:0016607
      label: nuclear speck
    evidence_type: IDA
    original_reference_id: PMID:15520190
    review:
      summary: +KTS isoform (isoform 1) localizes to nuclear speckles 
        [PMID:15520190].
      action: ACCEPT
      reason: Isoform-specific localization related to RNA processing.
      supported_by:
        - reference_id: PMID:15520190
          supporting_text: SUMO-1 modification of the Wilms' tumor suppressor 
            WT1.
    isoform: P19544-1
  - term:
      id: GO:0000976
      label: transcription cis-regulatory region binding
    evidence_type: IDA
    original_reference_id: PMID:16467207
    review:
      summary: WT1 binds to erythropoietin (EPO) gene promoter [PMID:16467207].
      action: ACCEPT
      reason: Core molecular function for EPO regulation.
      supported_by:
        - reference_id: PMID:16467207
          supporting_text: Feb 7. Wilms tumor suppressor, Wt1, is a 
            transcriptional activator of the erythropoietin gene.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:16467207
    review:
      summary: WT1 activates EPO gene transcription [PMID:16467207].
      action: ACCEPT
      reason: Core activator function.
      supported_by:
        - reference_id: PMID:16467207
          supporting_text: Feb 7. Wilms tumor suppressor, Wt1, is a 
            transcriptional activator of the erythropoietin gene.
  - term:
      id: GO:0000122
      label: negative regulation of transcription by RNA polymerase II
    evidence_type: IDA
    original_reference_id: PMID:7585606
    review:
      summary: WT1 represses BCL2 and MYC via RNA Pol II [PMID:7585606].
      action: ACCEPT
      reason: Core repressor function.
      supported_by:
        - reference_id: PMID:7585606
          supporting_text: Regulation of the proto-oncogenes bcl-2 and c-myc by 
            the Wilms' tumor suppressor gene WT1.
  - term:
      id: GO:0044027
      label: negative regulation of gene expression via chromosomal CpG island 
        methylation
    evidence_type: IMP
    original_reference_id: PMID:23042785
    review:
      summary: WT1 regulates DNMT3A, leading to DNA methylation changes at 
        specific promoters. WT1 overexpression causes hypermethylation and 
        silencing [PMID:23042785].
      action: ACCEPT
      reason: Novel regulatory function linking WT1 to epigenetic regulation via
        DNMT3A. Well-supported by the study.
      supported_by:
        - reference_id: PMID:23042785
          supporting_text: 'human embryonal kidney cells over-expressing WT1 acquire
            DNA methylation changes at specific gene promoters where DNMT3A recruitment
            is increased, with hypermethylation being associated with silencing of
            gene expression'
  - term:
      id: GO:0000122
      label: negative regulation of transcription by RNA polymerase II
    evidence_type: IMP
    original_reference_id: PMID:23042785
    review:
      summary: WT1 depletion affects transcription of methylated genes.
      action: ACCEPT
      reason: Supported by knockdown studies in the paper.
      supported_by:
        - reference_id: PMID:23042785
          supporting_text: 'depletion of WT1 in Wilms'' tumour cells can lead to reactivation
            of gene expression from methylated promoters'
  - term:
      id: GO:0010628
      label: positive regulation of gene expression
    evidence_type: IMP
    original_reference_id: PMID:23042785
    review:
      summary: WT1 positively regulates DNMT3A expression.
      action: ACCEPT
      reason: Direct evidence from the study.
      supported_by:
        - reference_id: PMID:23042785
          supporting_text: 'depletion of WT1 by short-interfering RNAs leads to reduced
            DNMT3A in Wilms'' tumour cells'
  - term:
      id: GO:0045944
      label: positive regulation of transcription by RNA polymerase II
    evidence_type: IDA
    original_reference_id: PMID:23042785
    review:
      summary: WT1 activates DNMT3A transcription.
      action: ACCEPT
      reason: Core activator function demonstrated by reporter assays.
      supported_by:
        - reference_id: PMID:23042785
          supporting_text: 'Wilms'' tumour 1 (WT1), a developmental master regulator
            that can also act as a tumour suppressor or oncoprotein, transcriptionally
            regulates the de novo DNA methyltransferase 3A (DNMT3A)'
  - term:
      id: GO:1902895
      label: positive regulation of miRNA transcription
    evidence_type: IMP
    original_reference_id: PMID:23042785
    review:
      summary: WT1 may regulate miRNA transcription through DNMT3A-mediated 
        epigenetic effects.
      action: UNDECIDED
      reason: The PMID:23042785 paper focuses on DNMT3A regulation. The 
        connection to miRNA transcription is not directly documented in the 
        abstract. Need to verify this specific claim.
      supported_by:
        - reference_id: PMID:23042785
          supporting_text: Control of epigenetic states by WT1 via regulation of
            de novo DNA methyltransferase 3A.
  - term:
      id: GO:0032836
      label: glomerular basement membrane development
    evidence_type: IMP
    original_reference_id: PMID:19205749
    review:
      summary: WT1 mutation associated with glomerular defects.
      action: ACCEPT
      reason: WT1 is essential for podocyte function and glomerular development.
        Mutations cause glomerular disease.
      supported_by:
        - reference_id: PMID:19205749
          supporting_text: 2009 Feb 11. Membranoproliferative glomerulonephritis
            associated with a mutation in Wilms' tumour suppressor gene 1.
  - term:
      id: GO:0007507
      label: heart development
    evidence_type: IGI
    original_reference_id: PMID:10101119
    review:
      summary: Wt1 knockout mice show heart defects with pericardial bleeding. 
        YAC rescue experiments demonstrate WT1 requirement for heart development
        [PMID:10101119].
      action: KEEP_AS_NON_CORE
      reason: Valid developmental role but secondary to kidney/gonad functions. 
        Heart involvement is through epicardial development.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: 'Lack of WT1 leads to severe defects in the epicardial
            layer and a concomitant absence of SEMCs, which explains the pericardial
            bleeding and subsequent embryonic death observed in Wt1 null embryos'
  - term:
      id: GO:0030325
      label: adrenal gland development
    evidence_type: IGI
    original_reference_id: PMID:10101119
    review:
      summary: Partially rescued Wt1 mutant embryos show severely affected 
        adrenal gland development [PMID:10101119].
      action: KEEP_AS_NON_CORE
      reason: Valid developmental role but less prominent than kidney/gonad. 
        Related to WT1's role in intermediate mesoderm-derived organs.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: 'the development of adrenal glands is also severely affected
            in partially rescued embryos'
  - term:
      id: GO:0072284
      label: metanephric S-shaped body morphogenesis
    evidence_type: IGI
    original_reference_id: PMID:10101119
    review:
      summary: WT1 required for nephron morphogenesis including S-shaped body 
        stage.
      action: ACCEPT
      reason: Core kidney development function.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: 'Analysis of the observed hypoplastic kidneys demonstrate
            a continuous requirement for WT1 during nephrogenesis, in particular,
            in the formation of mature glomeruli'
  - term:
      id: GO:0061032
      label: visceral serous pericardium development
    evidence_type: IGI
    original_reference_id: PMID:10101119
    review:
      summary: WT1 is expressed in epicardium and required for its development.
      action: KEEP_AS_NON_CORE
      reason: Valid but secondary to kidney/gonad roles.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: 'WT1 is expressed in the early proepicardium, the epicardium
            and the subepicardial mesenchymal cells (SEMC)'
  - term:
      id: GO:0001658
      label: branching involved in ureteric bud morphogenesis
    evidence_type: IGI
    original_reference_id: PMID:10101119
    review:
      summary: WT1 regulates ureteric bud development.
      action: ACCEPT
      reason: Core kidney development function.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: 'a general requirement for this protein in the formation
            of organs derived from the intermediate mesoderm'
  - term:
      id: GO:0001822
      label: kidney development
    evidence_type: IGI
    original_reference_id: PMID:11912180
    review:
      summary: Reduced WT1 levels cause crescentic glomerulonephritis or 
        mesangial sclerosis depending on dosage. WT1 regulates podocyte genes 
        nphs1 and podocalyxin [PMID:11912180].
      action: ACCEPT
      reason: Core biological process. WT1 is essential for all stages of kidney
        development and podocyte maintenance.
      supported_by:
        - reference_id: PMID:11912180
          supporting_text: 'WT1 is a key regulator of podocyte function: reduced expression
            levels cause crescentic glomerulonephritis and mesangial sclerosis.'
  - term:
      id: GO:0032835
      label: glomerulus development
    evidence_type: IGI
    original_reference_id: PMID:10101119
    review:
      summary: WT1 required for mature glomeruli formation.
      action: ACCEPT
      reason: Core kidney development function.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: 'a continuous requirement for WT1 during nephrogenesis,
            in particular, in the formation of mature glomeruli'
  - term:
      id: GO:0043066
      label: negative regulation of apoptotic process
    evidence_type: IGI
    original_reference_id: PMID:10101119
    review:
      summary: WT1 prevents apoptosis in developing kidney/epicardium.
      action: KEEP_AS_NON_CORE
      reason: Likely secondary to WT1's role in regulating survival genes.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: YAC complementation shows a requirement for Wt1 in 
            the development of epicardium, adrenal gland and throughout 
            nephrogenesis.
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IGI
    original_reference_id: PMID:11912180
    review:
      summary: WT1 activates podocyte-specific genes like nphs1 and podocalyxin.
      action: ACCEPT
      reason: Core function in podocyte gene regulation.
      supported_by:
        - reference_id: PMID:11912180
          supporting_text: 'WT1 is a key regulator of podocyte function: reduced expression
            levels cause crescentic glomerulonephritis and mesangial sclerosis.'
  - term:
      id: GO:0072207
      label: metanephric epithelium development
    evidence_type: IEP
    original_reference_id: PMID:7856737
    review:
      summary: WT1 expressed in developing metanephric epithelium, consistent 
        with role.
      action: ACCEPT
      reason: Expression pattern supports functional role in kidney development.
      supported_by:
        - reference_id: PMID:7856737
          supporting_text: Comparative in situ hybridization analysis of PAX2, 
            PAX8, and WT1 gene transcription in human fetal kidney and Wilms' 
            tumors.
  - term:
      id: GO:0071320
      label: cellular response to cAMP
    evidence_type: IEP
    original_reference_id: PMID:15961562
    review:
      summary: WT1 expression regulated by cAMP signaling in placenta.
      action: KEEP_AS_NON_CORE
      reason: IEP evidence only. Expression response to cAMP does not indicate 
        direct function in cAMP signaling pathway.
      supported_by:
        - reference_id: PMID:15961562
          supporting_text: Jun 16. Expression, regulation, and function of 
            paired-box gene 8 in the human placenta and placental cancer cell 
            lines.
  - term:
      id: GO:0071371
      label: cellular response to gonadotropin stimulus
    evidence_type: IDA
    original_reference_id: PMID:15961562
    review:
      summary: WT1 expression responsive to gonadotropin in placenta.
      action: KEEP_AS_NON_CORE
      reason: Placental expression context. Not a core function but reflects 
        tissue-specific regulation.
      supported_by:
        - reference_id: PMID:15961562
          supporting_text: Jun 16. Expression, regulation, and function of 
            paired-box gene 8 in the human placenta and placental cancer cell 
            lines.
  - term:
      id: GO:0008584
      label: male gonad development
    evidence_type: IEP
    original_reference_id: PMID:17848411
    review:
      summary: WT1 expressed during fetal testis development.
      action: ACCEPT
      reason: Supports core role in gonad development. Expression pattern is 
        consistent with functional requirement.
      supported_by:
        - reference_id: PMID:17848411
          supporting_text: Epub 2007 Sep 11. Developmental changes in human 
            fetal testicular cell numbers and messenger ribonucleic acid levels 
            during the second trimester.
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:15961562
    review:
      summary: Nuclear localization in placental cells.
      action: ACCEPT
      reason: Consistent with nuclear localization in all tissues.
      supported_by:
        - reference_id: PMID:15961562
          supporting_text: Jun 16. Expression, regulation, and function of 
            paired-box gene 8 in the human placenta and placental cancer cell 
            lines.
  - term:
      id: GO:0001228
      label: DNA-binding transcription activator activity, RNA polymerase 
        II-specific
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse WT1. Well-supported by direct human evidence.
      action: ACCEPT
      reason: Human WT1 has documented transcription activator activity (IDA 
        evidence exists).
  - term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse WT1. Core function.
      action: ACCEPT
      reason: Well-supported by human experimental evidence.
  - term:
      id: GO:2001076
      label: positive regulation of metanephric ureteric bud development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse knockout studies.
      action: ACCEPT
      reason: Consistent with human WT1's role in kidney development.
  - term:
      id: GO:0007356
      label: thorax and anterior abdomen determination
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse. This is a Drosophila-centric term.
      action: REMOVE
      reason: This GO term is specific to Drosophila body segmentation. Not 
        applicable to mammalian WT1 biology. Likely annotation error.
  - term:
      id: GO:0008406
      label: gonad development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse knockout studies. Core function.
      action: ACCEPT
      reason: Well-supported by human genetics (DDS, Frasier syndrome).
  - term:
      id: GO:0060421
      label: positive regulation of heart growth
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse. Heart involvement via epicardium.
      action: KEEP_AS_NON_CORE
      reason: Valid but secondary to kidney/gonad roles.
  - term:
      id: GO:0060539
      label: diaphragm development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse. WT1 mutations cause Meacham syndrome with 
        diaphragm defects.
      action: KEEP_AS_NON_CORE
      reason: Documented in Meacham syndrome but not core function.
  - term:
      id: GO:0072075
      label: metanephric mesenchyme development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse. Core kidney development function.
      action: ACCEPT
      reason: WT1 essential for metanephric mesenchyme development and MET.
  - term:
      id: GO:0035802
      label: adrenal cortex formation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse. Adrenal development affected in Wt1 mutants.
      action: KEEP_AS_NON_CORE
      reason: Valid but secondary developmental role.
  - term:
      id: GO:0060923
      label: cardiac muscle cell fate commitment
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse. Epicardial progenitor role.
      action: KEEP_AS_NON_CORE
      reason: Secondary to kidney/gonad functions.
  - term:
      id: GO:0001570
      label: vasculogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Transfer from mouse. Related to epicardial/heart development.
      action: KEEP_AS_NON_CORE
      reason: Secondary developmental role.
  - term:
      id: GO:0001657
      label: ureteric bud development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Core kidney development function.
      action: ACCEPT
      reason: Essential for nephrogenesis.
  - term:
      id: GO:0003156
      label: regulation of animal organ formation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Generic term for developmental regulation.
      action: MARK_AS_OVER_ANNOTATED
      reason: Overly broad term. More specific terms for kidney, gonad, heart 
        development are more appropriate.
  - term:
      id: GO:0005737
      label: cytoplasm
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 can be cytoplasmic but primarily nuclear.
      action: KEEP_AS_NON_CORE
      reason: Minor localization compared to nucleus.
  - term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Core function.
      action: ACCEPT
      reason: Well-supported by human evidence.
  - term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Core function.
      action: ACCEPT
      reason: Well-supported by human evidence.
  - term:
      id: GO:0007281
      label: germ cell development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 role in germ cell development via gonad function.
      action: KEEP_AS_NON_CORE
      reason: Related to gonad development but indirect.
  - term:
      id: GO:0008380
      label: RNA splicing
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: +KTS isoform participates in RNA processing/splicing, interacting
        with RBM4 and other splicing factors [PMID:16934801].
      action: ACCEPT
      reason: Isoform-specific function of +KTS variant.
  - term:
      id: GO:0009888
      label: tissue development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Generic developmental term.
      action: MARK_AS_OVER_ANNOTATED
      reason: Too broad. More specific terms exist.
  - term:
      id: GO:0030539
      label: male genitalia development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 required for male genital development. DDS patients have 
        genital abnormalities.
      action: ACCEPT
      reason: Core function in sex development.
  - term:
      id: GO:0030855
      label: epithelial cell differentiation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 drives mesenchymal-to-epithelial transition in nephrogenesis.
      action: ACCEPT
      reason: Core function in kidney development.
  - term:
      id: GO:0043010
      label: camera-type eye development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Eye involvement in WAGR syndrome includes aniridia, but that is 
        due to PAX6.
      action: REMOVE
      reason: WT1 is not the cause of eye defects in WAGR syndrome - that is due
        to contiguous deletion including PAX6. This appears to be an annotation 
        error.
  - term:
      id: GO:0060231
      label: mesenchymal to epithelial transition
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: Core function in nephrogenesis. WT1 required for MET during 
        kidney development.
      action: ACCEPT
      reason: Well-documented developmental function.
  - term:
      id: GO:0072166
      label: posterior mesonephric tubule development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 required for mesonephric development.
      action: ACCEPT
      reason: Part of urogenital development.
  - term:
      id: GO:0072302
      label: negative regulation of metanephric glomerular mesangial cell 
        proliferation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 regulates mesangial cell proliferation. Reduced WT1 causes 
        mesangial sclerosis.
      action: ACCEPT
      reason: Consistent with podocyte/glomerular function.
  - term:
      id: GO:2000020
      label: positive regulation of male gonad development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 activates SRY and promotes male gonad development.
      action: ACCEPT
      reason: Core function in sex determination.
  - term:
      id: GO:2000195
      label: negative regulation of female gonad development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 promotes male development, which indirectly suppresses female
        pathway.
      action: UNDECIDED
      reason: The relationship is complex. WT1 is required for gonad development
        of both sexes. The negative regulation of female gonad development may 
        be overstated.
  - term:
      id: GO:0072112
      label: podocyte differentiation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: WT1 essential for podocyte differentiation and maintenance.
      action: ACCEPT
      reason: Core function. WT1 regulates podocyte-specific genes (nphs1, 
        podocalyxin) [PMID:11912180].
  - term:
      id: GO:0005654
      label: nucleoplasm
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-9767700
    review:
      summary: Reactome pathway annotation. WT1 binds CDH1 gene promoter.
      action: ACCEPT
      reason: Consistent with nuclear localization.
  - term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    evidence_type: NAS
    original_reference_id: PMID:7862533
    review:
      summary: Review article documenting WT1 as transcription factor.
      action: ACCEPT
      reason: Core function with extensive experimental support.
      supported_by:
        - reference_id: PMID:7862533
          supporting_text: High affinity binding sites for the Wilms' tumour 
            suppressor protein WT1.
  - term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    evidence_type: NAS
    original_reference_id: PMID:7862533
    review:
      summary: Core function from review.
      action: ACCEPT
      reason: Well-supported.
      supported_by:
        - reference_id: PMID:7862533
          supporting_text: High affinity binding sites for the Wilms' tumour 
            suppressor protein WT1.
  - term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    evidence_type: NAS
    original_reference_id: PMID:8393820
    review:
      summary: Review characterizing WT1 as transcription factor.
      action: ACCEPT
      reason: Core function.
      supported_by:
        - reference_id: PMID:8393820
          supporting_text: 'The WT1 Wilms tumor gene product: a developmentally regulated
            transcription factor in the kidney that functions as a tumor suppressor.'
  - term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    evidence_type: NAS
    original_reference_id: PMID:8393820
    review:
      summary: Core function from review.
      action: ACCEPT
      reason: Well-supported.
      supported_by:
        - reference_id: PMID:8393820
          supporting_text: 'The WT1 Wilms tumor gene product: a developmentally regulated
            transcription factor in the kidney that functions as a tumor suppressor.'
  - term:
      id: GO:0003344
      label: pericardium morphogenesis
    evidence_type: TAS
    original_reference_id: PMID:10101119
    review:
      summary: WT1 is expressed in proepicardium and epicardium. Wt1 null mice 
        die at E13.5 due to heart failure from defective epicardial development.
        YAC complementation studies demonstrate continuous requirement for WT1 
        in epicardial/pericardial development.
      action: NEW
      reason: Well-supported by knockout studies showing WT1 is essential for 
        epicardial development. The epicardium is the visceral layer of the 
        pericardium.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: YAC complementation shows a requirement for Wt1 in 
            the development of epicardium, adrenal gland and throughout 
            nephrogenesis.
        - reference_id: file:human/WT1/WT1-deep-research-cyberian.md
  - term:
      id: GO:0060317
      label: cardiac epithelial to mesenchymal transition
    evidence_type: TAS
    original_reference_id: PMID:10101119
    review:
      summary: WT1 is required for epicardial epithelial-to-mesenchymal 
        transition (EMT) that generates cardiovascular progenitor cells. WT1 
        regulates epicardial EMT through Wnt/beta-catenin signaling and retinoic
        acid signaling via direct Raldh2 regulation.
      action: NEW
      reason: WT1 drives EMT in epicardium (opposite to MET in kidney), 
        generating cardiac fibroblasts, vascular smooth muscle cells, and 
        coronary endothelial cells.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: YAC complementation shows a requirement for Wt1 in 
            the development of epicardium, adrenal gland and throughout 
            nephrogenesis.
        - reference_id: file:human/WT1/WT1-deep-research-cyberian.md
  - term:
      id: GO:0060947
      label: cardiac vascular smooth muscle cell differentiation
    evidence_type: TAS
    original_reference_id: PMID:10101119
    review:
      summary: Epicardial EMT driven by WT1 generates cardiac vascular smooth 
        muscle cells that contribute to coronary vasculature formation. Wt1 null
        mice show impaired coronary plexus formation.
      action: NEW
      reason: WT1-dependent epicardial EMT produces vascular smooth muscle cells
        for coronary vessels.
      supported_by:
        - reference_id: PMID:10101119
          supporting_text: YAC complementation shows a requirement for Wt1 in 
            the development of epicardium, adrenal gland and throughout 
            nephrogenesis.
        - reference_id: file:human/WT1/WT1-deep-research-cyberian.md
  - term:
      id: GO:0045893
      label: positive regulation of DNA-templated transcription
    evidence_type: IDA
    original_reference_id: PMID:9815658
    negated: true
    isoform: P19544-1
    review:
      summary: The +KTS isoform (P19544-1) does NOT activate transcription. 
        PMID:9815658 shows the SRY promoter was strongly activated by WT1(-KTS) 
        isoforms but was NOT activated by WT1(+KTS) isoforms. The +KTS 
        tripeptide insertion alters DNA binding capability. This is a classic 
        example of isoform-specific function where the two splice variants have 
        opposite activities.
      action: ACCEPT
      reason: Well-documented isoform-specific NOT annotation. The +KTS isoform 
        lacks transcriptional activation ability that the -KTS isoform 
        possesses, due to altered DNA binding from the KTS insertion. This is a 
        paradigm case of functional divergence between splice isoforms.
      supported_by:
        - reference_id: PMID:9815658
          supporting_text: by the WT1 isoforms without the KTS tripeptide, 
            WT1(-)KTS, but was not activated by the WT1 isoforms with the KTS 
            tripeptide, WT1(+)KTS, in all cells tested
references:
  - id: GO_REF:0000002
    title: Gene Ontology annotation through association of InterPro records with
      GO terms
    findings: []
  - id: GO_REF:0000024
    title: Manual transfer of experimentally-verified manual GO annotation data 
      to orthologs by curator judgment of sequence similarity
    findings: []
  - id: GO_REF:0000033
    title: Annotation inferences using phylogenetic trees
    findings: []
  - id: GO_REF:0000043
    title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword 
      mapping
    findings: []
  - id: GO_REF:0000044
    title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular 
      Location vocabulary mapping
    findings: []
  - id: GO_REF:0000052
    title: Gene Ontology annotation based on curation of immunofluorescence data
    findings: []
  - id: GO_REF:0000117
    title: Electronic Gene Ontology annotations created by ARBA machine learning
      models
    findings: []
  - id: GO_REF:0000120
    title: Combined Automated Annotation using Multiple IEA Methods
    findings: []
  - id: PMID:10101119
    title: YAC complementation shows a requirement for Wt1 in the development of
      epicardium, adrenal gland and throughout nephrogenesis.
    findings:
      - statement: WT1 expressed in proepicardium, epicardium, and subepicardial
          mesenchymal cells
        supporting_text: Using a lacZ reporter gene inserted into a YAC 
          construct, we demonstrate that WT1 is expressed in the early 
          proepicardium, the epicardium and the subepicardial mesenchymal cells 
          (SEMC).
      - statement: Wt1 null mice die at E13.5 due to heart failure
        supporting_text: Knock-out mice were shown to have defects in the 
          urogenital system and to die at embryonic day E13.5, probably due to 
          heart failure.
      - statement: Continuous requirement for WT1 during nephrogenesis
        supporting_text: Analysis of the observed hypoplastic kidneys 
          demonstrate a continuous requirement for WT1 during nephrogenesis, in 
          particular, in the formation of mature glomeruli.
      - statement: Adrenal gland development severely affected
        supporting_text: Finally, we show that the development of adrenal glands
          is also severely affected in partially rescued embryos.
  - id: PMID:11912180
    title: WT1 is a key regulator of podocyte function
    findings:
      - statement: Reduced WT1 causes crescentic glomerulonephritis or mesangial
          sclerosis
        supporting_text: we demonstrate that reduced expression levels of WT1 
          result in either crescentic glomerulonephritis or mesangial sclerosis 
          depending on the gene dosage.
      - statement: WT1 regulates nphs1 and podocalyxin expression
        supporting_text: Strikingly, the two podocyte-specific genes nphs1 and 
          podocalyxin are dramatically downregulated in mice with decreased 
          levels of Wt1, suggesting that these two genes act downstream of Wt1.
  - id: PMID:1332065
    title: Human platelet-derived growth factor A chain is transcriptionally 
      repressed by the Wilms tumor suppressor WT1.
    findings:
      - statement: WT1 represses PDGFA transcription
        supporting_text: WT1 bound to several sites in this region of the 
          promoter, as demonstrated by gel-shift analysis and DNase I 
          footprinting, and functioned as a powerful repressor of PDGF-A 
          transcription in vivo.
  - id: PMID:14701728
    title: BASP1 is a transcriptional cosuppressor for the Wilms' tumor 
      suppressor protein WT1.
    findings:
      - statement: BASP1 interacts with WT1
        supporting_text: WT1 and BASP1 associate within the nuclei of cells that
          naturally express both proteins.
      - statement: BASP1 converts WT1 from activator to repressor
        supporting_text: BASP1 can confer WT1 cosuppressor activity in 
          transfection assays, and elimination of endogenous BASP1 expression 
          augments transcriptional activation by WT1.
  - id: PMID:15518539
    title: Why zinc fingers prefer zinc
    findings:
      - statement: NMR structure of WT1 zinc fingers with zinc
  - id: PMID:15520190
    title: SUMO-1 modification of the Wilms' tumor suppressor WT1.
    findings:
      - statement: +KTS isoform localizes to nuclear speckles
      - statement: -KTS isoform has diffuse nuclear distribution
  - id: PMID:1662794
    title: Characterization of the zinc finger protein encoded by the WT1 Wilms'
      tumor locus.
    findings:
      - statement: WT1 binds EGR consensus sequence
      - statement: Nuclear localization demonstrated
  - id: PMID:16467207
    title: Wilms tumor suppressor, Wt1, is a transcriptional activator of the 
      erythropoietin gene.
    findings:
      - statement: WT1 activates EPO gene transcription
  - id: PMID:16934801
    title: WT1 interacts with the splicing protein RBM4
    findings:
      - statement: WT1 interacts with RBM4
        supporting_text: Here we show that WT1 interacts with the novel splicing
          regulator RBM4.
      - statement: +KTS isoform modulates RBM4 splicing activity
        supporting_text: We found that overexpressed WT1(+KTS) abrogated this 
          effect of RBM4 on splice-site selection, whereas WT1(-KTS) did not. We
          conclude that the (+KTS) form of WT1 is able to inhibit the effect of 
          RBM4 on alternative splicing.
      - statement: Colocalization in nuclear speckles
        supporting_text: Each protein was found to colocalize in nuclear 
          speckles and to cosediment with supraspliceosomes in glycerol 
          gradients.
  - id: PMID:23042785
    title: Control of epigenetic states by WT1 via regulation of de novo DNA 
      methyltransferase 3A.
    findings:
      - statement: WT1 transactivates DNMT3A expression
        supporting_text: We demonstrate that depletion of WT1 by 
          short-interfering RNAs leads to reduced DNMT3A in Wilms' tumour cells 
          and human embryonal kidney-derived cell lines.
      - statement: WT1 recruited to DNMT3A promoter by ChIP
        supporting_text: Chromatin immunoprecipitation assays demonstrate WT1 
          recruitment to the DNMT3A promoter region and reporter assays confirm 
          that WT1 directly transactivates DNMT3A expression.
      - statement: WT1 overexpression causes promoter methylation changes
        supporting_text: Using genome-wide promoter methylation arrays, we show 
          that human embryonal kidney cells over-expressing WT1 acquire DNA 
          methylation changes at specific gene promoters where DNMT3A 
          recruitment is increased, with hypermethylation being associated with 
          silencing of gene expression.
  - id: PMID:25258363
    title: Wilms tumor protein recognizes 5-carboxylcytosine within a specific 
      DNA sequence
    findings:
      - statement: WT1 binds 5'-GCG(T/G)GGGCG-3' motif
        supporting_text: Consequently, WT1 binds the same consensus sequence as 
          Egr1/Zif268 (Stoll et al. 2007)
      - statement: High affinity for unmethylated and 5mC-containing DNA
        supporting_text: Egr1/Zif268 and WT1 showed slightly higher affinity for
          the fully methylated sequence by factors of ∼2.8 (Egr1) and ∼1.8 (WT1)
      - statement: Lower affinity for oxidized forms (5hmC, 5fC, 5caC)
        supporting_text: Both displayed high affinity for the sequence when C or
          5 mC was present and much reduced affinity when 5 hmC or 5 fC was 
          present
  - id: PMID:7585606
    title: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor
      suppressor gene WT1.
    findings:
      - statement: WT1 represses BCL2 and MYC transcription
        supporting_text: We found that WT1 can repress transcription of both the
          bcl-2 and c-myc promoters. This suggests that WT1 regulates bcl-2 and 
          c-myc during renal development, and the loss of functional WT1 results
          in deregulation of bcl-2 and c-myc, contributing to tumor formation.
  - id: PMID:7720589
    title: Repression of Pax-2 by WT1 during normal kidney development.
    findings:
      - statement: WT1 binds PAX2 promoter elements
        supporting_text: Binding of WT1 to three high affinity sites in the 5' 
          untranslated Pax-2 leader sequence was demonstrated by DNAseI 
          footprinting analysis.
      - statement: WT1-dependent transcriptional repression of PAX2
        supporting_text: Furthermore, co-transfection assays using CAT reporter 
          constructs under the control of Pax-2 regulatory sequences 
          demonstrated WT1-dependent transcriptional repression.
  - id: PMID:7862533
    title: High affinity binding sites for the Wilms' tumour suppressor protein 
      WT1.
    findings:
      - statement: Characterized WT1 DNA-binding consensus
  - id: PMID:8119964
    title: WT1 is negatively autoregulated
    findings:
      - statement: WT1 represses its own transcription
      - statement: WT1 homodimerization via zinc fingers
  - id: PMID:8393820
    title: 'The WT1 Wilms tumor gene product: a developmentally regulated transcription
      factor in the kidney that functions as a tumor suppressor.'
    findings:
      - statement: Review of WT1 function in development and cancer
  - id: PMID:9553041
    title: Inhibition of cellular proliferation by the Wilms tumor suppressor 
      WT1 requires association with the inducible chaperone Hsp70.
    findings:
      - statement: WT1 interacts with Hsp70
        supporting_text: By immunoprecipitation and protein microsequencing 
          analysis, we have identified a major cellular protein associated with 
          endogenous WT1 to be the inducible chaperone Hsp70.
      - statement: Hsp70 required for WT1 antiproliferative function
        supporting_text: These observations indicate that Hsp70 is an important 
          cofactor for the function of WT1, and suggest a potential role for 
          this chaperone during kidney differentiation.
      - statement: WT1 localizes to nuclear speckles
        supporting_text: Hsp70 is recruited to the characteristic subnuclear 
          clusters that contain WT1.
  - id: PMID:9815658
    title: 'The Wilms'' tumor gene WT1 can regulate genes involved in sex determination
      and differentiation: SRY, MΓΌllerian-inhibiting substance, and the androgen receptor.'
    findings:
      - statement: WT1 activates SRY promoter
        supporting_text: SRY (the sex-determining region of the Y chromosome) 
          promoter was strongly activated by the WT1 isoforms without the KTS 
          tripeptide, WT1(-)KTS, but was not activated by the WT1 isoforms with 
          the KTS tripeptide, WT1(+)KTS, in all cells tested.
      - statement: WT1 represses MIS and androgen receptor
        supporting_text: The MΓΌAdullerian-inhibiting substance (MIS) promoter 
          was strongly repressed by WT1(-)KTS isoforms and more weakly repressed
          by the WT1(+)KTS isoforms in Sertoli cells but not in HeLa cells.
      - statement: Isoform-specific effects (-KTS vs +KTS)
        supporting_text: The second alternative splicing site, which inserts the
          tripeptide KTS, alters the DNA binding capability.
  - id: PMID:19447967
    title: Shifted Transversal Design smart-pooling for high coverage 
      interactome mapping.
    findings: []
  - id: PMID:21900206
    title: A directed protein interaction network for investigating 
      intracellular signal transduction.
    findings: []
  - id: PMID:25416956
    title: A proteome-scale map of the human interactome network.
    findings: []
  - id: PMID:25601757
    title: WT1 recruits TET2 to regulate its target gene expression and suppress
      leukemia cell proliferation.
    findings: []
  - id: PMID:27229929
    title: Systematic interactome mapping of acute lymphoblastic leukemia cancer
      gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common 
      interactor.
    findings: []
  - id: PMID:31515488
    title: Extensive disruption of protein interactions by genetic variants 
      across the allele frequency spectrum in human populations.
    findings: []
  - id: PMID:21390327
    title: PINCH1 is transcriptional regulator in podocytes that interacts with 
      WT1 and represses podocalyxin expression.
    findings:
      - statement: PINCH1 interacts with WT1 via LIM1 domain and zinc-finger 
          domain
  - id: PMID:9178767
    title: Differential regulation of the human Wilms tumour suppressor gene 
      (WT1) promoter by two isoforms of PAX2.
    findings: []
  - id: PMID:8132626
    title: Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell
      type-specific enhancer and promiscuous promoter.
    findings: []
  - id: PMID:7588596
    title: WT1 suppresses synthesis of the epidermal growth factor receptor and 
      induces apoptosis.
    findings:
      - statement: WT1 represses PDGF-A transcription
  - id: PMID:19050011
    title: Dynamic interaction between WT1 and BASP1 in transcriptional 
      regulation during differentiation.
    findings: []
  - id: PMID:9765217
    title: Induction of Rb-associated protein (RbAp46) by Wilms' tumor 
      suppressor WT1 mediates growth inhibition.
    findings:
      - statement: WT1 inhibits cell proliferation
  - id: PMID:8306891
    title: Nuclear localization of the protein encoded by the Wilms' tumor gene 
      WT1 in embryonic and adult tissues.
    findings:
      - statement: WT1 localizes to nucleus
  - id: PMID:12802290
    title: 'Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative
      transcriptional targets using cDNA microarray expression profiling of genetically
      defined Wilms'' tumors.'
    findings: []
  - id: PMID:19205749
    title: Membranoproliferative glomerulonephritis associated with a mutation 
      in Wilms' tumour suppressor gene 1.
    findings:
      - statement: WT1 role in glomerular basement membrane development
  - id: PMID:7856737
    title: Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 
      gene transcription in human fetal kidney and Wilms' tumors.
    findings:
      - statement: WT1 expression during kidney development
  - id: PMID:15961562
    title: Expression, regulation, and function of paired-box gene 8 in the 
      human placenta and placental cancer cell lines.
    findings:
      - statement: WT1 response to gonadotropin stimulus
      - statement: WT1 response to cAMP
  - id: PMID:17848411
    title: Developmental changes in human fetal testicular cell numbers and 
      messenger ribonucleic acid levels during the second trimester.
    findings:
      - statement: WT1 expression in male gonad development
  - id: Reactome:R-HSA-9767700
    title: Reactome pathway annotation
    findings: []
  - id: file:human/WT1/WT1-deep-research-falcon.md
    title: Deep research report (falcon provider) - WT1 functional annotation
    findings:
      - statement: WT1 contains four C2H2 zinc fingers mediating high-affinity 
          binding to GC-rich motifs such as 5'-GCG(T/G)GGGCG-3' in target 
          promoters/enhancers
        supporting_text: 'Domain architecture and nucleic-acid interactions: WT1 contains
          four C2H2 zinc fingers (exons 7-10) mediating high-affinity binding to GC-rich
          motifs such as 5''-GCG(T/G)GGGCG-3'' in target promoters/enhancers'
      - statement: The -KTS isoform binds DNA sequence-specifically and drives 
          transcriptional programs, while +KTS shows low DNA affinity and has 
          RNA-binding/processing roles
        supporting_text: The -KTS isoform binds DNA sequence-specifically and 
          drives transcriptional programs, whereas the +KTS isoform shows low 
          DNA affinity, associates with spliceosomal components, and has 
          RNA-binding/processing roles
      - statement: WT1(+KTS) co-localizes with splicing speckles and interacts 
          with splicing factors U2AF65 and WTAP
        supporting_text: WT1(+KTS) co-localizes with splicing speckles, 
          interacts with splicing factors (U2AF65, WTAP), forms complexes with 
          ZNF255 and BASP1 that participate in RNA maturation
      - statement: WT1 is essential for nephron development and adult podocyte 
          integrity
        supporting_text: 'Nephrogenesis and podocyte maintenance: WT1 binds and regulates
          kidney lineage and podocyte genes and is essential for nephron development
          and adult podocyte integrity'
      - statement: WT1 mRNA is overexpressed in >80% of AML and used for MRD 
          monitoring
        supporting_text: WT1 mRNA is overexpressed in >80% of AML; standardized 
          ELN qRT-PCR thresholds are widely used for MRD risk stratification and
          post-transplant surveillance
  - id: file:human/WT1/WT1-deep-research-cyberian.md
    title: Deep research report (cyberian provider) - WT1 comprehensive 
      functional analysis
    findings:
      - statement: WT1 zinc fingers 2-4 insert into major groove for 
          base-specific DNA contacts; ZnF1 amplifies affinity without 
          contributing to sequence specificity
        supporting_text: The second, third, and fourth zinc finger domains 
          insert deep into the major groove of DNA where they make base-specific
          contacts. Zinc fingers 2 and 3 are primarily responsible for most of 
          the binding affinity and can function as a minimal DNA binding domain,
          while zinc finger 4 is indispensable for target specificity
      - statement: WT1-DNA binding has Kd of 1.14 x 10^-9 M and is 
          entropy-driven, unlike EGR1
        supporting_text: Quantitative binding studies have demonstrated that 
          recombinant WT1 zinc fingers bind to the dodecamer DNA sequence 
          GCG-TGG-GCG-TGT with high affinity, exhibiting a dissociation constant
          (Kd) of 1.14 x 10^-9 M under physiological conditions. Thermodynamic 
          analysis revealed that WT1-DNA interaction is an entropy-driven 
          process
      - statement: KTS insertion increases linker flexibility between ZnF3-4, 
          abolishing ZnF4 DNA contact
        supporting_text: The molecular basis for the functional differences 
          between +KTS and -KTS isoforms was elucidated by NMR structural 
          studies demonstrating that the KTS insertion increases the flexibility
          of the linker between fingers 3 and 4, abrogating the binding of the 
          fourth zinc finger to its cognate site in the DNA major groove
      - statement: Normal +KTS/-KTS ratio is 2:1; Frasier syndrome results from 
          altered ratio to 1:2
        supporting_text: The physiological importance of maintaining the correct
          ratio of +KTS to -KTS isoforms (normally approximately 2:1) is 
          dramatically illustrated by Frasier syndrome, in which mutations 
          disrupting the +KTS splice site alter this ratio to 1:2
      - statement: p53 interaction converts WT1 from repressor to activator; WT1
          stabilizes p53 protein
        supporting_text: In the absence of p53, WT1 functions as a potent 
          transcriptional activator of EGR1-like promoter sequences rather than 
          as a repressor. WT1 expression can stabilize p53 protein, enhance its 
          DNA binding to target sequences
      - statement: BASP1 myristoylation recruits PIP2 to promoters, enabling 
          HDAC1-mediated repression
        supporting_text: Mechanistically, myristoylated BASP1 binds to nuclear 
          phosphatidylinositol 4,5-bisphosphate (PIP2), which leads to the 
          recruitment of PIP2 to the promoter regions of WT1-dependent target 
          genes. This association with PIP2 is required for the interaction of 
          BASP1 with histone deacetylase 1 (HDAC1), enabling chromatin 
          deacetylation and gene silencing
      - statement: WT1 directly activates nephrin (NPHS1) transcription >10-fold
          via specific promoter element
        supporting_text: WT1 binds to a specific responsive element in the 
          nephrin promoter and activates transcription more than 10-fold. 
          Transgenic mouse analysis confirmed that this WT1 binding site is 
          required for podocyte-specific nephrin expression in vivo
      - statement: WT1 directly activates SF1 and SRY in gonad development; DDS 
          mutations fail to activate SRY
        supporting_text: The -KTS isoform of WT1, but not the +KTS form, 
          directly binds to and transactivates the Sf1 promoter through four 
          identified binding sites. WT1 also directly regulates the 
          sex-determining gene SRY by activating its expression. Mutant WT1 
          proteins found in Denys-Drash syndrome patients fail to activate the 
          SRY promoter
      - statement: WT1 required for epicardial EMT in heart development via 
          Wnt/beta-catenin and retinoic acid pathways
        supporting_text: WT1 is expressed in the proepicardium and developing 
          epicardium, where it is required for epithelial-to-mesenchymal 
          transition (EMT) that generates cardiovascular progenitor cells. WT1 
          regulates epicardial EMT through multiple signaling pathways including
          canonical Wnt/beta-catenin signaling and retinoic acid signaling 
          through direct regulation of Raldh2 expression
      - statement: WT1 ZnF1 is more important for RNA binding than DNA binding; 
          +KTS and -KTS bind RNA similarly
        supporting_text: While zinc fingers 2, 3, and 4 are required for 
          high-affinity DNA binding, zinc finger 1β€”which is dispensable for DNA 
          bindingβ€”is more important for RNA binding. Consequently, the KTS 
          insertion has minimal effect on RNA affinity
core_functions:
  - description: Sequence-specific DNA-binding transcription factor (-KTS 
      isoform) that regulates kidney development by activating podocyte-specific
      genes (nphs1, podocalyxin) and repressing PAX2 during 
      mesenchymal-to-epithelial transition. Binds the 5'-GCG(T/G)GGGCG-3' 
      consensus motif via C2H2 zinc fingers.
    molecular_function:
      id: GO:0000981
      label: DNA-binding transcription factor activity, RNA polymerase 
        II-specific
    directly_involved_in:
      - id: GO:0001822
        label: kidney development
      - id: GO:0072112
        label: podocyte differentiation
      - id: GO:0060231
        label: mesenchymal to epithelial transition
    locations:
      - id: GO:0005654
        label: nucleoplasm
    anatomical_locations:
      - id: UBERON:0000074
        label: renal glomerulus
      - id: UBERON:0002113
        label: kidney
  - description: Transcription factor (-KTS isoform) that regulates gonad 
      development and sex determination by activating SRY and regulating MIS/AMH
      and androgen receptor expression. Isoform-specific activity is critical as
      Frasier syndrome results from splice site mutations altering +KTS/-KTS 
      ratio.
    molecular_function:
      id: GO:0001228
      label: DNA-binding transcription activator activity, RNA polymerase 
        II-specific
    directly_involved_in:
      - id: GO:0007530
        label: sex determination
      - id: GO:0008406
        label: gonad development
    locations:
      - id: GO:0005654
        label: nucleoplasm
    anatomical_locations:
      - id: UBERON:0000473
        label: testis
      - id: UBERON:0000992
        label: ovary
  - description: Transcriptional repressor (-KTS isoform) that suppresses cell 
      proliferation by repressing growth-promoting genes including BCL2, MYC, 
      PDGFA, and EGFR. Growth suppression requires Hsp70 association. 
      Loss-of-function mutations cause Wilms tumor.
    molecular_function:
      id: GO:0000981
      label: DNA-binding transcription factor activity, RNA polymerase 
        II-specific
    directly_involved_in:
      - id: GO:0008285
        label: negative regulation of cell population proliferation
      - id: GO:0000122
        label: negative regulation of transcription by RNA polymerase II
    locations:
      - id: GO:0005654
        label: nucleoplasm
  - description: RNA-binding protein (+KTS isoform) that participates in 
      post-transcriptional regulation. Localizes to nuclear speckles where it 
      interacts with splicing factors (U2AF65, RBM4) and modulates alternative 
      splicing. ZnF1 is more important for RNA binding than DNA binding. The 
      +KTS isoform has reduced DNA-binding affinity due to the three amino acid 
      insertion between zinc fingers 3 and 4 which increases linker flexibility 
      and abolishes ZnF4 DNA contact.
    molecular_function:
      id: GO:0003723
      label: RNA binding
    directly_involved_in:
      - id: GO:0008380
        label: RNA splicing
    locations:
      - id: GO:0016607
        label: nuclear speck
  - description: Transcription factor required for epicardial 
      epithelial-to-mesenchymal transition (EMT) during heart development. 
      Expressed in proepicardium and epicardium, WT1 regulates EMT through 
      Wnt/beta-catenin signaling (via Lef1, Ctnnb1), non-canonical Wnt5a 
      signaling, and retinoic acid signaling (via direct Raldh2 regulation). 
      Epicardial EMT generates cardiac fibroblasts, vascular smooth muscle 
      cells, and coronary endothelial cells. WT1 null embryos die at E13.5 due 
      to heart failure from defective epicardium.
    molecular_function:
      id: GO:0000981
      label: DNA-binding transcription factor activity, RNA polymerase 
        II-specific
    directly_involved_in:
      - id: GO:0003344
        label: pericardium morphogenesis
      - id: GO:0060317
        label: cardiac epithelial to mesenchymal transition
      - id: GO:0060947
        label: cardiac vascular smooth muscle cell differentiation
    locations:
      - id: GO:0005654
        label: nucleoplasm
    anatomical_locations:
      - id: UBERON:0002348
        label: epicardium
      - id: UBERON:0000948
        label: heart
    supported_by:
      - reference_id: PMID:10101119
      - reference_id: file:human/WT1/WT1-deep-research-cyberian.md
proposed_new_terms: []
suggested_questions:
  - question: What is the precise mechanism by which WT1 switches between 
      activator and repressor function?
  - question: What are the distinct RNA targets of the +KTS isoform?
suggested_experiments:
  - description: ChIP-seq for WT1 isoforms to systematically identify 
      genome-wide binding sites for -KTS vs +KTS isoforms, which would clarify 
      their distinct transcriptional targets.
  - description: CLIP-seq for +KTS isoform to identify RNA binding targets, 
      which would elucidate its post-transcriptional regulatory functions.